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ABSTRACT 
The prevention and cure of malaria is difficult as it thrives under poor socio- and 
pharmacoeconomic conditions in third world, tropical and subtropical regions. It is a parasitic 
disease spread through the bite of an infected Anopheles mosquito. In humans, malaria can be 
caused by several Plasmodium species that include: Plasmodium falciparum, Plasmodium vivax, 
Plasmodium ovale, Plasmodium malariae and Plasmodium knowlesi.  
The natural product artemisinin is a sesquiterpene lactone with an endoperoxide bridge 
isolated from the Chinese annual herb qinghao (Artemisia annua L or sweet wormwood). The 
relatively stable endoperoxide bridge is essential for their antimalarial activity.  
The synthesis of rac-6-Desmethyl-5β–hydroxy-D-secoartemisinin (a 1,2,4-trioxane) 
afforded a starting point upon which to conduct heretofore unexplored structure-activity 
relationships (SAR) about the C5 position. Additionally, as the C4 position is quintessential, via 
a C4 radical, to issues related to the molecular details of the mechanism of action of artemisinin, 
C5 derivatives were hypothesized and synthesized in order to test the effect of stabilization of the 
C4 radical.  
Previous studies from the literature of separate enantiomeric peroxides revealed that 
chirality was unimportant for bioactivity. It was felt that this could not be true in all cases 
because clear bioorganic and biological evidence for the intermediacy of protein receptors exists. 
By separating  two Mosher ester diastereomers of the title compound followed by saponification 
iii 
into the (3R, 5R, 5aR, 9aS) and (3S, 5S, 5aS, 9aR) enantiomeric alcohols. It was found that all 
activity was associated with the (3R, 5R, 5aR, 9aS) diastereomer. This mirror image overlays 
with the x-ray structure of the natural product, R-(+)-artemisinin (the 3R trioxane). This is logical 
as the mechanism of action (MOA) of artemisinin and related 1,2,4-trioxanes appears to be 
related to protein binding followed by a Fe(II)-mediated C4 radical hypothesized to react 
covalently with a plasmodial SERCA cysteine moiety, blocking the SERCA Ca-channel. This 
radical is produced by an O1-O2/C3-C4 ring cleavage, suggesting that logical modifications at 
C5 would be expected to test this aspect of the proposed MOA and provide additional SAR to 
complement known modifications elsewhere in the backbone of the natural product.   
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1.1.MALARIA   
Malaria is one of the Third World’s most lethal infectious diseases that are transmitted to 
humans by female Anopheles mosquitoes.  Even though the insect vector can be avoided in 
principle using mosquito netting or eradicated with pesticides, its wide distribution in 
economically depressed, remote tropical regions reduces the effectiveness of implementing these 
obvious modalities. As a result, the scientific and endemic communities are forced into 
expensive pharmaceutical interventions. The obvious end-game for malaria is a vaccination, but 
the parasite stays out of reach by facile mutation 
Despite a century of antimalarial drug research; malaria remains a substantial global 
health burden [1] that causes hundreds of thousands of deaths every year [2]. Globally, about 3.3 
billion people in 106 countries are at risk of contracting malaria [3]. According to a 2015 World 
Health Organization (WHO) [1]report, there were 214 million (range: 149–303 million) reported 
cases of malaria in 106 malaria endemic countries: the African Region (88%), followed by 
South-East Asia (10%) and the Eastern Mediterranean (2%). The estimated number of deaths in 
2015 from malaria was 438,000 with approximately 90% of the deaths occurring in the African 
Region. During the same year, malaria killed about 306,000 children under the age of five years. 
In addition, malaria is still the leading cause of death in children, especially in sub-Saharan 
Africa; it takes the life of a child every 2 minutes [4].  
In humans, malaria can be triggered by several Plasmodium (P) species that include: P. 
falciparum, P. vivax, P. oval, P. malariae and P. knowlesi [5]. After the bite of an infected 
2
  
female Anopheles mosquito, sporozoites reach the blood stream and the parasites invade the liver 
within 30 minutes and start replicating there forming schizonts. Within 5–10 days, merozoites 
invade the red blood cells and rapidly proliferate after the rupture of the liver cells. This leads to 
the appearance of clinical symptoms such as fever, fatigue, and chills. In the intraerythrocytic 
phase, different forms of merozoites take place (rings, trophozoites, and schizonts), which will 
proliferate and release into the bloodstream and infect new red blood cells (See Figure 1). 
 
Figure 1: Plasmodium life cycle. Liver, blood (= erythrocytic), transmission, and mosquito 
stages
1
. 
Decreased symptoms and mortality rate of the malaria disease are the advantages of 
drugs that target the blood stages of the parasite. Inside the erythrocyte some parasites 
differentiate into male and female gametocytes after many cycles of asexual reproduction. The 
3
  
male and female gametocytes after being ingested by mosquitoes reproduce sexually to form the 
zygote which differentiates to form sporozoites. These sporozoites migrate to mosquito salivary 
glands and are ready to infect the next host [5, 6]. P. falciparum is considered the most fatal, 
especially in Africa. Also, malignant malaria, if left untreated, P. falciparum causes organ 
failures which leads to severe malaria. It accumulates in the brain capillaries and forms cerebral 
malaria, leading to coma and death [5, 7].  
1.2. FREQUENTLY USED ANTIMALARIAL DRUGS 
Depending on the stages of the malaria life cycle, antimalarial agents can be generally 
classified as blood schizonticides, in which drugs acting on asexual intraerythrocytic stages, or 
tissue schizonticides which inhibit the development of hepatic schizonts and gametocides which 
act by killing the intraerythrocytic sexual gametes of the parasite and block the transmission 
from human to mosquito. Many antimalarial drugs can target more than one stage of the 
Plasmodium life cycle [2, 3].  
Quinine 1.1 as shown in  
Figure 2, has been the backbone for the treatment of severe malaria for centuries ever 
since it was introduced into European medicine during the 17
th
 century. Quinine is a quinolone 
derivative occurring naturally in the bark of the Cinchona tree; and is the only drug that has 
continued successfully in the treatment of malaria. Until very recently, quinine was no longer 
recommended by the WHO [4] as the first-line of treatment for malaria; currently is only used in 
the treatment of severe malaria or when there is limited access to artemisinins [4-6].The 
4
  
mechanism of action of quinine is not fully known, however, it has been hypothesized that 
quinine and other quinolone antimalarial agents, act by inhibiting hemozoin  bicrystallization  in 
the heme detoxification pathway. This helps the aggregation of cytotoxic heme, causing heme to 
accumulate in the parasite which leads to its death
 
[7]. 
Chloroquine 1.2 as shown in  
Figure 2, was a very effective drug for both treatment and prophylaxis. It was heavily 
used in the 1940’s after World War II for healing all forms of malaria. Due to its extensive use, 
resistance of P. falciparum to chloroquine developed and by the 1980’s resistance spread to most 
areas of P. falciparum malaria endemic zones. Chloroquine has similar antimalarial activity 
similar to quinine which acts by inhibiting hemozoin bicrystallization in the heme detoxification
 
[8-10]. Besides the antimalarial effects of chloroquine, it has also shown broad-spectrum 
antiviral activity and anti-cancer therapeutic effects [11].  
Primaquine 1.3a as shown in  
Figure 2, is 8-aminoquinoline which can target preerythrocytic stages of P. falciparum, P. 
vivax, and P. ovale, including hypnozoites, with excellent prophylactic activity [12]. Albeit not 
active against blood-stage parasites, primaquine has been shown to inhibit the maturation of 
fertile gametocyte [13]. Its mechanism of action believed to be interfering with mitochondrial 
function and its activity against liver-stage parasites and gametocytes [14]. The main drawbacks 
of primaquine include its oxidative conversion to carboxy primaquine 1.3b [15] and toxic effects 
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such as hemolytic anemia in patients with Glucose-6-phosphate dehydrogenase deficiency 
(G6PD) deficiency [16].  
Mefloquine 1.4, is structurally related to quinine, and was first introduced in the 1970s. It 
was used in the treatment of malaria as well as a prophylactic agent due to its long half-life
 
[10]. 
It is not useful against severe malaria, but is used to treat chloroquine-resistant P. falciparum 
malaria and is an affordable alternative for uncomplicated chloroquine-resistant P. vivax  malaria 
[17]. Mefloquine antimalarial activity is thought to be the same as quinine and chloroquine. 
Mefloquine use is associated with multiple neuropsychiatric side effects such as dizziness, 
tinnitus, anxiety, hallucinations, depression, and suicidal thoughts
 
[18, 19]. 
Halofantrine 1.5, is not structurally correlated to quinine and was introduced in the 1980s. 
It is not used as a prophylactic agent because it has a very short half-life (1 to 2 days) [10]. Its 
mode of action is not clear, however, a crystallographic study exhibited that halofantrine forms 
complexes with ferriprotoporphyrin IX (Fe(III)PPIX) and inhibits formation of beta hematin 
[20]. Halofantrine has several undesirable side effects, e.g., abdominal pain, diarrhea, vomiting, 
rash, headache, itching, and cardiac arrhythmias [21]. In addition, many neuropsychiatric 
disturbances have been reported with the antimalarial use of halofantrine. 
Malarone 1.6 is a combination of atovaquone and proguanil, which are shown  
Figure 2. Atovaquone is related to a family of anti-infective compounds, the 
hydroxynaphthoquinones and has been known for a long time to be active against P. falciparum. 
Atovaquone acts by inhibiting mitochondrial electron transport in the parasite, decreasing 
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pyrimidine synthesis and causing the collapse of the mitochondrial membrane potential. 
Proguanil is an antifolate which an antimetabolite that blocks the actions of folic acid. Malarone 
is used in the treatment and prophylaxis of malaria. The atovaquone-proguanil combination has 
been commercially available in the US since 2000. Several clinical trials were conducted on the 
drug combination, and it was found to be more than 95% effective against drug resistant strains 
of falciparum malaria. Widespread use of malarone as a prophylactic agent is not recommended 
except in pregnancy for trepidation regarding the emergence of resistance, furthermore, the drug 
is too costly
 
[10, 22].   
1.3.ARTEMISININ   
Artemisinin 1.7 is a sesquiterpene lactone with an endoperoxide bridge as shown in 
Figure 3 which was isolated from a Chinese annual herb qinghao (Artemisia annua L or sweet 
wormwood). Artemisia is mentioned in the ‘Chinese Handbook of Prescriptions for Emergency 
Treatments’ and was recommended for the treatment of fevers in 340 AD [3]. In 1967, the 
Chinese army began a plant screening research program, Project 523, to find a new antimalarial 
medicine. In 1972 through a systematic examination of Artemisia annua L, artemisinin was 
isolated by Youyou Tu at the Chinese Academy of Traditional Chinese Medicine. A crystalline 
compound was obtained after low temperature extraction from this plant.  
7
  
 
Figure 2: Structures of frequently used antimalarials.       
Chinese researchers named it qinghaosu [25] [26] .The chemical abstracts adopted 
artemisinin as the official name. Artemisinin structure was elucidated in 1979 [27].  In 2015 the 
Nobel Prize in Physiology or Medicine was awarded to Youyou Tu for her discovery of 
artemisinin and dihydroartemisinin for malaria treatment. The unique chemical structure with a 
stable endoperoxide bridge is essential for the antimalarial activity of artemisinin. Recently, 
artemisinin and its derivatives (dihydroartemisinin DHA 1.8, artemether 1.9, arteether 1.10 and 
artesunate 1.11), as shown in Figure 3, have been reported to have antiviral, antifungal, and 
anticancer properties [28].  
Artemisinin and its derivatives are still the foundation for treatment of cerebral malaria 
and chloroquine-resistant falciparum malaria. The WHO recommended artemisinin-based 
combination therapies (ACTs), instead of using the single drug to avoid parasite recrudescence 
[29]. Artemisinin and its derivatives, in this combination therapy, have a short plasma half-life 
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but a rapid onset of action which can eliminate a large fraction of parasites. The other drug in 
this combination with a long plasma half-life can kill the remaining parasites [5]. This resulted in 
an efficient parasite clearance and prevented the risk of resistance development. The most 
commonly used combinations are artemether-lumefantrine (Coartem), artesunate-amodiaquine, 
artesunate-mefloquine, and artesunate-sulfadoxine-pyrimethamine [30] as shown in Figure 3. 
 
Figure 3: Structures of artemisinin, its known synthetic derivatives and ACTs partners. 
1.3.1. TOTAL SYNTHESIS AND SEMISYNTHETIC ANALOGS OF ARTEMISININ 
Besides its great antimalarial activity, artemisinin has disadvantages such as a short 
plasma half-life, low bioavailability, poor solubility in oil and water, and relatively low yield of 
artemisinin from natural sources
 
[23]. Scientists’ efforts towards the improvement of these 
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properties resulted in the development of first-generation artemisinin derivatives 1.8-1.11 as 
illustrated in Figure 3. Of these, dihydroartemisinin (DHA) 1.8, which can be synthesized by the 
reduction of artemisinin with sodium borohydride, is 6 times more active in vitro than 
artemisinin
  
[24]. Oil-soluble ether derivatives 1.9 and 1.10 are good for intramuscular (im) 
administration. In contrast, water-soluble artesunate 1.11 is commonly used intravenously (iv)
 
[25].These semisynthetic derivatives are active against uncomplicated P. falciparum malaria, 
blood-stage Plasmodium vivax and severe malaria infections. They also have gametocidal 
activities. 
Besides the good antimalarial activity of analogs 1.9-1.11, they contain acid-labile acetal 
functions and display short biological half-lives. In addition, they metabolize to DHA which has 
been identified to cause neurotoxicity in animal models [26, 27]. 
a. C-10 derivatives of artemisinin 
Many modifications at C-10 of artemisinin have been conducted by the introduction of 
different chemical groups to improve chemical and metabolic stability, and could prevent the 
metabolism to DHA. The most promising of the series was artelinic acid 1.16 with improved 
hydrolytic stability compared to artesunate. When tested in vitro against P. falciparum, it showed 
a comparable activity to artemisinin. On the other hand, it was found more active in vivo against 
P. berghei infected mice when administered subcutaneously (sc) at dose 40mg/kg/day than 
artemisinin. Artelinic acid showed a 100% cure (mice surviving 60 days post infection) whereas 
artemisinin showed about 60% [28] as illustrated in Figure 4. 
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Efforts to identify more metabolically stable derivatives appropriate to deliver a good 
efficacy with shorter treatment time period are ongoing and have presented a series based on the 
10-alkylamino artemisinins, illustrated by artemisone 1.17 in Figure 4. In preclinical studies on 
safety, tolerability, and pharmacokinetics conducted in human subjects, artemisone has greater 
efficacy than artesunate, and lacks the neurotoxicity associated with dihydroartemisinins.
 
[29]. 
Phenoxy derivatives were synthesized to avoid metabolism by phase I oxidation, which is 
a problem associated with first-generation ether derivatives 1.9 and 1.10. When phenoxy 
derivative 1.18 is administered orally (po) to mice infected with P. berghei, the ED50 was 2.7 
mg/kg/day whereas ED50 of sodium artesunate was 4.0 mg/kg/day and it did not metabolize to 
DHA [30].  
 
Figure 4: C-10 derivatives of artemisinin. 
In a correlated approach, Magueur, et al., synthesized a series of C-10 trifluoromethyl 
ethers of artemisinin in order to improve the hydrolytic stability of the acetal functional group. 
Of these, the lead candidate 1.19  as in Figure 4, was found > 30 times more stable than 
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artemether in simulated stomach acid conditions and when tested intraperitoneally (ip) in mice 
infected with P. berghei, the ED50 was 1.25 mg/kg/day (artemether ED50= 2.5 mg/kg/day)
 
[31].  
b. C-3, C-9, and O-11derivatives of artemisinin 
 Different chemical derivatization approaches were applied to develop new artemisinin 
analogs with better therapeutic profiles at positions C-3, C-9, and O-11. The C-3 substitution 
analogs of artemisinin were obtained mostly via total synthesis. Posner, et al., synthesized a 
series of carboxyphenyl trioxanes. Of these, analog 1.20 as shown in Figure 5 maintained good 
thermal stability and aqueous solubility and when tested po against P. berghei-infected mice the 
ED50/ED90 values were 15/51mg/kg/day (artelinic acid = 9.6/29 mg/kg/day)
 
[32]. The C-3 
modified analogs were studied extensively but were not a good competitor to reach the phase of 
clinical development compared to the C-10 modified analogs. 
Avery, et al., [33] have synthesized a series of C-9 modified analogs by total synthesis 
via a common intermediate 1.25c (Scheme 1) or by converting artemisinin to artemisitene 
followed by radical-based Michael addition of different donor synthons (Scheme 2). Of these, 
1.21 as shown in Figure 5 which when tested orally in mice infected with P. berghei (N) the 
ED50 was 1.25 mg/ kg/day (sodium artesunate ED50 = 2.4 mg/kg)
 
[34, 35]. Several of C-9β-
phenethyl analogs of artemisinin in this series were highly potent, but had low solubility and low 
solubility and oral bioavailability. The addition of polar side-chains mitigated oral administration 
by improving aqueous solubility, and despite high LogP, were still quite potent on oral 
administration in mice when administered in peanut oil. Advancing these compounds to clinical 
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trials was a distinct possibility, but financial concerns (expensive, toxic reagents) interrupted 
their advancement when other compounds were selected by WHO as they were less expensive. 
Were these compounds of utility in a common American disease such as diabetes, they would 
surely have been advanced. Process development to find alternatives to the conjugate addition 
step to artemisitene would have surely been possible but without WHO support, there was no 
point in continuing the efforts.  
Grellepois, et al., have also synthesized a number of C-9 analogs using the intermediate 
16-bromo-10-trifluoromethyl anhydrodihydroartemisinin which can be easily prepared from 
artemisinin [36]. Of these, piperazinoethanol derivative 1.22 as shown in Figure 5, demonstrated 
a great ED90 value which was < 10 mg /kg/day when tested po and sc in mice infected with P. 
berghei. Also, it gave 100% reduction in parasitemia by day 4 at the same dose. Interestingly, it 
was more potent than sodium artesunate (ED90 = 10.5 mg /kg/day sc and 15.3 mg /kg/day po) 
and only gave 90% reduction in parasitemia by day 4. Moreover, pharmacokinetic studies 
exhibited that 1.22 has 25 times greater oral bioavailability in rats than artemether [36]. 
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Figure 5: C-3, C-9, and O-11derivatives of artemisinin. 
Avery, et al., synthesized an array of C-3 substituted artemisinin and C-3,9-disubstituted 
artemisinin analogs as shown in Scheme 1. Of these, 1.23 as shown in Figure 5, contains 
propionate ethyl ester substitution at C-3 which was twice as potent as artemisinin when tested in 
vitro against drug- resistant strains of P. falciparum. The dual substituted analog 1.24, was 14-23 
fold more active than artemisinin
 
[33]. 
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Scheme 1: Avery et al., approach to numerous analog types from common intermediate 
1.25b. 
 
Scheme 2: Semisynthetic approach to C-16 (C-9) substituted analogs of artemisinin. 
 
Aza analogs were first reported by Avery, et al., [37, 38] as shown in Scheme 1. The O-11 
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position of artemisinin could be replaced by RN by conversion of the carboxylic acid of 1.25b to 
an amide prior to ozonolysis giving the N-11 lactam 1.25a. While the acidic side chain was 
shown in the scheme, dimethylamino or alkyl side chains were also possible. Subsequently, 
Ziffer, et al., [39] were able to treat artemisinin directly with amines to obtain transient ring 
opened amides that upon acidification, led to the lactams 1.25b.  N-Amino-11-Aza analogs were 
also constructed by Singh et al., [40] and showed promising antimalarial activity when tested 
orally against multidrug-resistant P. yoelii in Swiss mice. Of these, hydrazone 1.26 as shown in 
Figure 5, was the most active compound of the series, showed 100% and 80% protection at 12 
mg/kg × 4 days and 6 mg/kg × 4 days, respectively (β-arteether gave100% protection at a dose of 
48 mg/kg × 4 days and 20% protection at 24 mg/kg × 4 days). In addition, 1.26 and 1.27 showed 
100% protection at 12 mg/kg × 4 days. All these analogs were 4-fold more potent than β-
arteether when tested orally [40].  
c. C-4 to C-8 derivatives of artemisinin 
Using chemical synthesis methods to introduce a variety of substituents at positions C-4 
to C-8 were still a challenge due to the lack of accessible functional groups at these positions. 
However, microbial fermentation technique can be a substitute. As illustrated in Figure 6, new 
artemisinin derivatives such as 1.28, 1.29, 1.30 and 1.31 were generated through this route
 
[41-
43]. Analogs 1.32 and 1.33 were synthesized from 7α-hydroxylarteether and 15- 
hydroxylarteether, respectively they were obtained from the microbially-mediated oxidation of 
arteether
 
[44] when tested in vitro against drug-resistant strains of P. falciparum, a several fold 
increase in antimalarial activity was observed [44].  
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Avery et al., have synthesized a dimers from 1.28 as shown in Figure 6 which found to 
have high antimalarial activity. In addition, the dimers were studied In vitro, in vivo and 
underwent pharmacokinetic profiling [45]. Heterodimerization of 7β-hydroxyartemisinin 
furnished the asymmetrical carbamate (1.28a, ARB-89) whereas homodimerization provided the 
carbonate (1.28b, ARB-92). These two compounds exhibited potent antimalarial activity when 
tested in vitro against P. falciparum infected human red blood cells (RBC) with an IC50 of 0.50 
nM (1.28a) and 0.32 nM (1.28b). In addition, both compounds were tested against P. berghei N 
in male CD1 mice (~20 g). The carbamate (1.28a) and carbonate (1.28b) demonstrated 
parasitemia suppression of >96 and >99% at a dose of 3.3 mg/kg as compared to 94% 
suppression displayed by artesunate at the same dose. No signs of obvious cytotoxicity were 
observed with these compounds [45]. Furthermore, 1.18a exhibited a high clearance (92.8 ± 5.6 
L/h kg), short elimination half-life ( t1/2, 1.2 ± 0.2 h) and moderate oral bioavailability (23.4%). 
1.18a was found to be excreted unchanged in feces, which perhaps due to its high lipophilicity, 
molecular weight and low oral exposure. 1.18b was designed to be more water soluble than 
1.18a. As anticipated, 1.18b displayed a lower clearance (2.9 ± 0.7 L/h kg) and subsequently a 
longer t1/2 (2.3 ± 0.2 h) compared to 1.18a. The oral bioavailability of 1.18b was found to be 34% 
in rats, a value slightly better than the marketed artemisinin derivatives artenimol (19.3%), 
artemether (19.7%) or artesunate (29.5%). This newly synthesized artemisinin based carbonate, 
1.18b, ARB-92, displayed acceptable pharmacokinetic and pharmacodynamic potential that can 
be used in further development of 1.18b as an antimalarial candidate drug [45].  
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Figure 6: C-4 to C-8 artemisinin derivatives. 
d. 4,5-seco artemisinin 
Avery et al., have synthesized a series of tricyclic seco artemisinin analogs [46] that lack 
the B ring as illustrated in Figure 7. These compounds were designed to see if the distinctive 
scaffold in artemisinin is crucial for its biological activity. These compounds showed variable 
activities. For instance, compound 1.35 maintained in vitro potency similar with that of 
artemisinin. Their percentage relative activities against the drug resistant Sierra Leone clone of 
P. falciparum (D6) were 20:108:7:0, respectively (artemisinin = 100). The peroxide groups in 
this series are flexible compared with artemisinin, but radical formation with Fe(II) would not be 
expected to yield the usual C4-radical as C4 is unattached to the cyclohexyl ring (ring B) in these 
structures. It is conceivable that a methyl radical is released by these molecules giving 1.34d 
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upon exposure to Fe(II). While it seems more likely that acetone would be liberated with 
simultaneous D-ring opening to afford 1.34b as shown in Scheme 3, no radical would be formed 
and the compounds would be devoid of activity. The structures 1.34-7 were reported before the 
importance of Fe(II) in the MOA of artemisinin, thus their Fe(II) chemistry was not studied.  
 
Figure 7: 4,5-Seco artemisinin derivatives. 
 
Scheme 3: Fe(II) mediated ring opening of 1.34. 
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1.3.1. AVERY’S GROUP CONTRIBUTION TO THE FIELD OF ARTEMISININ  
The interest of our group in this great molecule started with a successful total synthesis 
[38]. This synthetic route significantly facilitated subsequent artemisinin analogs synthesis. 
Utilizing this route, our group has synthesized over 200 analogs of artemisinin which include; C-
13 carbon analogs[47], N-11 derivatives [37], C-3 (alkyl, arylalkyl  and carboxyalkyl ) analogs 
[33], C-9 analogs[48, 49] and 9β-16-(arylalkyl)-10-deoxoartemisinins [35]. The plethora of these 
compounds was more active than artemisinin and presented a great value of contribution towards 
the quantitative structure-activity relationship (QSAR) [33] [48-50].  
1.3.2. MODE OF ACTION 
As mentioned earlier, artemisinins have an endoperoxide bridge that is essential for their 
antimalarial activity. The way this endoperoxide bridge helps in killing the parasite is still a 
debatable subject. Several theories have been proposed over the years ranging from an 
interaction of artemisinin with Fe
2+
-heme in the parasite that could create toxic carbon-centered 
free radicals that have a destructive effect on the parasite biomolecules, probably through 
alkylation, and causing cell death. Another proposed mechanism of artemisinin action included 
the disruption of a protein export system of the parasite tubulovesicular network. It has also been 
proposed that artemisinin could inhibit the parasite endocytic pathways or the disruption of 
mitochondrial function. In addition, the artemisinin mode of action may also include inhibiting 
the malarial sarcoplasmic-endoplasmic reticulum (ER) Ca
2+
-ATPase (SERCA) known as 
PfATP6
 
[51].  
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a.  Heme mechanism 
A large amount of the life cycle of P. falciparum, as mentioned previously, takes place in 
the erythrocyte, or red blood cell, of a human host. It is through this stage that hemoglobin is 
utilized by the parasite as a food source. The hemoglobin is introduced into a food vacuole which 
is a specific acidic place in the parasite, and broken down by proteolytic enzymes called 
plasmepsins. The degraded hemoglobin is further broken down into amino acids by food vacuole 
cysteine proteases known as falcipains
 
[52].  
The proposed heme mechanism is that heme which is ferroprotoporphyrin IX, or 
Fe(II)PPIX is released and oxidized to hematin Fe(III)PPIX. Hematin in its reduced ferrous free 
form Fe(II)PPIX is toxic to the cells, and the parasites convert it to an insoluble crystalline form 
called malaria pigment or hemozoin. In addition, hematin, when it is reduced to heme, is the 
source of ferrous iron that causes the bioactivation of the endoperoxide bridge of artemisinin to 
the cytotoxic radical species. Artemisinin-mediated oxidative stress is the suggested mechanism 
of action depends on in vitro experiments with infected red blood cells or parasite membranes. In 
vitro studies showed that heme catalyzes the reductive decomposition of artemisinin. 
When artemisinin was incubated with normal erythrocytes, the concentration of 
methemoglobin was increased along with a minor reduction in the intracellular glutathione and 
membrane fatty acid concentrations. This will cause a dose-dependent increase of cell lysis
 
[52]. 
The possible mechanism is illustrated in Scheme 4.  
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Scheme 4: The possible mechanism for the artemisinin mediated lipid peroxidation of cell 
membranes. 
 
The lipid solubilized heme interacts with artemisinin followed by ferrous-mediated 
generation of oxyl and carbon radicals. These reactive intermediates will be a target of allylic 
hydrogens of unsaturated lipid bilayers. Lipid hydroperoxides will be generated as result of 
hydrogen abstraction and allylic carbon radical formation followed by oxygen capture.  
Fenton cleavage of the hydroperoxide forms reactive oxygen species such as hydroxyl 
radicals and superoxide which is responsible for the damage to the lipid bilayer of the cell 
membrane. This damage causes vacuolar rupture and parasite autodigestion. In contrast  to what 
is presented here, several researchers have proposed that parasite death is possibly not due to 
random cell damage from freely diffusing reactive oxygen species, but may include specific 
radicals and targets [52]. Further studies by Meunier on the alkylating activity of artemisinin 
with manganese(II) tetraphenylporphyrin (Mn
II
TPP ) instead of Fe porphyrin were conducted  
because of the several possible alkylation sites on iron protoporphyrin IX. The reaction of 
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artemisinin with Mn
II
TPP in dichloromethane (DCM), generated a chlorine-type adduct due to 
the reaction of the macrocycle with an alkyl radical 1.45 as shown in Scheme 5 [52, 53].  
Scheme 5: Isolated reaction product of artemisinin with Mn
II
TPP. 
 
b. Carbon radicals mechanism    
Artemisinin free radical chemistry is well characterized now. Within the malaria parasite, 
at an early stage, a chemical decomposition induced by ferrous ions, creates an oxy radical that 
later rearranges into one or both of two well-defined carbon-centered radicals. Scheme 6 
demonstrates the main radical pathways for artemisinin after the bioactivation of endoperoxide 
[52].  
Fe- (II)-mediated cleavage of artemisinin 1.7 peroxy bond via a single electron transfer 
(SET). Due to the asymmetric nature of the peroxy bond, an O1 radical 1.49 or O2 radical 1.46 
can be generated.  These oxygen free radicals are not stable and rapidly rearrange to carbon 
centered radicals. O2 radical 1.46 can give a C-4 primary radical 1.47 through a C-C β- scission 
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process which undergoes ring-contraction to form the tetrahydrofuran product 1.48. In addition, 
the primary radical 1.47 is thought to be scavenged by molecules such as heme or glutathione to 
create the corresponding adducts. O1 radical 1.49 can undergo a 1,5-H shift to generate a 
secondary C-4 radical 1.50 which forms a stable end-product, i.e., hydroxydeoxoartemisinin 
(HDA) 1.30. These C-centered reactive intermediate radicals can alkylate heme and specific 
proteins inside the parasite leading ultimately to parasite death
 
[52] [54]. 
Scheme 6: Proposed mechanism of the in vitro reaction of artemisinin with Fe(II). 
 
A total synthesis of 13-carba-artemisinin, 10-deoxo-13-carbaartemisinin 1.53 and (+)-10-
deoxo-13-carbaartemisinin 1.60 by Avery, et al., in which, they have replaced a C for O at the C-
13 position of artemisinin 1.7 as illustrated in Scheme 7 and Scheme 8. This should create a 
more stable C-4 radical because of the destabilizing effect of the β-oxygen which was removed 
and also should have an influence on antimalarial potency [47, 52]. Avery, et al., have found that 
increased stability of an intermediate radical at C-4 leads to decreased antimalarial activity and 
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potency.  
It has also been suggested that the non-isolable epoxide intermediate 1.52 was 
responsible for protein alkylation and has a significance role in the mode of antimalarial action 
of the 1,2,4-trioxane endoperoxides. This contradicts with the results obtained from the reaction 
of 1.53 with 2 equivalents FeBr2 at ambient temperature in Tetrahydrofuran (THF). The products 
of this reaction were vinyl ether in 39% yield 1.56 and a stable epoxide 1.59 in 20 % yield. 
Neither 1.56 nor 1.59 showed in vitro antimalarial activity, yet their peroxy precursor 1.53 was 
of similar potency to artemisinin as illustrated in Scheme 7.    
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Scheme 7: Proposed mechanism of the in vitro reaction of 10-deoxo-13-carbaartemisinin 
with FeBr2. 
 
In addition, compound 1.60, did not display a significant antimalarial potency in vitro 
against P. falciparum and when treated with FeBr2, the only end-product alcohol 1.63 was 
isolated in 79% yield as shown in Scheme 8. In fact, the more rational product of the radical 1.65 
might be the epoxide 1.66 which was not formed in this reaction. Compound 1.63 did not exhibit 
any antimalarial activity [47].   
26
  
Scheme 8: Proposed mechanism of the in vitro reaction of (+)-10-deoxo-13-
carbaartemisinin with FeBr2. 
 
Compounds 153, 156, 159, 160 and 1.63 were tested in vitro in parasitized whole human 
blood against drug-resistant Indochina (W-2) and D-6 strains of P. falciparum. The relative 
potencies for the analogs were calculated as follows: (IC50 of artemisinin divided by the IC50 of 
analog) x 100% (i.e., the relative activity of artemisinin = 100%). Artemisinin IC50 = 0.97 ng/mL 
(D-6) and 0.48 ng/mL (W-2). The IC50 of 1.53 = 1.72 ng/mL (D-6) and 0.78 ng/mL (W-2) and 
the IC50 of 1.60 = 2.87 ng/mL (D-6) and 2.79 ng/mL (W-2). When the IC50 values converted to 
relative activity to artemisinin, 1.53 maintained 53 % (D-6) and 58 % (W-2) of the activity while 
1.60 just maintained 32 % (D-6) and 16 % (W-2) of the activity. Compounds 1.56, 1.59, and 1.63 
were inactive [47]. 
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These studies clearly demonstrate that the epoxide 1.52 proposed by Posner as shown in 
Scheme 6, is an unlikely intermediate, even though it perhaps formed, it would not be a critical 
for activity.  
c. Cysteine mechanism 
The ability of artemisinin to alkylate heme in heme-based models has been examined. For 
instance, it has been proposed that the formation of heme-artemisinin adducts could lead to 
inhibition of heme polymerization to nontoxic hemozoin. In theory, the accumulation of active 
alkylated porphyrins can cause parasite death. Haynes, et al., have opposed this possible 
mechanism by showing that artemisinin 1.7 and DHA 1.8 can inhibit β-hematin formation in 
vitro. However, the potent antimalarial and structurally related 10-deoxodihydroartemisin 1.67 as 
shown in Figure 8, has no effect on hemozoin formation. Thus, the result of the inhibition effect 
in the heme polymerization inhibitory assay (HPIA) for 1.7 and 1.8 but not 1.67, reflects a 
reactivity that is not connected to their antimalarial mechanism of action [52], [55].  
 
Figure 8: Structure of 10-deoxodihydroartemisin. 
Wu, et al., reported that free Fe(II) can activate artemisinin, and in the presence of 
28
  
cysteine, form a covalent bond with a cysteine S atom through a Fe(III)-S-cysteine intermediate 
[56]. Also, Wu, et al., argued that at near physiological conditions, free Fe(II) plays an 
insignificant role, yet can form complexes with amino acids and be activated. For instance, the 
degradation of artemisinin can be very fast in the presence of cysteine. In the presence of one 
equivalent ferrous sulfate (FeSO4) and cysteine each (with respect to artemisinin) in aqueous 
acetonitrile (CH3CN) at 38 °C, artemisinin can be degraded immediately. In addition, when the 
amount of added iron was reduced, the reaction rate decreased.  
As Wu uses Fe(II) in this reaction, how can he claim that Fe(II) plays an insignificant 
role under physiological conditions? Is this claim made because his proposed mechanism 
requires R-S-Fe(III)? 
It was believed that infected erythrocytes have a higher concentration of free amino acids 
than uninfected ones, and that could be due to the catabolism of hemoglobin. In addition, the 
malaria parasite has a great concentration of reduced glutathione which is the major source of 
sulfhydryl-containing reducing agent in humans. Thus, Wu, et al., argued that the mechanism 
they illustrated, which involved the non-heme iron mediated degradation of artemisinin, could 
operate well in physiological systems. The evidence of the impotence of the presence of cysteine 
in the activation of artemisinin was that the newly isolated aldehyde product 1.69 (Scheme 9) 
can be formed only from the radical 1.47 by abstraction of a hydrogen atom from the SH group 
of cysteine followed by the elimination of an acetate as demonstrated in [56].  
As suggested by Wu et al., 1.71 (Scheme 10) can be generated as a result of an 
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intramolecular attack of the primary C-4 radical with the cysteine sulfur atom covalently 
attached to Fe(III) in 1.70, release a free Fe(II) ion and the cysteine-C-4 artemisinin adduct 1.71 
[56]. To verify the formation of the adduct 1.71, treatment with acetic anhydride furnished a 
tractable tricyclic [b.c] fused tetrahydro-2H-thiopyran ring 1.72.  
Scheme 9: Wu observation of primary radical abstraction by H-atom donor (e.g. cysteine) 
and elimination of acetate. 
 
Scheme 10: Wu primary radical intramolecular attack of a cysteine sulfur and the 
formation of a neutral thioether complex. 
 
Our interpretation of  Wu’s analysis is somewhat different. First, let us list the homolytic 
bond-dissociation energies (BDE’s) of ethane, ethanol, ethylthiol and tetrahydrofuran as shown 
in Table 1.  
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As one can see, oxygen radical formation from abstraction of the alcohol hydrogen atom 
(RO-H) has the highest energy, costing about 5 Kcal/M relative to a primary alkane. An alkyl 
radical would be expected to extract a hydrogen atom from a primary thiol with a driving force 
of -13 Kcal/M. Clearly, an oxy radical would abstract a H-atom from a thiol (RS-H) with -17 
Kcal/Mol favoring the exchange.   
Table 1: Homolytic bond-dissociation energies of relevant organic molecules. 
Organic Molecules 
Bond-
Dissociation 
Energy (BDE) 
Kcal/Mol 
Energy 
Release 
Reference 
CH3CH2CH2-H  →  CH3CH2CH2٠ 100.5 0 [57, 58] 
CH3CH2O-H  →  CH3CH2O٠ 104.6 4.6 [59] 
CH3CH2S-H  →  CH3CH2S٠ 87.4 -13.1 [60] 
 
92.1 -7.9 [61] 
From a thermodynamic standpoint, in Scheme 9, the radical 1.47 should prefer to abstract 
a H atom from a free thiol to give a thio radical and the neutralized ethane side chain in 1.68. If 
this were to occur with any regularity, high, non-physiological concentrations of thiols would be 
a minimal requirement.  Furthermore, the resulting cysteine radical would be far less damaging 
to the parasite than a carbon radical. Since these reactions are conducted in vitro in THF, and the 
relative energy for -H atom abstraction is -8 Kcal/M, it seems more likely that Wu’s radical 
1.47 would have reacted with solvent (THF) before abstracting a thiol H-atom. Our explanation 
for the formation of the neutral product 1.68 takes into consideration both kinetic and 
thermodynamic factors.   
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To explain the biological activity of the radical 1.47, Wu observed formation of a 
cysteine adduct upon conducting the reaction in the presence of cysteine. As this result was in 
thermodynamic conflict, Wu hypothesizes formation of a cysteine-S-Fe(III) bonding 
arrangement in 1.70 (Scheme 10, the Wu hypothesis). We agree that from this intermediate, 
formation of the adduct is reasonable. Unfortunately, thiols do not undergo covalent bond 
formation with Fe(II) or Fe(III) ((Equation (Eq) 1, Figure. 9)) in the absence of strong base 
(pKa glutathione SH = 7.9; cysteine ester SH = 8.6, NaOH = 15.7). Hence, how does one explain 
the formation of 1.70?. 
 
Figure 9: Reactions of thiols with Fe (cation). 
We feel that formation of intermediate 1.70 under physiological conditions is 
implausible, thus another explanation must be advanced. We hypothesize instead that a thiol 
complex with Fe(II) is reasonable as illustrated in Eq 3 (Figure 9) and Scheme 11 and Scheme 
12. This allows for an association between Fe(II) and a cysteine thiol group, bringing the S atom 
into proximity with the penultimate C4 radical (Scheme 11 and Scheme 12). What is now 
required is the formation of a radical cation upon reaction of a RHS. Fe(II) with 1.47a which is 
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shown in Scheme 11. 
The radical 1.47a (simplified 1.47) collapses to the radical cation 1.47RC which then 
undergoes intramolecular single electron transfer (SET) to neutralize the ion affording 1.47b and 
restoring iron in the Fe(II) oxidation state for recycling. 
Scheme 11: Stepwise thiol-radical reaction. 
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An alternate explanation for reaction of radical 1.47(a) is an intramolecular SET reaction 
from the C4 radical to Fe(III) generating a carbonium ion 1.47CI, in which the carbonium ion is 
captured by the cysteine thiol nucleophile to give the adduct 1.47c that then simply undergoes 
intramolecular acid-base neutralization to the neutral product 1.47b (akin to 1.68). Another 
rationalization that we prefer is a synchronous mechanism shown in Scheme 12. The advantage 
of this proposed mechanism is that the transition state (TS) energy (ETSsync) for the synchronous 
process should be lower than the combined energies of a stepwise mechanism involving multiple 
high E intermediates (ETS = ETS1 + ETS2 + ETSxyz). That is, ETSsync << ETS = ETS1 + ETS2 + 
E
TSxyz
).  
Scheme 12: Synchronous Cys-SH—Fe(II) mechanism with artemisinin. 
 
The complication of a synchronous mechanism comes from a high entropic term 
(STSsync) in the TS. The stereochemical necessity for the cysteine thiol group to be within ~3Å 
of C-4 while at the same time, Fe(II) must be associated with the peroxide oxygen atoms.  
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To our delight and surprise, extensive protein modeling of PfATP6 located two highly probably 
sites within this SERCA’s calcium channel, cys1031 and cys92, where artemisinin can 
simultaneously bind and have a cysteine moiety in exactly the arrangement shown in Scheme 12 
and in Figure 11 and Error! Reference source not found.. An additional remarkable finding was 
hat an arrangement of amino acid residues is located adjacent to both the cysteine SH group and 
the artemisinin binding site and is in the correct position to simultaneously bind the ferrous ion in 
its essential location [62]. 
 
Figure 10: Different views of the docked pose of artemisinin in Cys-92 site.  
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Figure 11: Different views of the docked pose of artemisinin in Cys-1031 site.  
d. Avery-Krishna SERCA/PfATP6 mechanism 
As proposed previously, studies illustrate that heme which formed from proteolysis of 
ingested hemoglobin can activate the peroxy bond of artemisinins inside the parasite’s food 
vacuole [63, 64]. However, artemisinins were found to affect the parasite membrane integrity 
instead of being accumulated in the digestive vacuole. In addition, they have the parasitical effect 
in the absence of hemazoin which oppose the hypothesis of the food vacuole being a main place 
for artemisinins action [65, 66] . 
Krishna, et al., have found that artemisinins but not quinine or chloroquine can inhibit 
PfATP6, the Plasmodium falciparum orthologue of the sarco/endoplasmic reticulum Ca
2+ 
ATPase (SERCA) when expressed in Xenopus laevis oocytes
 
[66]
 
. However, they are inactive 
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against other transporters, such as PfATP4 which is a P. falciparum non-SERCA Ca
2+
 ATPase. 
This inhibitory activity was found to be similar to thapsigargin 1.73 as shown in Figure 10, is 
sesquiterpene lactone with structural resemblances to artemisinins. Also, artemisinins 
parasiticidal activity can be antagonized by thapsigargin. On the other hand, desoxyartemisinin 
1.74 which lacks the endoperoxide bridge was inactive as an inhibitor of PfATP6 and has no 
antimalarial activity as shown in Figure 10. 
 
Figure 12: Structures of thapsigargin, desoxyartemisinin and desferrioxamine. 
Different studies in oocytes have shown that amino acid mutations at residue 263 (L263, 
263S, and 263A), placed at the head of artemisinins binding pocket can affect the inhibitory 
action of PfATP6 by artemisinins [51]. In a study by Krishna, et al., they found that the 
sensitivity of  P. falciparum to artemisinins was significantly decreased in a single amino acid 
mutation L263E of PfATP6
 
 [51]. In addition, they found that PfATP6 as a target of artemisinins 
can work through Fe
+2
 triggering a mechanism. This is consistent with our hypotheses in 
Scheme 11 and Scheme 12, as is more specifically shown in Scheme 13. 
The coordinating residues, Lys-85 and His-86, are shown a close distance from the iron 
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atom which, in turn, is in close proximity to the peroxide bridge of artemisinin. Cys-92 is also 
seen to be only a few Å away from C4 of artemisinin, which is the optimal location to intercept 
the carbon radical. 
Scheme 13: Synchronous PfATP6 cysteineSH----Fe(II)---Artemisinin rearrangement with 
covalent protein modification
a
 
 
a
Cysteine Residue(s) Cys1031, Cys92 
The coordinating residues, Glu-1025, Asn-1144, and Glu-1148, are shown a close 
distance from the iron atom which, in turn, is in close proximity to the peroxide bridge of 
artemisinin. Cys-92 is also seen to be only a few Å away from C4 of artemisinin, which is the 
optimal location to intercept the carbon radical. 
To confirm the importance of ferrous ions for activation of artemisinins, desferrioxamine 
1.75, as shown in Figure 10, which is an iron chelator when tested in the presence of 
artemisinins, abolishes their antiparasitic activity and subsequently decreases inhibition of 
PfATP6. Moreover, the single-cell imaging of living parasites with a fluorescent derivative of 
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thapsigargin (BODIPY-thapsigargin) exhibits cytosolic labeling and was competed by 
artemisinin [66]. These studies supported the hypothesis that artemisinins could act, at least in 
part, through the inhibition of PfATP6 and it likely was activated by a Fe
2+
-dependent 
mechanism. This offered a rational biological target-guided drug design to proceed forward. 
e. Haynes cofactor mechanism 
Haynes, et al., argued based on several experiments, that there is not a constant  
relationship between artemisinin antimalarial activity and the cleavage of the peroxide bond by 
Fe
2+
 which leads to C radicals formation
  
and the implausibility in the role of heme as an initiator 
of the antimalarial activity of artemisinins [67, 68]. Instead, Haynes, et al., have a different 
hypothesis for the mechanism of action.  Methylene blue (MB), the antimalarial agent, disturbs 
the redox behavior of parasite flavin-dependent disulfide reductases such as glutathione 
reductase (GR) that regulate oxidative stress in the malaria parasite. Due to the synergistic action 
between MB and artesunate, Haynes suggested that artemisinins could have a complementary 
mode of action. Also, due to the quite inert activity of artemisinins towards human GR, he 
proposed a mechanistic model that accounts for artemisinins selectivity to the malaria parasite, 
which did not involve ferrous iron or carbon-centered free radicals [68].  
In this schematic representation, artemisinin 1.7 is converted to peroxy radical anion 1.7
•‒     
by single electron transfer (SET) from leucomethylene blue radical 1.70
•
 which can be  generated 
from methylene blue and ascorbic acid (AA) in situ in aqueous buffer at a  physiological pH. The 
radical anion 1.7
•‒ 
then rearranges through an O1 radical to the ketyl 1.77 by insertion into the 
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C3–C4 bond. 1.77 is then oxidized to the carbonyl product 1.78 [68] as shown in Scheme 14. 
Scheme 14: SET between artemisinin and MB–AA. 
 
Haynes, et al., have concluded that the antimalarial activity of artemisinins can be due to 
their activity as both one-electron transfer molecules and two-electron acceptors in the lack of 
Fe(II). Additionally, artemisinins activity is due to interference with redox-active cofactors such 
as flavoenzymes within malaria parasite
 
[68]. 
1.3.3. ARTEMISININS METABOLISM 
Artemisinin metabolized by phase I human cytochrome P450 (CYP450) enzymes 
CYP2B6, CYP2C19 and CYP3A4
 
[69]. CYP3A4 is the mainly metabolizing enzyme of arteether 
1.10 and  artemether 1.9 to DHA 1.8 (reactive antimalarial metabolites), occurred in the liver and 
intestine as enteric first-pass metabolism [70] [71]. Hydroxylation by P-450 includes a substrate, 
reducing cofactor, and heme iron that proceeds via the Fe(II) and Fe(III) oxidation states. 
Oxygen transfer comes from a perferryl Fe(V)=O species produced by a reaction between 
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dioxygen (O2) and the Fe(II) complex.  
The presence of B- or C-ring of artemisinin tetracycle in the reactive perferryl center of 
the P450 enzyme active place makes them sites for hydroxylation metabolism as shown in Error! 
eference source not found.. No evidence exists for artemisinin analogs to act as irreversible 
inhibitors of the cytochrome P450 subfamily in all mammalian drug metabolism studies. In other 
words, heme-based P450 iron does not reductively stimulate artemisinins to radical species that 
consequently alkylate the protein cavity nearby the active site of the enzyme. Apparently, 
cytochrome P450 catalyzes hydroxylation and O-dealkylation without an effective reach to the 
shielded endoperoxide bridge. Furthermore, these observations highlight the fact that heme in its 
redox active form in the food vacuole, is not associated with protein and it is possible to be in an 
environment dissimilar from that of the CYP P450 active site [52].  
Scheme 15: Sites of P450 monohydroxylation on artemether and DHA glucuronidation.  
 
Some of the hydroxylated metabolites of B- and C-ring derived from artemisinin 
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derivatives have antimalarial activity, even though these metabolites could be eliminated through 
phase II glucuronides conjugates. For instance, Maggs, et al., have shown that 9β-
hydroxyartemether glucuronide maintains substantial antimalarial activity. In contrast, 7α-
hydroxyglucuronide which is the main biliary metabolite of artemether in rats does not form a 
considerable reactive plasma metabolite in addition to 1.8 which loses activity by 
glucuronylation [72] [73]. Artemether as shown in Scheme 15, oxidized by P450 on the methyl 
group of the C-10 methoxy function and releases a hemiacetal which collapses to 1.8. Then, 1.8 
is quickly excreted as glucuronidated conjugates 1.82. From a medicinal chemistry viewpoint, 
the short half-life of artemisinin derivatives as illustrated for artemether in Scheme 15, is due to 
the combined phase I and phase II conjugation reaction. Thus, an enormous amount of work has 
been performed to increase the potency and stability of the first generation analogs [52].  
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CHAPTER II 
SYNTHETIC PEROXIDES AS ARTEMISININ MIMICS 
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Since its discovery in 1972, artemisinin 1.7 opened a new era in antimalarial drug 
treatment. Despite rapid action, potency and clinically valuable antimalarial drugs, semisynthetic 
artemisinin derivatives suffer from drawbacks such as having short half-lives and must be 
administered to patients over a period of 5–7 days, causing noncompliance and recrudescence. 
With these problems in mind, medicinal chemists over the last twenty years tried to identify 
orally active synthetic peroxide drug candidates that are easier to synthesize, cost effective and 
with a good pharmacokinetic profile [4, 74]. The importance of artemisinins, comes from the fact 
that they are the only class of compounds still effective against drug-resistant strains of P. 
falciparum. Artemisinin IC50 against P. falciparum was 5.4 nM and in vivo ED50/ED90 values 
against in P. berghei-infected mice were 0.95/2.5 mg/kg/day (sc) and 5.0/14.0 mg/kg/day (po)
 
[74].  
Synthetic peroxides should help medicinal chemists to answer some questions such as 
whether their mode of action and the antimalarial activities are related to artemisinin.  Reviews 
by Tang, et al., [74] and Jefford [75] [76] have focused in the area of synthetic peroxides.  
2.1. 1, 2-DIOXANES (ENDOPEROXIDES)   
Many peroxides, naturally occurring or synthetic, are known to have varying degrees of 
antiamalarial activity, e.g. peroxides such as 2,3-dioxabicyclo[3.3.1]nonanes. One example is 
Yingzhaosu A 2.1, a natural product endoperoxide prototype with antimalarial activity
 
[77] was 
isolated from the traditional Chinese herb, Yingzhao, or Artabotrys uncinatus L. Merr. (Figure 
13). Yingzhaosu A was selected as a lead compound by Hoffmann-La Roche as in vitro and in 
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vivo bioassay
 
[78] against the chloroquine-resistant K1 strain of P. falciparum exhibited an IC50 
value of 115 nM; in vivo activity revealed an ED50 value of 50 mg/kg/day when was 
administered (sc) to mice infected with P. yoelii ssp NS.  
 
Figure 13: Yingzhaosu A and related compounds. 
The synthetic Yingzhaosu mimic, arteflene 2.2, demonstrated better in vivo activity than 
2.1 with an ED50 value against P. berghei ANKA of 2.7 mg/kg/day and IC50 value is equal to 2.1 
[79]. Despite exceptional stability and safety profiles for 2.2 in the development phase
 
[63], it 
was discontinued as a drug candidate after phase III trials
 
[75] because of high recrudescence 
rates. The related analog 2.3 showed an ED50 value of 4.2 mg/ kg and exhibited good safety 
profiles
 
[80]. (Error! Reference source not found.). 
2.2. TRICYCLIC AND TETRACYCLIC 1,2,4-TRIOXANES 
Avery et al., have synthesized a series of tricyclic seco artemisinin analogs [46] that lack the B    
ring as mentioned early and illustrated in Figure 7. 
These compounds were designed to see if the distinctive scaffold in artemisinin is crucial 
for its biological activity. Also, they displayed conformational flexibility about the 
trioxane/lactone rings. Analogs 1.34-1.37 showed variable in vitro activities. Their percentage 
45
  
relative activities against the drug resistant Sierra Leone clone of P. falciparum (D6) were 
20:108:7:0, respectively (artemisinin = 100). A similar conceptual was applied also by Avery et 
al.,[81] that scission of the D-ring (bond 8a, 9) provides 8a,9-secoartemisinin derivatives, such as 
2.4, 2.4a, 2,4b, 2.5, 2.6 and 2.7, that mimic the relative orientation of the A,B, and C rings of 
artemisinin as illustrated in Figure 14.  
 
Figure 14: 8a,9-secoartemisinin derivatives. 
Avery et al., in continuation of their work, constructed analogs 2.8-2.10 as shown in Figure 
15. These C-8 substituted artemisinin analogs lacking the D-ring  [81, 82] were designed 
originally to in order improve the activity of  2.6 by partially filling the volume of 2.4-2.6 in the 
area formerly occupied by the δ-lactone of artemisinin. When tested in vitro against the W-2 
clone of P. falciparum, compounds 2.9 and 2.10 showed IC50 values of 13 and 132 ng/ml 
respectively, while the IC50 value for artemisinin was 4.2 ng/ml.   
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Figure 15: 8,8-disubstituted tricyclic analogs of artemisinin. 
The tricyclic trioxanes 2.11 with an α-methoxy substituent when tested in vitro against P. 
falciparum D-6 and W-2 clones, the IC50 values were 12.10 nM and 30.40 nM respectively  
which was less potent than artemisinin ((IC50 = 1.56 nM (D-6) and 0.65 nM  (W-2)) [83, 84]. No 
in vivo data was reported. However, the β-methoxy epimer 2.12 when tested in vitro against 
chloroquine-sensitive P. falciparum (NF54) parasite, it displayed an IC50 of 960 nM. The IC50 
value for artemisinin was 9.2 nM [85]. When the bridgehead methyl in 2.11 was replaced with a 
phenyl group, as in 2.13, the IC50 was 110 nM [85] when tested in vitro against chloroquine-
sensitive P. falciparum (NF54) parasite. The IC50 value for artemisinin was 9.2 nM. Enhancing 
the lipophilicity of 2.11 by substituting the methoxy with a benzyloxy group such as 2.14 
resulted in an increase in potency. When tested in vitro against P. falciparum D-6 and W-2 
clones, the IC50 values were 13.93 nM and 0.86 nM respectively which was almost as potent as 
artemisinin ((IC50 = 1.56 nM (D-6) and 0.65 nM  (W-2)) [84].  
A more complex series of trioxanes derivatives were synthesized by Posner, et al., in 
which an ethanol side-chain corresponding to C-8a in 1.7 was installed. The primary alcohol 
could be derivatized as ethers, esters, phosphate esters, carbamates, and sulfonates. All 
derivatives had good in vitro potency [86]  [87]. As shown in Error! Reference source not found., 
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rioxanes 2.15 and 2.16 have IC50s values of 25 nM and 14 nM
 
respectively. Only 2.16 was 
partially curative at a dose of 640 mg/kg x 5days tested in P. berghei-infected mice. On the other 
hand, no antimalarial activity was seen at a dose of 160 mg/kg/day. When trioxanes 2.15 and 
2.16 were additionally tested in Aotus monkeys infected with multi drug resistant P. falciparum, 
both compounds cured each of the infected animals when 3 x 48 mg/kg doses were administered 
5 days post-infection. In addition,  a t.i.d dose of 12 mg/kg per day of 2.16 cured one of two 
infected animals, but the same dose of 2.15 was ineffective
 
[88]. The SAR of this series showed 
that the addition of lipophilic substituents increased the antimalarial potency
 
[87] while polar 
functional groups such as amines and quaternary ammonium salts decreased activity.  
        
          
        
Figure 16: Tricyclic and tertacyclic 1,2,4-trioxanes. 
Posner, et al., synthesized a series of C4- substituted analogs of 2.11 and 2.12 as 
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exemplified by 2.17 and analogs of 2.15 and 2.16, e.g., 2.18 as illustrated in Figure 16.  In vitro 
antimalarial studies of these trioxanes demonstrated that the C4β-substituted diastereomers were 
moderately potent while the corresponding C4α-substituted epimers were inactive. It was 
hypothesized that the C4α-substituted epimers, would be incapable of undergoing a 1,5-hydrogen 
shift following Fe(II) initiated oxyradical formation due to the absence of a 4 H atom. The SAR 
for the 2.17 and 2.18 families showed that compounds with more lipophilic substitutents were 
usually more potent than polar analogs. For instance, the IC50 of p-fluorobenzyl ether 2.17 was 
19 nM, whereas its parent alcohol 2.19 was 230 nM
 
[89]. Also, 2.18 displayed an in vitro IC50 
value of 6.9 nM against chloroquine-sensitive P. falciparum infected red blood cell culture. The 
IC50 value for artemisinin was 9.9 nM. No in vivo data was reported for these analogs. 
Replacement of the C3- methyl in 2.11/2.12 by a C3-phenyl, 2.13, led to enhanced 
potency [83], A series of C3-phenyl analogs were synthesized by the Posner group [85]. A 
number of these 3-aryl trioxanes, including 2.20 and 2.21 (Figure 16) had promising antimalarial 
activities. For example, The IC50 of 2.20 against chloroquine-sensitive P. falciparum (NF54) 
parasites was 30 nM and the in vivo ED50/ED90 in P. berghei-infected mice was 6.8/13 
mg/kg/day (sc) and 10/23 mg/kg/day (po).  
In addition, a number of sulfide, sulfone, and sulfonamide 3-aryl substituted analogs of 
2.20 were synthesized 
 
[90]. When these analogs were tested in vitro against the chloroquine-
sensitive strain NF-54 of P. falciparum IC50s values ranging from 33 to 92 nM were observed to 
be only slightly less potent than 2.20
 
[90]. No in vivo testing was conducted for these derivatives.
 
Trioxane alcohol 2.21 was 3-fold less potent than artemisinin with in vitro IC50 15 nM and in 
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vivo ED50/ED90 in P. berghei-infected mice was 3.4/6.8 mg/kg/day (sc) and 5.5/12 mg/kg/day po 
which is similar to 1.7. The potential metabolite of 2.21 and the more water-soluble trioxane 
carboxylic acid 2.22 was 3-fold less active than 2.21 and an order of magnitude less potent than 
1.7 when it was administered subcutaneously to P. berghei-infected mice (Error! Reference 
ource not found.). The ED50/ED90 values were 11/20 mg/kg/day (sc) and 17/48 mg/kg/day (iv)
 
[91]. No in vitro data for 2.22 was reported.  
Carboxyphenyl trioxanes 2.23 and 1.20, analogs of 2.22 were synthesized (Error! 
eference source not found.). No in vitro data was reported for both analogs because the in vitro 
antimalarial testing commonly shows very low activity for water-soluble trioxanes [32].The in 
vivo testing, however, was conducted for both 2.23 and 1.20 against P. berghei-infected mice via 
oral administration and the ED50/ED90 values  for 2.23 were 17/59 mg/kg/day and for 1.20  were 
mentioned earlier (Figure 5) which were only 3- to 4-fold less effective than artemisinin. 
The principle conclusion that was derived from the activities of the synthetic peroxides in 
Figure 16 was that the intact tetracyclic artemisinin scaffold is not vital for antiparasitic action. 
From a historical perspective, the SAR that Posner derived from his trioxanes was: (i)  analogs 
substituted at C-4β which stabilize radicals formed by intramolecular 1,5~H abstraction (e.g., 
2.17 and 2.18) are better antimalarials than the unsubstituted analogs 2.11 and 2.12; (ii) C4α-
substituted epimers where 1,5~H shift is impossible inactive; (iii) increasing overall lipophilicity 
leads to an increase in potency (e.g., 2.11 vs. 2.14); and (iv) replacement of the C3- methyl by 
aryl group leads to increased potency (e.g., 2.11 vs 2.13). However, Posners conclusions in 
regards to the necessity of intramolecular 1,5~H transfer were important 25 years ago, and gave 
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many researchers food for thought, and may even hold true under certain circumstances. 
However, today the prevalent mechanistic fate of artemisinin upon exposure to transition metals, 
either chelated (thiols, porphyrins) or free (FeX2), appears to be centered about the C3-C4 radical 
cleavage pathway (e.g., Scheme 5, 1.45; Scheme 6, 1.46 to 1.47). The increased potency of 4-
substituted trioxanes is likely due to enhanced C3 and/or C4 radical stabilities, while the lack of 
activity of 4 alkyl-substituted trioxanes is likely due to steric hindrance of the peroxide O 
and/or ionic repulsion of the transition metal by the hydrophobic -substituent.   
2.3. SPIRORING –FUSED 1,2,4-TRIOXANES 
As illustrated in Figure 17, while exploring the SAR for artemisinin 1.7, a spiro ring-
fused 1,2,4-trioxane 2.24 was synthesized. When it was tested in vitro against P. falciparum,  the 
IC50  value was 7.5 nM  which was only marginally less potent than 1.7 [74]. No, in vivo data was 
reported. When the spirocyclopentane ring was substituted with geminal methyl groups, the 
formed analog was 9-fold less potent than 2.24 [83] [92].  Evaluation of a large series of cis-
fused cyclopenteno-1,2,4-trioxanes,  led to identification of  a lead candidate Fenozan B07 2.25 
[93]. The SAR of this trioxane family was disclosed by Jefford, et al., [92] [94] [95].  Fenozan 
B07 2.25
 
when tested in vitro, the IC50 was 7.3 nM and when tested in mice infected with P. 
berghei, was equally active both orally and subcutaneously with ED50/ED90 values were 2.5/6.0 
mg/kg/day (sc) and 2.5/6.0 mg/kg/day (po) which was effective as artemisinin. The IC50 of 2.26 
was 2.8 nM which seemed more active than 2.25. However, when it tested in vivo was less active 
than 2.25 with ED50/ED90 13/25 mg/kg/day (sc) and 25/75 mg/kg/day (po). Obviously, the 
activity was improved by the p-fluoro substitution.  
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Figure 17: Spiro ring-fused 1,2,4-trioxanes. 
In addition, 3,3-spirocyclopentane 2.26 exhibited greater antimalarial profiles than its 
analogue 3,3-spirocyclohexane  2.27 in which the IC50 was 11 nM and ED50 was > 10 mg/kg/day 
(sc). When a spiropyran substitutes the spirocyclohexane, potency was regained for 2.28 with 
IC50 3.3 nM and ED50/ED90 6.8/20 mg/kg/day (sc).  
Allylic alcohol 2.29 with IC50 2.4 nM and ED50/ED90 29/42 mg/kg/day (sc) and its related 
enone were as potent as 2.26. Cyclohexene trioxane 2.30 with IC50 370 nM was less potent than 
its cyclopentene homolog 2.26 by two orders of magnitude. No in vivo data was reported. 
Because of the outstanding activity profile among all cis-fused cyclopenteno-1,2,4-trioxanes, 
Fenozan B07 2.25 was chosen for further development
 
[94, 96, 97].  
When 2.25 was administered to malaria-infected mice, noticeable ultrastructural 
alterations in the membranes and ribosomes of trophozoites, young schizonts, and immature 
gametocytes were seen. In contrary, little ultrastructural changes in mature gametocytes were 
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detected. No toxicity was observed when it was administered in single 3,000 mg/kg (po) or 600 
mg/kg (sc) doses in mice. Even though having a very promising therapeutic profile, 2.25 has not 
yet advanced to the level of clinical development  [3].  
2.4.  SPIRO 1,2,4- TRIOXANES                                                
As illustrated in Figure 18, the first four were synthesized in this series were monocyclic and 
spirobicyclic 1,2,4- trioxanes, of which 2.31 was the most potent [98] with IC50 830 nM. No, in 
vivo data was reported. O’Neill, et al., reported 11 spiro trioxanes. Of these trioxane 2.32, was 
the most potent when tested in vitro against chloroquine resistant K1 P. falciparum with IC50 95 
nM  [99], which was an order of magnitude less potent than artemisinin. No, in vivo data was 
reported.  
 
Figure 18:Spiro 1,2,4-trioxanes. 
Singh, et al., disclosed a series of hydroxy diene spiro trioxanes. Of these, 
spirocyclohexyl analog 2.33 and spiroadamantane 2.34 were the most active. When both tested 
in vitro against P. falciparum (NF-54 strain), IC50 values were 440 nM and 93 nM respectively in 
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which the more sterically hindered 2.34 was 4.7-fold more potent than its less sterically hindered 
analog 2.33. No in vivo data was reported for 2.33. When 2.34 was administered intramuscularly  
in 96 mg/kg/day doses to Swiss mice infected with multi-drug resistant P. yoelii was able to cure 
(survival >10 days) all of the malaria-infected mice
 
[100].  
Another series of spiro trioxanes have been synthesized by Singh, et al., [101] [102] 
[103].The SAR trend from in vivo data demonstrated that: (i) the order of efficacy was 
spiroadamantane > spirocyclopentane > spirocyclohexane, (ii) introduction of a methyl group at 
the carbon atom carrying the α-arylvinyl group abrogated activity (e.g. 2.35) (iii) introduction of 
an electronegative group in the benzene ring increases the antimalarial activity (e.g. 2.36). When 
2.36 was administered i.p. to mice infected with P. berghei, at a divided daily dose of 60 
mg/kg/day x 5days, trioxane 2.36 suppressed parasitemia on day 6 post-infection by 100%.  
A recent study by Tripathi, et al., 
 
[104] has shown that 2.36 when administered by i.m. 
route to rhesus monkeys infected with P. knowlesi (W1 strain) with a dose of 80 mg/kg/day × 5 
days it failed to clear the infection after 5 doses. In contrary, the lead candidates in this series 
spiroadamantane trioxanes 2.37 and 2.38, showed 100% protection and cure at 80 mg/kg/day × 5 
days and have the potential for preclinical safety and toxicity assessment.
 
In addition, synthetic 
peroxides could assist in creating a more effective trioxanes to combat  a drug resistant malaria 
[104]. 
2.5.  1,2,4,5-TETRAOXANES                                                              
As illustrated in Figure 19, a series of dispiro 1,2,4,5-tetraoxane  were synthesized by 
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Vennerstrom,  et al.,. Of these, 2.39 was the most active with IC50 30 nM
  
when tested in vitro 
against P. falciparum and  had a curative activity at single doses against P. berghei infected mice 
administered s.c. with ED50 640mg/kg/day
 
[105]. In addition, 2.39 showed synergistic effect with 
chloroquine, quinine, mefloquine, and artemisinin against P. falciparum
 
[106].  In order to 
examine dispiro-1,2,4,5-tetraoxane SAR and to find tetraoxanes with improved oral antimalarial 
activity than 2.39, Vennerstrom, et al., synthesized sixteen dispiro tetraoxane analogs of 2.39. 
Several of these proposed tetraoxanes were inactive or weakly active such as 2.40 and 2.41 
respectively due to steric effects precluding or hindering peroxide bond access to parasite heme
 
[107] [108]. 
Tetraoxane 2.42 when tested in vitro against P. falciparum the IC50 was 42 nM. While its 
potency is similar to 2.39, it had the greatest oral activity of the series. Tetraoxane 2.42 cured 
three out of seven infected mice when it was administered p.o. at a dose 128 mg/kg/day twice a 
day to Dong Y P. berghei-infected mice on days 3, 4, and 5 post-infection. At the same dose, 
only artemether 1.9 was totally curative, but not 2.39 nor artemisinin. In addition, there was no 
correlation between antimalarial activity and neurotoxicity for these synthesized tetraoxanes
 
[107]. 
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Figure 19: 1,2,4,5-tetraoxanes. 
While continuing  their work to enhance the oral antimalarial activity of prototype 
tetraoxane 2.39, Vennerstrom, et al., synthesized eleven dispiro tetraoxanes containing 
unsaturated and polar functional groups
 
[109]. Dispiro tetraoxanes 2.43 and 3.44 were inactive 
when tested in vitro against P. falciparum K1 strains. In contrast, the more lipopholic ethyl ester 
2.45 and methyl ether 2.40 exhibited great in vitro potency with IC50s of 6.2 and 15 nM 
respectively. When 2.45 and 2.46 tested p.o. in mice infected with P. berghei at a single dose of 
100 mg/kg administered on the first day post-infection, these tetraoxanes showed low activity 
compared to artemisinin or 2.39. 
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A series of twelve disubstituted  tetraoxanes,  as shown in Figure 19, were synthesized 
by Kim and colleagues
 
[110]. When tested in vitro against P. falciparum, the range of the IC50s of 
these tetraoxanes was between 20 nM to 200 nM.  The in vitro results revealed that steric and 
electronic properties of the substituents attached to the tetraoxane heterocycle influenced their 
potency. Tetraoxanes 2.47 and 2.48 found the best of these and have a potential of being new 
antimalarial agents. The IC50s were 200 nM and 500 nM respectively and when tested in mice 
infected with P. berghei NK 65 strain s.c., the ED50 was 20 mg/kg/day which was less active 
than artemisinin (ED50 = 5.4 mg/kg/day)
 
[110].  
Solaja, et al., synthesized a series of mixed tetraoxanes bearing spirocycloalkane and 
spirocholic acid-derived steroid substructures as a carrier as illustrated in Figure 19.  The cholic 
acid derived carrier was predicted to reduce solubility under physiological conditions and to 
increase cell membrane permeability because of its amphiphilic character [111]. The lead 
candidate from this group was 2.49 (IC50 (W2) = 0.58 nM) which was 6 times more potent than 
artelinic acid (IC50 (W2) = 3.30 nM) and 2.5 times more potent than arteether (IC50 (W2) = 1.4 
nM). No in vivo data for any of these mixed tetraoxanes was released
 
[111]. The SAR trend of 
these tetraoxanes showed that: (i) mixed tetraoxanes with a spirocyclohexane were more potent 
than spirocyclopentane and spirocyclooctane analogs (ii) tetraoxane amides were more potent 
than their corresponding esters and acids (iii) stereochemistry and substitution at C(4″) position 
was very crucial for antimalarial potency (methyl improved the activity against both P. 
falciparum clones, in comparison to the ethyl group) (iv) mixed tetraoxanes were mostly more 
active against the W2 strain of P. falciparum than D6. 
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In order to develop a drug candidate with improved solubility and bioavailability profiles 
than their 1,2,4-trioxolane or 1,2,4-trioxane counterparts, O’Neill, et al., synthesized and 
screened over 150 novel 1,2,4,5- tetraoxanes [112]. The lead drug candidate of these with 
outstanding in vitro and in vivo antimalarial activity, pharmacokinetics, drug metabolism, 
stability, and low toxicity was piperidinyl piperazine functionalized tetraoxane 2.50 (RKA 182) 
as shown in Figure 19. When tested in vitro against chloroquine sensitive (3D7) and resistant 
strain (K1) of P. falciparum, the IC50 values were 0.8 nM and 1.1 nM respectively. Artemether 
(IC50 against P. falciparum 3D7= 7.8 nM and K1= 3.2 nM) and chloroquine (IC50 against 3D7= 
12.5 nM and K1= 250 nM). When RKA 182 administered p.o. in mice infected with the P. 
berghei ANKA parasite, the ED50/ED90 = 1.33/4.18 mg/kg/day (artemether, ED50/ED90 = 
3.80/12.24). At a dose of 3 x 10 mg/kg/day at day 4 post-infection, the % suppression of 
parasitemia was 99.99%. The oral bioavailability of RKA 182 was 38% in the rat and 42% in the 
mouse models. Regardless of good in vitro and in vivo data (IC50 values < 6 nM against both 
3D7 and K1 strains of P. falciparum and ED50/ED90 values of < 3.5/ 9.5 mg/kg/day), tetraoxanes 
2.51, 2.52 and 2.53 were excluded from any further studies because of the poor bioavailability 
and a very short half-life. 
Tetraoxane pharmacophore exemplified in 2.50 (RKA 182) can offer the next generation 
of synthetic drugs to control and eradicate malaria as an element of combination chemotherapy 
[112].  
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2.6.  SPIROCYCLIC 1,2,4-TRIOXOLANES 
As illustrated in Figure 20, dispiro-1,2,4-trioxolanes are one of the great discoveries of 
fully synthetic endoperoxides. These simple, easily scalable endoperoxides have been 
synthesized by Vennerstrom, et al., [113, 114]. The first four trioxolanes of five were 
synthesized as initial efforts to understanding the SAR of these ozonide class-type compounds. 
The result of this study showed that the antimalarial activity is associated with the accessibility 
of Fe(II) species to the peroxide bond of the molecule. Albeit, the less sterically hindered 
peroxide moiety of 2.48 exhibited in vitro antimalarial activity, the sterically hindered 2.49 was 
nearly inactive. All in vitro studies of these trioxolanes were conducted against the K1 strain of 
P. falciparum and the in vivo activity was measured as a clearance or percent reduction in 
parasitemia on day 3 post infection of P. berghei infected mice dosed p.o. Cures (%) calculated 
as the survival of infected mice at day 30. The IC50s of artemisinin and artemether were1.6 and 
0.74 ng/ml respectively and parasitemia clearance were 99.99% at dose 100mg/kg  p.o. for both 
and cures 60 and 100% respectively.  
When tested in vitro the IC50 value of 2.54 was 100 ng/ml and when administered in vivo 
at 100 mg/kg, the clearance was 0%. The IC50 value of 2.55 was 950 ng/ml and when 
administered in vivo the clearance was 0%. A good balance between hindrance and accessibility 
of the peroxide bond is presented in 2.56 and 2.57 in which one side of the trioxolane is sterically 
hindered whereas the other permits for an interaction of iron (II) with a less sterically hindered 
peroxide oxygen atom.  
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Trioxolanes 2.56 and 2.57 with IC50s of 0.97 and 0.48 ng/ml respectively and clearance of 
99.99% each; these activities were comparable to artemisinin controls. Trioxolanes 2.58 and 2.59 
were found inactive as 2.55 and the authors claimed that this was due to steric hindrance to the 
electron transfer from iron (II) to the peroxide bond. We find this argument to be unacceptable as 
the suspect substituents were far removed from the peroxide bond and furthermore, all of the 
other 4-substituted cyclohexyl derivatives such as the OZ compounds were potent antimalarials 
(e.g. 2.63 is just as hindered to the approach of Fe(II) as 2.59). Of the nonpolar series, 2.54-2.59, 
it seems more likely that 2.58 and 2.59 were sufficiently less soluble and perhaps came out of 
solution. At the high dilutions of the test conditions, it is frequently hard to visually determine 
solubility problems.  
In continuation of their work toward identifying a trioxolane development candidate, 
Vennerstrom and colleagues synthesized 2.60 and 2.61 to improve aqueous solubility and 
enhance oral bioavailability for the prototypes 2.56 and 2.57. For instance, trioxolane 2.57 
showed low aqueous solubility (<1 µg/ml) and low oral bioavailability (<1%) in rats
 
[114]. The 
IC50 value of 2.60 was 34 ng/ml, clearance was 50% at dose 3mg/kg/day and the oral 
bioavailability was 74.1% (50mg/kg). 
Trioxolane 2.61 delivered an excellent combination of antimalarial activity with a good 
oral bioavailability in rats. Its IC50 was 0.39 ng/ml, clearance was 99.99% at dose of 
30mg/kg/day, cures 100% and the oral bioavailability was 27.5% (18.8mg/kg). Moreover, 2.61 
has shown prophylactic activity against malaria parasites
 
[114]. In this study, artesunate IC50 was 
1.3 ng/ml, clearance was 97% at dose 30mg/kg/day and cures 0%.  
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Figure 20 Spirocyclic 1,2,4-trioxolanes. 
The synthesis of carboxylic acid and primary amine containing-trioxolanes as in 2.60 and 
2.61 as shown in Figure 20 facilitated in applying  numerous chemical modifications to 
synthesize several derivatives, among which was trioxolane 2.62 (also known as OZ277, RBx-
11160 or arterolane maleate), the first ozonide that reached clinical trials. With an IC50 of 0.7 
ng/ml, it showed a comparable in vitro activity to artemether (IC50 = 1.3 ng/ml). At a dose of 30 
mg/kg/day, OZ277 clearance was 99.99% but only cures 67% with an oral bioavailability of 13 
% (3 mg/kg). In addition, further screening using the P. berghei murine model showed that 
OZ277 demonstrated an extended duration of action compared with artesunate and artemether. 
 Due to an improved toxicological profile and proof for decreased concentrations in brain 
tissue after oral dosing, OZ277 was selected as the development candidate over trioxolane 2.61 
regardless of the fascinating activity of trioxolane 2.61. Studies showed that reaction of OZ277 
with endogenous sources of Fe(II) in blood and tissues was a possible mechanism for the rapid 
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clearance of OZ277. Its half-life when incubated in healthy rat blood at 37°C was about one hour 
(h), decomposing to adamantane lactone and substituted cyclohexanone [115]. 
In 2012, OZ277 was approved in India as a combination product with piperaquine phosphate 
(Synriam) for the treatment of malaria
 
[116]. 
When the metabolically labile amide function of OZ277 was substituted by the 
morpholino ethoxyphenyl group, it led to the discovery of the new drug candidate 2.63 (ozonide 
OZ439). The IC50 was 1.6 ng/ml, clearance was 99.99% at dose 30mg/kg/day, cures 100%, the 
oral bioavailability was 76.0 % (3mg/kg) and had a half-life of 23 h after oral dosing to rats (3 
mg/kg). On the other hand, the half-life for DHA was ∼0.5 h and 1 h for 2.62 following oral 
dosing to rats. In this study, artesunate IC50 was 1.2 ng/ml, clearance was 92% at dose 30 
mg/kg/day and cures 0%. Interestingly, OZ439 exhibited in vivo prophylaxis activity at dose 1 × 
30 mg/kg p.o. given 24 h before infection to P. berghei-infected mice. Neither artesunate nor 
OZ277 had the prophylaxis activity at the same dose
 
[115]. 
In a comparison study between the stability of OZ277 and OZ439 when they were 
incubated at 37 °C in plasma containing suspended human red blood cells, non-infected or 
infected with P. falciparum, revealed that about 70% of OZ439 remained untouched after 2 h. In 
contrast, only 50% and 7% of OZ277 withstood decomposition throughout the same time period 
in the non-infected and infected suspensions, respectively [76] [115] 
The improved biopharmaceutical profile of the drug candidate OZ439 with the potential 
to provide a single dose cure of malaria as well as illustrating a good safety profile in phase I 
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clinical trials, OZ439 is currently in phase II trials
 
[117].  
2.6.1. REACTIONS WITH IRON (II) 
To test the electronic and steric effects in dispiro-1,2,4-trioxolane that influences the 
formation of  one of two possible oxy radicals which was created by delivery of an electron from 
Fe(II) to the peroxide bond antibonding σ* orbitals. Upon reaction of 2.56 with FeBr2 in THF, 
the formed products resulted from the major (Fe(II) bind to O1) and minor (Fe(II) bind to O2) 
reaction pathways as in Scheme 16. 
Compounds formed from the reaction were: the lactone 2.66 (64%), the bromo-acid 2.68 
(2%), the olefinic acid 2.69 (6%) and bromocaproic acid 2.75 (3%)
 
[76, 118].The ratio of the 
formed ketones, cyclohexanone 2.67 and 2-adamantanone 2.74 demonstrated that Fe(II) 
preferred attack on the less hindered peroxide bond oxygen atom (O1) of cyclohexane over the 
adamantine by 22:1. 
In addition, the indication for the secondary radical 2.65 was attained by adding the 
radical trap 2,2,6,6-tetramethyl-4-oxopiperidin-1-oxyl (4-oxo-TEMPO) to the reaction mixture. 
When 2.56 was treated with 1.5 equivalents of each of FeBr2 and 4-oxo-TEMPO, it formed the 
expected trapped radical 2.76 but only in a 7% yield. However, the main product was 2.66 (70%) 
followed by 2.68 (8%), 2.69 (3%), and 2.75 (6%). 
 Repeating the reaction using 1.5 equivalent of ferrous acetate, which has a non-
nucleophilic counterion and 2 equivalent of 4-oxo-TEMPO in 1:1 CH2Cl2/CH3CN, the yield of 
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2.76 was enhanced to 56% followed by 2.66 and 2.69 in yields of 28 and 6% respectively. 
Formation of the lactone 2.66 is possibly due to the nearness of the secondary radical of 2.65 to 
the ester group. Attack by the carbonyl group of 2.65 along with loss of ferrous ion in a 
concerted radical fashion, could generate 2.66 and 2.67. With simultaneous oxidation of 2.65 by 
ferric ion to the oxonium cation 2.70 could result to a lesser extent. When presented, bromide ion 
can react with 2.70 and forms 2.68. Competitive deprotonation of 2.70 could generate 2.69. The 
minor pathway for the reaction of 2.56 with FeBr2 pursues a comparable mechanistic pattern. 
The primary carbon radical 2.72, generated by scission of the first-formed oxy radical 2.71, 
oxidized  to 2.73 followed by the addition of bromide ion, loss of ferric ion, and protonation, 
forming adamantanone 2.74 and bromocaproic acid 2.75
 
[76, 118].  
Scheme 16: Proposed mechanism of the reaction of dispiro-1,2,4-trioxolane with Fe(II). 
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CHAPTER III 
SYNTHESIS, CHEMISTRY, BIOLOGICAL EVALUATION AND 
STRUCTURE-ACTIVITY RELATIONSHIPS OF RAC- AND CHIRAL 6-
DESMETHYL-5β –HYDROXY-D-SECOARTEMISININ AND ANALOGS 
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3.1.AIM OF THIS STUDY 
Artemisinin 1.7 and many of its derivatives are highly effective against the most lethal 
drug-resistant strain of P. falciparum malaria in vitro
 
as mentioned earlier. In vivo activity does 
not always follow in vitro SAR and this is an important issue in antimalarial drug design. Over 
the past forty years, SAR of artemisinin and many abbreviated derivatives has encompassed 
modification at positions 3, 6, 7, 9, 10, 11 and 13, but notably, the C4 and C5 positions have 
remained synthetically elusive due to the absence of accessible functional groups at these 
positions. Earlier work in our group has shown that many analogs modified at C-9 (technically it 
is the C-16 methyl group that is being homologated hence modification occurs at the C-16 
position) of artemisinin had improved physiochemical properties as well high antimalarial 
activity (in some cases, 20-50 fold enhancement of antimalarial potency in vitro).  
Herein synthesis of 6-Desmethyl-5β–Hydroxy-D-Secoartemisinin, a (1,2,4-trioxane) that 
retains the A, B and C rings of artemisinin, can offer an opportunity to explore SAR about the C5 
position. Because the mechanism of action (MOA) of artemisinin and related 1,2,4-trioxanes 
seems to be related to a C4 radical by Fe(II)-mediated O1-O2/C3-C4 ring cleavages, rational 
modifications at C5 would be expected to test the proposed the molecular mechanism of action 
(MMOA) and provide additional SAR to complement known modifications elsewhere in the 
backbone of the natural product. 
3.2. SYNTHESIS OF 6-DESMETHYL-5β –HYDROXY-D-SECOARTEMISININ 
Synthesis of the racemic mixture 3.7 (rac-3.7) was reported in 2012 by Wu, et al., [119] 
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with no further follow up of SAR by these researchers, we decided to synthesize rac-3.7 in order 
to use the C-5OH as a handle from which to make derivatives at C5 for SAR, and hopefully 
QSAR.  In addition, owing to the importance of the C-4 radical, modification at C-5 or perhaps 
C-4 would provide molecules to test our mechanistic hypotheses (1.3 Mechanism of Action, b. 
cysteine hypothesis; c. PfATP6/SERCA hypothesis). In addition, Wu conducted a chiral 
synthesis of 3.7 using L-proline to promote a chiral aldol condensation. The chiral structure 
reported by Wu was enantiomeric relative to artemisinin (i.e., 3S). We found this to be a surprise 
as no comment was made about the issue. We determined to synthesize both enantiomers, and by 
a combination of x-ray crystallography and bioassay, put the issue to rest, i.e., why did Wu et al., 
make the wrong enantiomer and not comment on it? Furthermore, are enantiomers of structures 
closely related to the ring structure of artemisinin of equal activity as reported by Posner et al.? 
We found in our ensuing efforts that many of the yields reported by Wu were not reproducible, 
even after extensive repeats of his reported procedures.  At one point, we actually contacted Prof. 
Wu for details regarding some reactions he reported, but his reply was to simply send us the 
same experimental procedure from the publication. This was a distressing evasion indicating that 
Wu had no answer for the unreproducible reactions we queried him about. We have a high 
overall opinion of Professor Wu and our goal is not punitive, but in retrospect, he most likely had 
an unscrupulous former graduate student(s) who reported grossly overinflated yields. For 
example, the chiral aldol reaction utilizing L-proline was reported to yield 30% of the chiral 
aldol adduct (3.23, Scheme 17), yet neither the author of this dissertation nor his advisor (Prof. 
Avery) were able to obtain more than a 10% yield. One can imagine that a desperate graduate 
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student could scale the reaction up to hundreds of grams in order to obtain enough aldol adduct 
to eventually generate enough (+)-3.7b to conduct structural analysis for publication purposes 
(Scheme 17). 
Scheme 17: Wu et al., reported chiral synthesis of 3.7b. 
 
Reported yield of 3.23: 30% (Wu et al.).  Actual Yield: 10% (Avery, Jihan, this dissertation). 
The reported route to 3.7 was attempted as follows (see Scheme 18). Repeating the 
reported synthesis, ethyl acetoacetate was ketalized under Dean-Stark conditions with ethylene 
glycol and p-toluenesulfonic acid monohydrate (p-TsOH•H2O) in benzene with azeotropic 
removal of water to produce 2-carbethoxymethyl-2-methyl-dioxolane 3.1 [120] which was then 
reduced to the aldehyde 3.2 using diisobutylaluminium hydride (DIBAL-H). The aldehyde 
underwent anti-selective aldol condensation with the lithium enolate of cyclohexanone to form 
the expected alcohol 3.3. The labile β-hydroxy group was protected as the tert-butyldimethylsilyl 
ether 3.4 which then underwent direct conversion to the spiro-epoxide 3.5 via the Corey-
Chaykovsky reaction [121]. This labile, unexpectedly volatile epoxide was then ring opened 
using ethereal hydrogen peroxide and a molybdenum catalyst [122] (sodium molybdate 
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dihydrate (Na2MoO4·2H2O)/glycine)) affording the unstable hydroperoxide 3.6. Finally, 
simultaneous deprotection, dehydration, desilylation and ring closure were affected readily in a 
one-pot reaction with p-TsOH•H2O in undried dichloromethane (DCM) to give racemic 1,2,4-
trioxane 3.7 as a stable, crystalline solid [119] in 32 % yield as shown in Scheme 18. 
Scheme 18: Schematic representation of the synthetic rout of rac-3.7. 
 
 
Reagents and conditions: a) DIBAL-H, -78 
o
C, DCM; b) cyclohexanone, LDA, THF, -78 
o
C; c) 
TBS-Cl, 2,6-Lutidine, DMF, at 0 
o
C to r.t., for 15 h; d) NaH, Me3S
+
I
-
, DMSO, THF, 
e)H2O2/ether, Na2MoO4/glycine; p-TsOH, DCM, r.t. 
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Scheme 19: Proposed mechanism of rac-3.7 formation. 
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During the synthesis of 3.7, numerous challenging steps were encountered such as very 
low stability of intermediates on silica gel, (e.g., epoxide 3.5 and hydroperoxide 3.6) such that 
scaling-up the reaction resulting in unpredictable results with low yields. Some of the 
compounds were amazingly volatile and some of the low yields were due to attempted solvent 
removal under high vacuum. Initially, these low yields were blamed on chromatographic 
instability, but it was later found that some intermediates evaporated under vacuum. A good 
example is the unexpected volatility of the epoxide 3.5 (C19H38SiO4, MW 358) which slowly 
evaporated at room temperature under 5 mm Hg vaccum (hours).  
To synthesize the ketal ester 3.1, ethyl acetoacetate, 2.98 molar equivalents (equiv) of 
ethylene glycol and catalytic amount of p-TsOH•H2O was refluxed in benzene for 5 h. The crude 
product 3.1 was purified by vacuum distillation (20-25 mbar, 109-110°C) to afford the 3.1 in 
83% yield as a viscous clear oil.   
Within the literature [120], the ketal ester was converted to the aldehyde by first reducing 
to the corresponding alcohol 3.2a (Figure 21) with lithium aluminium hydride (LAH) in dry 
THF at  ̶ 5 to 0 °C. The resulting alcohol was subsequently oxidized to the aldehyde 3.2 using a 
Swern oxidation (dry DMSO, 1,29 equiv of oxalyl chloride and 3.9 equiv of triethylamine (Et3N) 
stirred at  ̶ 78 °C to r.t.). As this procedure was somewhat tedious on large scales, we decided to 
use DIBAL-H as a reducing agent that converts the ketal ester 3.1 directly to the aldehyde 3.2 in 
a one step-reaction involving the use of DIBAL-H (1.29 equiv) in dry DCM at  ̶ 78 °C. 
Distillation under vacuum (41mbar) at 98-100°C affords 3.2 in 76% yield. Generally speaking, 
direct conversion of esters to aldehydes with DIBAL-H gives variable results, but with this 
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substrate, the product is produced cleanly if conducted carefully. We feel this is likely due to 
stabilization of the intermediate ketal-aluminate 3.1a by intramolecular chelation of a ketal 
oxygen atom with the empty p orbital of Al(III) as shown in Figure 21. 
 
Figure 21: Stabilization of the aluminate intermediate 3.1a during reduction of ester 3.1. 
As mentioned in the literature [119] synthesis of aldol product 3.3 was performed by 
generating  lithium diisopropylamide (LDA) in situ by reaction of 1.1 equiv of n-butyllithium (n-
BuLi) and diisopropylamine (i-pr2NH) in dry THF at 0 °C. Then, 1 equiv of cyclohexanone and 
hexamethylphosphoramide (HMPA) and subsequently aldehyde 3.2 were added at  ̶ 78°C to the 
stirring mixture. However, when the reaction was run using the same condition, a mixture of 3 
fractions was collected with retardation factors (Rf) of 0.21, 0.35 and 0.50 on thin layer 
chromatography (TLC). The fractions were separated and confirmation was provided by nuclear 
magnetic resonance (NMR) and infrared (IR). Data interpretation revealed that none of these 
fractions yielded the expected aldol product. 
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On the other hand, when the same reaction was run without HMPA and a kinetic quench 
was applied by addition of 2 equiv of acetic acid at  ̶ 78 °C to the reaction mixture of aldehyde 
3.2 and cyclohexanone, the expected aldol product 3.3 was formed as a colorless oil in 66% yield  
In order to protect the labile β-hydroxy group in 3.3, first we used 1.2 equivalent of N,N-
diisopropylethylamine (DIPEA) as non-nucleophilic base, 1 equiv of tert-butyldimethylsilyl 
trifluoromethanesulfonate (TBDMS triflate) in dry DCM at 0 °C to r.t., for 12 h. The tert-
butyldimethylsilyl ether 3.4 was formed but in a tiny amount. Thus, we decided to use 1.5 equiv 
of DIPEA and 1.5 equiv of tert-butyldimethylsilyl chloride (TBSCl) in dry dimethylformamide 
(DMF) at ambient temperature for 12 h. The expected product was not formed. When changing 
the base from DIPEA to 1.5 molar equivalents of 2,6-Lutidine, and using 1 equiv of TBDMS 
triflate in dry DCM for 12 h at ambient temperature, the expected product was not formed either.  
Three reactions were performed at the same time using the same conditions in the three 
reactions with some exceptions:  in the first reaction, we used 1equiv of 2,6-Lutidine and TBSCl  
in dry DMF at 0 °C to r.t., for 15 h. In the second reaction, the same condition was conducted 
except 1equiv of imidazole instead of 2,6-Lutidine. In the third reaction, however, the number of 
equivalents of 2,6-Lutidine and TBSCl were increased to 4.9 and 1.5 respectively and reaction 
time reduced to 12 h. All reactions did not complete until a catalytic amount of 4-
Dimethylaminopyridine (DMAP) was added to the three reactions for 3 more hours. Thus, we 
decided to use the same reaction conditions as in the third reaction i.e., 2,6-Lutidine and TBSCl 
in 4.9 and 1.5 equiv respectively in the presence of catalytic amount of DMAP in dry DMF at 0 
°C to r.t., for 15 h to afford 3.4 as a colorless oil in 72% yield.  
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To synthesize the epoxide 3.5, we tried a modified method of Corey–Chaykovsky 
epoxide synthesis or instant methylide method [123] (methylides are created in the presence of 
the carbonyl substrate) in which the methylides (Me2SO=CH2 and Me2S=CH2) were generated 
from reactions of 2 equiv of trimethylsulfoxonium iodide (Me3S(O)
+
I
-
) and potassium tert-
butoxide (KOt-Bu) and 3 equiv of trimethylsulfonium iodide (Me3S
+
I
-
) and sodium hydride 
(NaH) respectively. Upon addition  of  DMSO or DMSO/THF solution of 3.4 at 50-60 °C for 1 h 
and at 0°C to r.t., for 6 h, both reactions afforded epoxides but in low yields of 20 and 30 % 
respectively. Due to the low yields of the instant methylide method, we decided to use the 
standard Corey–Chaykovsky reaction [119, 121] in which NaH deprotonates an anhydrous 
DMSO to form a powerful Brønsted base, sodium methylsulfinylmethylide (dimsyl sodium), 
which then deprotonates Me3S
+
I
-
 (in DMSO/THF) and generates the methylene transfer agent 
Me2S=CH2. Subsequent treatment with ketone 3.4, at 0 °C to r.t., for 8 h afforded the epoxide 3.5 
in 54% yield. As mentioned elsewhere, the epoxide crude yields never gave reasonable product 
quantities based on TLC, after chromatography and vacuum drying. Eventually, we realized that 
the epoxide was quite volatile under high vacuum. 
The introduction of the key peroxy bond was conducted via perhydrolysis of the epoxide 
3.5 and formation of the β-hydroxy hydroperoxide 3.6. The epoxide 3.5 was treated with ethereal 
hydrogen peroxide
a
 and 11 mol % of phosphomolybdic acid hydrate (PMA) at ambient 
temperature for 12 h, afforded crude yellow oil of hydroperoxide 3.6 in 55%  yield. Caution: 
Even though no explosions were experienced in this work, generally speaking organic peroxides 
are potentially hazardous compounds and must be dealt with an extra care: Avoid direct exposure 
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to strong heat or light, mechanical shock, oxidizable organic materials, or transition-metal ions. 
A safety shield should be used for all reactions involving H2O2. 
Ethereal hydrogen peroxide was prepared using a literature[124, 125]  procedure:  
Et2O (50 mL) was poured in  a separatory funnel and washed with four portions (30 mL 
each) of NaCl-saturated H2O2 (prepared by stirring the commercially available 30% aqueous 
hydrogen peroxide with an extra amount of powdered NaCl at ambient temperature until the 
initially cloudy liquid phase turn into a clear solution; the supernatant was used; conducted 
behind a safety shield). The ethereal layer was then dried over anhy MgSO4. The supernatant 
was used directly in the PMA catalyzed perhydrolysis of epoxide. In order to increase the yield 
of the β-hydroxy hydroperoxide 3.6, a catalyst prepared from reaction of sodium molybdate 
dihydrate (Na2MoO4·2H2O) and glycine [119, 122]was added in 50 mol % to a mixture of 
epoxide 3.5 and ethereal hydrogen peroxide at ambient temperature for 12 h to afford the 
hydroperoxide 3.6 as clear yellow oil in 61 % yield without conducting column chromatography 
purification.  
3.2. X-RAY CRYSTALLOGRAOHY VERIFICATION 
The synthesis of the racemic mixture rac-3.7 was conducted with no modification in 
which 3.6 was treated by a catalytic amount of p-TsOH•H2O in DCM for 24 h to afford racemic 
3.7 in 32 % yield. Without crystallization, a white amorphous powder was obtained, however, 
upon recrystallization with hexane/EtOAc, nice crystals of 3.7 were obtained as needles. 
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A single crystal X-ray diffraction analysis was conducted to verify the structure of rac-
3.7. The X-ray confirms that the crystal structure of the rac-3.7 is an orthorhombic (P2l2l2l) with 
cell dimensions of a=5.7823 Å, b=7.6135 Å, and c =23.795 Å. The total volume of the unit cell 
is 1047.5 Å. It also confirmed that a hydrogen bond was present between H4O and O1 with a 
total length of 19 Å. In addition, a crystal structure was also generated for better visualization 
utilizing commercially available molecular software (Sciencomics, MAPS 3.4). The *cif 
coordinates file (generated from the X-ray analysis) was imported to molecular dynamics 
software and the atomic representation is shown in Error! Reference source not found.. The 
tomic structure is represented by the following color code: hydrogen white balls, carbon is grey 
balls and oxygen is blue balls. The hydrogen bond is also evident as represented by the dashed 
line (See Figure 22). 
 
 
 
 
 
 
 
 
 
Figure 22: X-ray crystallography confirmation and hydrogen bond presence. 
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Analysis of 3.7 by simple MM2 molecular mechanics, Figure 23, revealed the 
importance of the intramolecular H-bond in stabilizing the structural energy. The difference of 
nearly 2 Kcal/M between H-bonded and the non–bonded rotamer corresponds to an almost 
exclusive intramolecular H-bond (IMHB) in 3.7a. The significance of this H-bond in dictating 
the reactivity of 3.7 came as somewhat of a shock for surely solvent changes should have 
affected the extent of IMHB, but we were haunted by the abnormal reactivity of 3.7 as will 
become apparent in the following pages. 
 
Figure 23: Molecular mechanics calculations regarding the intramolecular H-bond in 3.7. 
Continuing the analysis of conformational effects, we noticed that two ring-flipped 
variants existed for artemisinin, both trioxane rings adopting a boat conformation. One of these, 
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the lower E variant we referred to as O1-UP because O1 is higher than O2 and both O1 and O13 
are shown as the stem and stern of the A-ring boat. That is, O1-C12a-C12-O13 forms the right 
side of a trioxane boat while O1-O2-C3-O13 form the left side of the trioxane boat. As shown in 
Figure 24, this is illustrated as (+)-artemisinin1UP. Its E in MM2 (Chem 3D, Perkin-Elmer Ver. 
16.0.1.4, 2017) is 60.32 Kcal/M. With some difficulty, the local minima (+)-artemisinin1DOWN 
has O1 and O13 in downward positions (the boat flipped over relative to 1UP) can be formed 
and its E was 6 Kcal/M higher than the other boat version representing the global minimum and 
corresponding to the X-ray of the natural product. 
 
Figure 24: Trioxane boat minima from MM2 force field calculation. 
Similar conformational effects can be seen for 3.7a in which O1 is up and O2 is down 
(Figure 25). Now the E is 48.7 Kcal/M which is higher than the O1 down/O2 up conformer and 
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no H-bond is possible (5 Å distance). The relative E difference between O1 up and O1 down 
with Hbond is 44.3 Kcal/M, or 46.3 Kcal/M without Hbond. Clearly, the heavily preferred 
conformer of 3.7a is O1 up with the IMHbond. How does this compare with artemisinin? The 
same conformation of the peroxide, O1 up, is energetically favored.  
 
Figure 25: Comparisons of ring conformers of 5 vs 5-hydoxy seco derivatives of 3.7. 
It was apparent that for the 5α-hydroxy epimer of 3.7a, that is 3.7a, that the O1down 
conformer would be needed for an intramolecular H-bond to form. Despite having to undergo O1 
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up to O1 down to effect H-bonding in 3.7a, we felt that there would be better steric availability 
for reaction chemistry. As will be discussed, the low reactivity of 3.7 prohibited its inversion by 
Mitsunobu reaction. Reduction of the ketone would still occur from the α-face, giving back 5β-
alcohol (See Figure 26). Hence, as the chemistry evolved, we found that very little could be 
done to 3.7, hampering the anticipated derivatization chemistry needed to build an adequate 
library of compounds for a full QSAR. 
 
Figure 26: Ketone MM2 force field calculation. 
3.3. DEVELOPMENT OF C-5 DERIVATIVES OF 6-DESMETHYL-5β –HYDROXY-D-
SECOARTEMISININ  
Due to structure similarity of 3.7 and artemisinin, and lack of synthetic derivatives of 
artemisinin at C-5 position, derivatization at this position in 3.7 should add to other known 
SAR’s of artemisinin. While a number of esters could be made, other chemistry at this position 
was difficult if not impossible. The combination of a preferred IMHB that also resulted in 
sterically hindering the 5OH limited our SAR efforts. When combined with unexpected 
difficulties in synthesizing the starting alcohol, progress on this program was limited. 
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a. Ester derivatives 
To synthesize a library of ester derivatives, first we tried Steglich esterification, in which 
1.2 equiv of acetic acid and dicyclohexylcarbodiimide (DDC) in presence of 19 mol% of DMAP 
were added to stirring solution of 30 milligrams (mg) of rac-3.7 in dry DCM at ambient 
temperature  for 48 h [126]. The acetate ester 3.8 was obtained, but to our surprise in only trace 
amounts as shown in Table 2. The same esterification reaction and condition mentioned above 
were conducted using 4-bromobenzoic acid instead of acetic acid and 60 mg of rac-3.7. After 48 
h, only a trace of 3.9 was formed even though the reaction mixture was refluxed at 50 °C for 1h.  
When DDC was replaced with 1.2 equiv of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) [127], and added to a stirring mixture of rac-3.7, 1.2 equiv of valeric acid 
and 19 mol-% of DMAP in dry DCM and stirred at ambient temperature for 4 days; TLC 
analysis  showed a slow product formation . After 4 days, an additional amount of all reagents 
were added, and the reaction mixture was stirred for 24 h., but was still exhibited an unreacted 
starting material in the reaction mixture. The mixture was allowed to stir for 1 h at 40 °C. 
Compound 3.10 was obtained only in an 11% yield as illustrated in Table 2 and an unreacted 
starting material 3.7 was recovered.  
In continuing efforts to find a suitable method for synthesis of the ester derivatives from 
3.7, 2 equivalents of benzoyl chloride was added to a suspension of  rac-3.7 and a 2 equiv of 
both N-methylimidazole (NMI) and N,N,N′,N′-tetramethylethylenediamine (TMEDA) in dry 
CH3CN at 0 °C to r.t., for 24 h [128]. It was hoped that the highly basic conditions would result 
in a competition of the H-bond for the diamine. However, reaction progress as monitored by 
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TLC analysis showed that the ester started to form but in only a tiny amount. This reluctance of 
the alcohol to behave in a normal fashion was basically the beginning of the end for all attempted 
chemistries in this project. Reaction progress was monitored by TLC analysis and showed that 
the ester started to form but in a tiny amount. Thus, one more equivalent of all reagents were 
added and reaction progress was monitored by TLC, reaction mixture left stir for 24 h, and 3.11 
was obtained in 42% yield as illustrated in Table 2. When the above condition was modified by 
adding a 4 equiv benzoyl chloride to a suspension of 3.7 and 4 equiv of both trimethylamine 
(Et3N) and DMAP in dry CH3CN at 0 °C to r.t., for 24 h, 3.11 was afforded in 70% yield. When 
the same reaction was repeated, but using 4 equiv of TMEDA instead of Et3N, the yield was a bit 
improved to afford 3.11 in 74% yield [128]. Thus, we decided to use the protocol of 4 equiv 
DMAP/TMEDA, which was used for the rest of the proposed esters in Table 2.  
Table 2: Various esters derived from rac-3.7. 
 
Compound R Yield (%) Compound R 
Yield 
(%) 
3.8 
 
a
Trace 3.13 
 
e
68 
82
  
Compound R Yield (%) Compound R 
Yield 
(%) 
3.9 
 
a
Trace 3.14 
 
e
36 
3.10 
 
b
11 3.15 
 
e
49 
3.11 
 
c
42, 
d
70, 
e
74 3.16 
 
e
Trace 
3.12 
 
e
70 3.17 
 
e
Trace 
Reagents and conditions: a) 1.2 eq (acetic acid/4-bromobenzoic acid)
aa
, 1.2 eq DDC,19 mol% 
DMAP, dry DCM, r.t., for 48 h and 50 °C
aa 
for 1 h ; b) 1.2 eq valeric acid, 1.2 eq EDC, 19 mol% 
DMAP, dry DCM, r.t., for 96 h; c) 3 eq benzoyl chloride, 3 eq N-methylimidazole, 3 eq TMEDA, 
dry CH3CN at 0 °C to r.t., for 24 h; d) 4 eq benzoyl chloride, 4 eq Et3N, 4 eq DMAP, dry CH3CN 
at 0 °C to r.t., for 24 h; e) 4 eq (benzoyl chloride, 4-fluorobenzoyl chloride, 4-methoxybenzoyl 
chloride, cinnamoyl chloride, 4-chlorobenzoyl chloride, propionyl chloride,1-
adamantanecarbonyl chloride), 4 eq TMEDA, 4 eq DMAP, dry CH3CN, 0 °C to r.t., for 24-72 h.    
Interestingly, when we were intended to synthesize 3-methyloctahydro-1H-3,9a-
epidioxybenzo[c]oxepin-5-yl 4-fluorobenzoate, 3.12 and extra equivalents of 4-fluorobenzoyl 
chloride (6 equivalents ) were added and the reaction mixture was allowed to stir for 4 days, 7a-
(acetoxymethyl) octahydrobenzofuran-3-yl 4-fluorobenzoate, 3.18 was formed instead of 3.12 in 
29% yield as shown in Scheme 20.  
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Scheme 20: Formation of ester 3.18 as a rearrangement product.  
 
Reagents and conditions: a) 6 eq 4-fluorbenzoyl chloride, 4 eq TMEDA, 4 eq DMAP, CH3CN, 
0 
o
C to r.t., for 4 days. 
Assignment of structure to 3.18 was based on spectral evidence; it displayed strong 
carbonyl and ether (C-O) stretching in the IR at 1720 and 1273 cm
-1
. In the proton NMR spectra 
which indicated the presence of a methyl ester (δ 2.12). Furthermore, heteronuclear multiple 
bond correlation (HMBC) and heteronuclear single quantum correlation (HSQC) experiments 
confirmed the connectivity shown for compound 3.20. For instance, the C-8 protons at δ 4.60 
(d, J = 12.5 Hz, 1H, CH2a-8), and 4.32 (d, J = 12.5 Hz, 1H, CH2b-8), and the methyl at δ 2.12 (s, 
3H, CH3-11), showed a strong HMBC correlations to C-10, a carbonyl assigned to δ 171.3.  
In retrospect, the formation of the rearrangement product 3.18 was in line with Fe(II) 
catalyzed rearrangement of 3.7 followed by esterification of the alcohol corresponding to 3.18. 
Since peroxide cleavage can occur by a number of transition metals, any traces of contaminant 
under forced conditions as in Scheme 20 would lead to 3.28 (Scheme 25) which would then 
esterify to 3.18. 
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b. Carbamate derivatives 
Several carbamate derivatives were proposed and several attempts were applied to 
synthesize carbamate 3.2, but unfortunately, we were not successful. For instance, when 20 mol 
% of NMI and 2 equiv of phenyl isocynate were added to a stirring solution of rac-3.7 in DCM 
at r.t., for 48 h [129], 3.19 was not formed (Scheme 21). When 1.5 equiv of Et3N and 2 equiv of 
phenyl isocynate were added to a stirring solution of 3.7 in DCM at 75 °C to r.t., for 48 h [130], 
3.19 did not form either. Changing the solvent to CH3CN [131] and keeping the same condition 
mentioned above i.e., 20 mol % of NMI and 2 equiv of phenyl isocynate were added to a stirring 
solution of  rac-3.7 in CH3CN at r.t., for 96 h, did not help and 3.19 was not formed.   
Scheme 21: Schematic representation of the unsuccessful carbamate synthesis. 
 
Reagents and conditions: a) 2 eq phenyl isocynate,  20 mol% NMI, DCM, r.t., for 48 h; b), 2 eq 
phenyl isocynate, 1.5 eq Et3N, DCM,75 °C to r.t., for 48 h; c) 2 eq phenyl isocynate, 20 mol% 
NMI, CH3CN, r.t., for 96 h. 
c. Ketone derivative 
Different methods were applied to oxidize the rac-3.7 to ketone. A mild condition 
including use a combination Oxone (potassium peroxymonosulfate) and TEMPO (2,2,6,6-
tetramethylpiperidine 1-oxyl) can offer an efficient catalyst system to oxidize secondary alcohol 
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3.7 to ketone 3.20. Two different solvent (toluene and DCM) were used to find the optimal 
condition for the oxidation process. Also, tetrabutylammonium bromide (Bu4NBr) will be added 
as an additive. The bromide ion will be oxidized to hypobromous acid (HOBr) by Oxone and 
that the HOBr promptly oxidizes the nitroxyl radical to the ultimate oxidant, an N-oxo 
ammonium ion [132].  Upon addition of 1 mol% of TEMPO and 2.2 equiv of Oxone to a 
solution of the rac-3.7 and 4 mol% of Bu4NBr in toluene, the mixture stirred at r.t., for 5 days to 
afford 3.20 in 40% yield with some unreacted alcohol 3.7. By changing the solvent to CDM and 
increasing the mol% of both TEMPO and Bu4NBr to 10 mol% and 3 equiv of Oxone, helped in 
enhancing the yield to 50%. However, the reaction time was the same as before i.e., 5 days as 
illustrated in Table 3. To increase the yield and decrease the reaction time, and keeping in mind 
to maintain the crucial trioxane system, we investigated a new protocol using an oxidant, 
pyridinium chlorochromate (PCC). When rac-3.7 was dissolved in DCM and added to a 
suspension of 1.5 equiv of PCC in DCM at r.t., for 48 h, 3.20 was obtained in 55% yield [133].  
Table 3: Methods used for oxidation of alcohol. 
 
Compound Method Yield % 
3.20 
a 40 
b 50 
c 55 
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Reagents and conditions: a) 1 mol% TEMPO, 2.2 eq. Oxone, 4 mol% Bu4NBr, toluene, r.t., for 5 
days ; b) 10 mol% TEMPO, 2.2 eq. Oxone, 10 mol% Bu4NBr, DCM, r.t., for 5 days; c) 1.5 eq. 
PCC, DCM, r.t., for 48 h.  
d. Exomethylene derivative 
We envisioned that ketone 3.20 could be converted to exomethylene or exo-olefin, 3.21 
by Wittig reaction with methyltriphenylphosphonium bromide (CH3P(C6H5)3Br) and KOt-Bu 
[134]. We initially conducted the Wittig reaction utilizing 1.25 equiv of commercial 
CH3P(C6H5)3Br, 2.5 equiv of KOt-Bu and 3.20 in dry THF at 0 °C to r.t., for 96 h. This protocol 
led to the expected compound 3.21, but in a trace amount (Error! Reference source not found.). 
hus, we decided to use a new protocol using an excess of both base and phosphonium salt [135]. 
Upon the addition of a solution of 3.20 to a mixture of 9.5 equiv of both potassium 
bis(trimethylsilyl)amide (KHMDS) and CH3P(C6H5)3Br in dry THF at 0 °C to r.t., for 12 h, 3.21 
was obtained in 24 % yield (Table 4). In addition, the Wittig reaction was used to synthesize a 
more stable vinyl substituted trioxane analog 3.22 [135, 136] (Table 4). When a solution of 
ketone 3.20 was added to a suspension of 9.5 equiv of both benzyltriphenylphosphonium 
bromide and KHMDS in dry THF at 0 °C to r.t., for 48 h, 3.22 was formed in a trace amount and 
some of unreacted ketone was recovered.  
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Table 4: Application of Wittig and Tebbe olefination in synthesis of 3.21 and 3.22 
 
Structure  R Wittig Yield % TebbeYield % 
3.21 
 
CH2 
a
Trace ‒ 
CH2 
b
24 ‒ 
3.22 C6H6 
c
Trace ‒ 
3.21 
CH2 ‒ dDecomposition 
CH2 
e
22 ‒ 
Reagents and conditions: a) 1.25 eq CH3P(C6H5)3Br, 2.5 eq KOt-Bu, dry THF, 0 °C to r.t., for 
96 h; b) 9.5 eq KHMDS, 9.5 eq CH3P(C6H5)3Br, dry THF, 0 °C to r.t., for 12 h; c) 9.5 eq 
benzyltriphenylphosphonium bromide, 9.5 eq KHMDS, dry THF, 0 °C to r.t., for 48 h; d) 1.8 eq 
Tebbe reagent, dry THF, 0 °C for 3 h; e) 4 eq KHMDS, 5 eq CH3P(C6H5)3Br, dry THF, 0 °C to ‒
45 °C to 0 °C for 3 h.  
Tebbe olefination was unsuccessful in converting ketone 3.20 to exo-olefin 3.21; instead, 
decomposed fractions were obtained. Treatment of ketone 3.20 with 1.8 equiv of Tebbe reagent 
[137] in dry THF at 0 °C for 3 h, gave a dark yellow precipitate which when purified through 
silica gel by eluting with 20% Et2O/ hexane, five fractions were isolated and checked by NMR, 
but unfortunately, none of them was the desired product. Finally, we decided to repeat the Wittig 
reaction, but decreasing the number of equivalents from both KHMDS and CH3P(C6H5)3Br and 
also, reaction temperature was ranging from  ̶ 45 °C to 0 °C to r.t,. Upon addition, a solution of 
ketone 3.20 to a mixture of 4 equiv of  KHMDS and 5 equiv of CH3P(C6H5)3Br in dry THF at 0 
°C to ‒45 °C to 0 °C for 3 h, 3.21 was obtained in 22% yield.  
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In hindsight, it was obvious that using a transition metal based reagent would just lead to 
radical decomposition products. It was a long-shot that missed. The use of bases with a 
unreactive ketone should have led to enolization and beta-elimination. Perhaps the hydroperoxy 
anion added back to the enone in Scheme 22. 
Scheme 22: Probable side-reactions in Wittig reaction of 3.20. 
  
3.4.DETERMINATION OF ABSOLUTE CONFIGURATION OF STEREOGENIC 
(CHIRAL) ALCOHOL 3.7 CARBON 
Chirality (a chiral molecule is non-superposable on its mirror image) is a critical issue 
especially in living systems, but this fact was not taken seriously because enantiomer separations 
are very challenging and ponderous. In addition, most synthetic chiral drugs were thus 
commercialized as racemates [138]. Due to the importance of chirality and as a consequence 
knowing which enantiomer is responsible for the biological activity, first we decided to 
synthesize optically active aldol product vide infra.  
 SYNTHESIS OF OPTICALLY ACTIVE ALDOL PRODUCT 3.23 3.4.1.
We tried as mentioned in the literature to synthesize optically active aldol product, then 
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protect the labile β -hydroxy group which then will be converted to epoxide, labile epoxide will 
then be ring opened to form the hydoperoxide and lastly deprotection, dehydration, desilylation 
and ring closure of the hydoperoxide could afford one of the enantiomers 3.7b as mentioned 
earlier. However, when 30 mol% of asymmetric catalyst, L-proline was added to stirring solution 
of the aldehyde 3.2 and 20 equiv of cyclohexanone 2.61 at r.t., for 36 h (Error! Reference source 
ot found.) it afforded the optically active aldol product 3.23 in only10% yield. 
 SEPARATION OF THE ENANTIOMERS 3.7a AND 3.7b 3.4.2.
Due to the low yielding of the optically active aldol product method, we decided to 
synthesize the rac-3.7 and then trying to separate the two enantiomers 3.7a and 3.7b.  
a.  Introduction 
Enantiomers, (optical isomer) in Greek it means opposite. They are stereoisomers (same 
molecular formula and arrangement of bonded atoms, however, have different spatial 
orientations of atoms in three-dimensional orientations) in which one of the two stereoisomers 
are mirror images of each other and non-superposable or not identical. Due to the presence of a 
single chiral atom (asymmetric carbon center) or similar structural feature within compound, 
leads to a creation of two possible structures which are mirror images of each other. [139] 
Enantiomers have equal chemical and physical properties if they exist in a symmetric 
environment. However, their capability to rotate plane-polarized light (+/−) are equal but in 
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opposite directions. A racemic mixture or racemate  is one that has equal amounts of enantiomers 
of a chiral molecule and has zero net rotation of plane-polarized light [139].  
Diastereomers or diastereoisomers, on the other hand, are a kind of stereoisomer in which 
two or more stereoisomers of a compound have dissimilar configurations at one or more, but not 
all of the equivalent (correlated) stereocenters (an atom with three or more different groups, and 
the interchanging of any two groups, creates a stereoisomer) and also are not mirror images of 
each other. Epimers, however, are diastereoisomers different from each other at only one 
stereocenter or stereogenic center (chiral center) [140]. Diastereomers unlike enantiomers, have 
dissimilar physical properties and chemical reactivity towards achiral and chiral reagents, make 
them easier to separate by conventional chemical processes. 
b. (−)-Menthoxyacetyl chloride analysis  
To resolve the rac-3.7, we first decided to convert the racemic mixture into diastereomers 
via a reaction with the enantiomerically pure chiral auxiliary (−)-menthoxyacetyl chloride. The 
reaction will form a mixture of diastereomers 3.24a and 3.24b that might be separated by 
common separation techniques, e.g., regular silica gel column chromatography. The reaction 
conducted by adding a 3 equiv of (−)-menthoxyacetyl chloride to a suspension of rac-3.7, a 3 
equiv of DMAP and TMEDA in  dry CH3CN [128] at 0 °C to r.t., for 48 h (Scheme 23).   
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Scheme 23: Schematic representation of application of (−)-menthoxyacetyl chloride in the 
synthesis of the two diastereomers 3.24a and 3.24b. 
 
Reagents and conditions: a) 6 eq TMEDA, 6 eq DMAP, 5 eq (−)-menthoxyacetyl chloride, 
CH3CN, 0
o
C to r.t. for 4 days.  
TLC analysis showed reaction did not complete after 48 h. Thus, 2 more equivalents of 
( )̶- menthoxyacetyl chloride were added and the reaction allowed to stir for 24 h more. After 72 
h, the reaction progress was checked by TLC using 20% EtOAc/Hexane solvent system and was 
visualized using p-anisaldehyde stain but still was not completed. Therefore, 3 more equivalents 
of DMAP and TMEDA were added and the reaction was allowed to stir for 24 h more. The 
reaction was completed and a mixture of two diastereomers 3.24 was obtained in 40%. These 
diastereomers were inseparable by regular silica gel column chromatography using different 
elution solvent systems. Due to the difficulty in the separation of the two diasteromers we 
decided to use a different chiral derivatizing agent.  
c. Mosher ester analysis 
Enantiopure (R)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride ((R)-(−)-
MTPA-Cl) or Mosher’s acid chloride) was used as a chiral derivatizing agent which will create a 
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diastereomeric, alpha-methoxy-alpha-trifluoromethylphenylacetic acid (MTPA) esters 3.25a and 
3.25b upon reaction with the rac-3.7 (Scheme 24). These diastereomers can be separated by 
regular silica gel column chromatography. Then, a basic hydrolysis will be applied for 3.25a and 
3.25b to obtain the enantiopure 3.7a and 3.7b respectively. In addition, optical activity of 3.7a 
and 3.7b will be determined.  
Upon addition of 2 equiv of (R)-(−)-MTPA-Cl  to a suspension of the rac-3.7, a 3 equiv 
of  both DMAP and TMEDA in dry CH3CN [128] at 0 °C to r.t., for 72 h,  TLC analysis using 
20% EtOAc/Hexane solvent system and visualized using p-anisaldehyde stain, showed  reaction 
completion. Also, TLC showed two separable spots of high Rf  (0.63) and low Rf  (0.58)  of 3.25b 
and 3.25a in 19% and 22% respectively (Error! Reference source not found.).   
Hydrolysis of the two Mosher’s esters 3.25a and 3.25b underwent smoothly without 
destruction of the essential trioxane system. They were first treated with a warm solution of 0.1N 
Sodium hydroxide (NaOH) in methanol (MeOH) [141] but after 24 h, reactions did not work. 
Thus, we decided to increase the alkalinity of the solution to 1N NaOH in MeOH. When the 
alkaline solutions were left to stir at ambient temperature for 36 h, reactions did work and 
furnished 3.7a and 3.7b in 27 and 24 % yield respectively (Scheme 24). Furthermore, the 
specific rotation [142], [α]D 
20 
were calculated for 3.7a and 3.7 b and were found
 ‒100.5°  and 
+100.5° for 3.7a and 3.7b respectively. In case of 3.7a where the sign is negative tells us that the 
(R) enantiomer is the dominant one. Whereas a positive sign of 3.7b indicated that it is the (S) 
enantiomer.  
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Scheme 24: Schematic representation of the application of the Mosher’s acid chloride in 
the synthesis of the two diastereomers 3.25a and 3.25b and basic hydrolysis to create 3.7a 
and 3.7b. 
 
Reagents and conditions: a) 2 eq (R)-(-)-MTPA-Cl, 3 eq DMAP, CH3CN 0 
o
C to r.t., for 72 h; b) 
1N NaOH/MeOH for 36 h.  
d. Determination of optical purity 
Optical purity or enantiomeric excess (ee) can be calculated for each enantiomer from the 
following Equations (4 and 5):  
)enantiomer pure a ofrotation  (specific
sample) ofrotation  (specific*100
 sample ofpurity  Optical%   :4 Eq  
])[](([
])[]([*100
ee%
SR
SR


  :5 Eq  
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where [-] indicates the concentration of the 3.7a and 3.7b. Thus, in case of 100% pure 
(R)-enantiomer 3.7a, the optical purity % = 100 * (-100.5
o
 / -100.5
o) = 100% and ee% = 100 * 
(100%  ̶  0%) / (100% + 0%) = 100%.  
In case of 100% pure (S)-enantiomer 3.7b, optical purity % = 100 * (+100.5
o
 / +100.5
o
) = 
100% and ee% = 100 * (0% - 100%) / (0% + 100%) = 100%. 
3.5.REARRANGEMENT CHEMISTRY (REACTION WITH IRON (II)) 
Within the malaria parasite, heme Fe(II) (reduced hemin) or other sources of ferrous iron 
can induce chemical decomposition of artemisinin and related tricyclic trioxanes (e.g.,3.7, 3.20) 
to generate an oxy radical that consequently rearranges into distinctive carbon-centered radical 
species. (e.g., 3.27 and 3.29) (Scheme 25 and Scheme 26). Using FeBr2 as a mimic of heme 
iron(II), we performed ferrous-mediated degradation of racemic 3.7 and ketone 3.20.  
3.5.1. REACTION OF RAC-3.7 WITH IRON (II) 
When Fe(II) associated with oxygen 1, forms an oxy radical 3.26 that goes on to provide 
a primary carbon-centered radical 3.27 after C3-C4 scission process. This intermediate radical 
species then underwent to ring-contracted tetrahydrofuran product 3.28, functions as a surrogate 
marker for this primary carbon-centered radical species (Scheme 25). As mentioned earlier, this 
reactive intermediate (e.g., 3.27) could be responsible for alkylation of biomacromolecules such 
as heme, specific proteins, and other targets that cause the death of malaria parasites. 
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Scheme 25: Fe(II)-mediated rac-3.7 degradation. 
 
Reagents and conditions: a) 2 eq FeBr2, THF, r.t., for 2 h 
Upon treatment rac-3.7 at ambient temperature in THF with 2 equiv of FeBr2 for 2 h 
[47], 3.28 was isolated by flash chromatograph in 47% yield as the only tractable product from 
rearrangement of rac-3.7. Assignment of a structure to 3.28 was based on spectral evidence; it 
showed in its IR spectra strong absorption bands at 3394 and 1740 cm
-1 
corresponding to 
hydroxyl and acetyl groups respectively. In the NMR, the presence of a methyl of the acetyl 
group was clearly indicated as a singlet at δ 2.11. In addition, HMBC and HSQC experiments 
confirmed the connectivity presented for compound 3.28. For example, the C-8 protons at δ 4.62 
(dd, J = 1.5, 12.3 Hz, 1H, CH2a-8), and 4.26 (d, J = 12.3 Hz, 1H, CH2b-8), and the methyl at δ 
2.11 (s, 3H, CH3-11), showed strong HMBC correlations to C-10, a carbonyl assigned to δ 171.8. 
Furthermore, the quaternary carbon at δ 81.8 showed strong HMBC correlations with the protons 
at CH-3, CH2-8 and CH2-2, confirming the THF ring in the molecule. The nuclear Overhauser 
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effect spectroscopy (NOESY) experiment showed a correlation between the protons at CH-3 and 
CH-3a indicating a cis configuration between these two protons. 
3.5.2. REACTION OF 3.22 WITH IRON (II) 
When ketone 3.20 was treated with 2 equiv of FeBr2 in THF, for 2 h, 3.35 was isolated by 
flash chromatograph in 50% yield as the only tractable product from the rearrangement of 3.20. 
The plausible mechanisms for generation of 3.35 include ;( path a) and (path b). The association 
of Fe(II) with oxygen 1 forms an oxy radical that formed a primary carbon-centered radical 3.29 
which abstracts a hydrogen atom from THF and generates 3.30 and 3.31. Involvement of a trace 
of water (path a) giving the protonated (tetrahydrofuran-2-yl)oxonium 3.32 that quenches the 
Fe(II)oxo intermediate 3.33 and generates 2-hydroxytetrahydrofuran 3.34 and the (2-acetyl-1-
hydroxycyclohexyl)methyl acetate 3.35 respectively. In case of a truly dry THF, 3.30 could lose 
a proton (path b) and protonate the Fe(II)oxo intermediate 3.33 which leads to the formation of 
3.35 and 2,3-dihydrofuran 3.36 (Scheme 26). 
Product 3.35 showed strong hydroxyl and carbonyl absorption in the IR at 3452, 1740 
and 1705 cm
-1
 and was confirmed in the proton NMR spectra which indicated the presence of an 
acetyl group at δ 2.08 and methyl ketone at δ 2.23. In addition, HMBC and HSQC experiments 
confirmed the connectivity shown for compound 3.37. For instance, the C-7 protons at δ 4.24 (d, 
J = 12.0 Hz, 1H, CH2a-7), and 4.18 (d, J = 12.0 Hz, 1H, CH2b-7), and the methyl at δ 2.08 (s, 3H, 
CH3-10), showed a strong HMBC correlations to C-9, a carbonyl assigned to δ 171.8. The C-2 
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carbon at δ 56.4 showed strong correlations with the protons at CH2-7 and the methyl signal at δ 
2.23 (s, 3H, CH3-12) confirming the presence of the methyl ketone. 
Scheme 26: Fe(II)-mediated ketone 3.20 degradation. 
 
Reagents and conditions: i) 2 eq FeBr2, THF, r.t., for 2 h; 50%. 
3.6.IN VITRO ANTIMALARIAL ACTIVITY  
Chloroquine 1.2, artemisinin 1.7, and the analogs rac-3.7, 3.7a, 3.7b, 3.10-3.15, 3.18, 
3.20, 3.21, diastereomers 3.24, 3.25a, 3.25b, 3.28 and 3.35 were tested in vitro in parasitized 
whole blood against drug-resistant strains of P. falciparum parasite clones D-6 and W-2 at The 
National Center for Natural Products Research (NCNPR) at The University of Mississippi. The 
IC50 values as shown in Table 5, ranges from 8.01 µM (D-6) and 8.30 µM (W-2) in case of the 
rac-3.7 to 0.15 µM (D-6) and 0.16 µM (W-2) in case of the ketone 3.20. It was found the 
98
  
enantiopure (‒)-3.7a was responsible for the antimalarial activity with IC50 5.80 µM (D-6) and 
4.13 µM (W-2), while the enantiopure (+)-3.7b was inactive. Of the ester derivatives, 4-fluoro 
ester 3.12 was the most active with IC50 = 0.24 µM (D-6) and 0.29 µM (W-2) and the 
diastereomers 3.24 was the least active with IC50 = 2.68 µM (D-6) and 2.81 µM (W-2). 
Compound 3.18 was devoid of antimalarial activity. 
The Fe(II)-induced rearrangement products 3.28 and 3.35 were devoid from activity. The 
ring-contracted product 3.28 seems to correlate with low antimalarial activity, presumably due to 
instability of that primary C-4 radical (e.g., 3.27) and thus has a less chance to alkylate protein.   
On the other hand, rearrangement product 3.35 appears to associate with high 
antimalarial activity probably due to a generation of a more stable primary C-4 radical (e.g., 
3.29) which did not undergo intramolecular ring-closure. This stable radical intermediate then 
has a better chance to alkylate malarial protein. The evidence supporting this assumption is that 
ketone 3.20 (IC50 = 0.15 µM (D-6) and 0.16  µM (W-2)) is 50 and 78 times more potent than the 
rac-3.7 (IC50 = 8.01 µM (D-6) and 8.30 µM (W-2)). Also, it is 37 and 38 times more potent than 
pure enantiomer 3.7a (IC50 = 5.80 µM (D-6) and 4.13 µM (W-2)). Surprisingly, the 
exomethylene 3.21 (IC50 = 1.64 µM (D-6) and 1.67 µM (W-2)) was 10 and 16 times less potent 
than 3.20 in (D-6) and (W-2) clones respectively, even though it has the exomethylene group 
which theoretically should be more stabilizing the intermediate C-4 radical that can be generated 
(from reaction with Fe(II)) than the stability effect due to the presence of carbonyl in 3.20 (See 
Table 5). 
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Finally, compounds 3.18, 3.30 and 3.37 as mentioned earlier, were devoid of antimalarial 
activity and that due to the loss of the natural product-like architecture and this is proof that a 
1,2,4-trioxane structure is essential for antimalarial activity. 
Table 5: In vitro antimalarial activity of the synthesized compounds
a
 against P. falciparum. 
Code Structure IC50 (µM) D-6 W-2 
rac-3.7 
 
8.01 8.30 
(-)-3.7a 
 
5.86 4.13 
(+)-3.7b 
 
b
NA 
b
NA 
3.10 
 
0.50  0.70  
3.11 
 
0.48 0.38 
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Code Structure IC50 (µM) D-6 W-2 
3.12 
 
0.24 0.29 
3.13 
 
0.33 0.48 
3.14 
 
0.38 0.43 
3.15 
 
0.41 0.34 
3.18 
 
b
NA 
b
NA 
3.20 
 
0.15 0.11 
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Code Structure IC50 (µM) D-6 W-2 
3.21 
 
1.64 1.67 
Diasteromers, 
3.24 
 
2.68 2.81 
3.25a 
 
0.35 0.83 
3.25b 
 
5.04 5.24 
3.28 
 
b
NA 
b
NA 
3.35 
 
b
NA 
b
NA 
Chloroquine 0.014 318 
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Code Structure IC50 (µM) D-6 W-2 
Artemisinin 0.025 0.018 
a
None of the synthesized compounds were cytotoxic against VERO cells up to 15.80 µM.  
b
Not active.   
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CHAPTER IV 
HOMOLOGY MODEL AND SAR ANALYSIS 
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4.1.HOMOLOGY MODELING 
The purpose of protein modeling is to anticipate a structure from its sequence with an 
accuracy that is very comparable to the results reached experimentally. Protein modeling is used 
when experimental techniques fail to gain structural information. Also, many proteins are very 
large for NMR analysis and cannot have X-ray crystal structures [143].  
Prof Avery’s former graduate student Dr. Shuneize Slater generated a homology model 
for Plasmodium falciparum ATPase6 that will be used in this study.   
The 1,228 amino acid sequence of Plasmodium falciparum ATPase 6 (PfATP6) was obtained 
from the Plasmo Database (PlasmoDB) website and is as follows: 
MEEVIKNAHTYDVEDVLKFLDVNKDNGLKNEELDDRRLKYGLNELEVEKKKSIFELILN
QFDDLLVKILLLAAFISFVLTLLDMKHKKIEICDFIEPLVIVLILILNAAVGVWQECNAEKS
LEALKELQPTKAKVLRDGKWEIIDSKYLYVGDIIELSVGNKTPADARIIKIYSTSLKVEQS
MLTGESCSVDKYAEKMEDSYKNCEIQLKKNILFSSTAIVCGRCIAVVINIGMKTEIGHIQH
AVIESNSEDTQTPLQIKIDLFGQQLSKIIFVICVTVWIINFKHFSDPIHGSFLYGCLYYFKIS
VALAVAAIPEGLPAVITTCLALGTRRMVKKNAIVRKLQSVETLGCTTVICSDKTGTLTTN
QMTTTVFHLFRESDSLTEYQLCQKGDTYYFYESSNLTNDIYAGESSFFNKLKDEGNVEA
LTDDGEEGSIDEADPYSDYFSSDSKKMKNDLNNNNNNNNNSSRSGAKRNIPLKEMKSN
ENTIISRGSKILEDKINKYCYSEYDYNFYMCLVNCNEANIFCNDNSQIVKKFGDSTELALL
HFVHNFDILPTFSKNNKMPAEYEKNTTPVQSSNKKDKSPRGINKFFSSKNDNSHITSTLN
ENDKNLKNANHSNYTTAQATTNGYEAIGENTFEHGTSFENCFHSKLGNKINTTSTHNNN
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NNNNNNSNSVPSECISSWRNECKQIKIIEFTRERKLMSVIVENKKKEIILYCKGAPENIIKN
CKYYLTKNDIRPLNETLKNEIHNKIQNMGKRALRTLSFAYKKLSSKDLNIKNTDDYYKL
EQDLIYLGGLGIIDPPRKYVGRAIRLCHMAGIRVFMITGDNINTARAIAKEINILNKNEGD
DEKDNYTNNKNTQICCYNGREFEDFSLEKQKHILKNTPRIVFCRTEPKHKKQIVKVLKDL
GETVAMTGDGVNDAPALKSADIGIAMGINGTEVAKEASDIVLADDNFNTIVEAIKEGRCI
YNNMKAFIRYLISSNIGEVASIFITALLGIPDSLAPVQLLWVNLVTDGLPATALGFNPPEH
DVMKCKPRHKNDNLINGLTLLRYIIIGTYVGIATVSIFVYWFLFYPDSDMHTLINFYQLSH
YNQCKAWNNFRVNKVYDMSEDHCSYFSAGKIKASTLSLSVLVLIEMFNALNALSEYNS
LFEIPPWRNMYLVLATIGSLLLHVLILYIPPLARIFGVVPLSAYDWFLVFLWSFPVIILDEII
KFYAKRKLKEEQRTKKIKID. 
Prime was used to construct a homology model of PfATP6. In the homology model 
building panel, the PfATP6 sequence was pasted into the text box, and a BLAST homology 
search was initiated to find homologous proteins. PDBID 1SU4 having an overall 44% identity 
with the input sequence was selected as the template. ClustalW was then used to align the two 
sequences. The calcium bound ions in the channel was chosen to be included in the model 
(Figure 27).  
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Figure 27: The best model predicted by Prime shown in green also showing the bound 
calcium ions in the channel. 
4.2. DEVELOPING A STRUCTURE-ACTIVITY RELATIONSHIP FOR THE 
SYNTHESIZED COMPOUNDS BY THEIR DOCKING INTO CYS-
1031ARTEMISININ BINDING SITE.  
4.2.1. INTRODUCTION 
Structure-activity relationship (SAR) is the study of the relationship between the structure 
of a drug and its biological activity. It is important for the design of therapeutics with the highest 
potency but the least adverse effects. SAR can be used as a guide in determining the functional 
groups at a specified position in the ligand structure that are responsible for generating a 
biological effect in the target organism. Medicinal chemists use SARs to modify ligand 
structures and test the modifications for their biological activities.[144]. 
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4.2.2. DOCKING PROCEDURE 
The synthesized compounds were drawn in ChemDraw and saved as individual .sdf files. 
The files were then uploaded to the Maestro interface of the Schrödinger suite and minimized to 
obtain their 3-D conformations. The 3-D structures were then prepared using the LigPrep module 
of Schrödinger which generates the ligands by converting them based on their tautomeric and 
protonization states at certain pH ranges, and then docked into both sites using both Glide 
docking and Induced Fit Docking to retrieve their docking scores and poses. Interestingly, the 
docking scores of synthesized compounds against the site containing Cys1031 were higher or 
comparable to artemisinin as shown in Table 6. 
Table 6: Docking scores of the synthesized compounds in Cys1031 site. 
Entry Docking scores (Kcal/mol) 
rac-3.7 -5.56 
3.7a -5.56 
3.7b -4.94 
3.10 -4.00 
3.11 -3.64 
3.12 -3.54 
3.13 -3.95 
3.14 -4.35 
3.15 -3.52 
3.20 -4.72 
3.21 -4.27 
3.24 -2.92 
3.25a -3.77 
3.25b -3.56 
Artemsinin -4.38 
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The 3D representation of the PfATP6 model shows that compound 3.14 with in the 
vicinity of cys-1031 as shown in Figure 28 that can explain the good docking score of -4.35. The 
presence of rac-3.7 and 3.20 in close proximity to cys-1031 as shown in Figure 29 and Error! 
Reference source not found. can explain the good docking scores of  rac-3.7( -5.56) and 3.20 (-
4.72).   
 
Figure 28: The 3D representation of the docked pose of 3.14 in Cys-1031 site. 
 
 
 
 
 
 
Figure 29: Docked pose of rac-3.7 in Cys-1031 site. 
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Figure 30: Docked pose of 3.20 in Cys-1031 site. 
The 2D representations of the 3.25a and 3.13 protein binding showed the importance of 
the hydrophobic and hydrogen bond interactions. For instance, the important interactions of 
3.25a with the receptor through hydrophobic amino acid residue Tyr966 and hydrogen bonding 
with Tyr1143 and Lys1217 (Figure 31). Interactions of 3.13 with the receptor were through 
hydrogen bonding with Tyr1143 and His1035 (Error! Reference source not found.). In addition, 
he energetics of interaction of 3.25a and 3.13 with the protein showed good docking scores of -
3.77 and -3.13 respectively.  
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Figure 31: 2D protein-3.25a interaction profile shows hydrophobic and hydrogen bond 
interactions.  
  
 
 
 
 
 
 
 
Figure 32: 2D protein-3.13 interaction profile shows hydrogen bond interactions. 
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4.2.3. SUMMARY OF OVERALL SAR 
The low antimalarial activity of pentanoate ester 3.10 in comparison to the other esters 
(IC50 = 0.50 µM (D-6) and 0.70 µM (W-2)) perhaps was due to its susceptibility to ester 
hydrolysis. In addition, oxidative metabolism could take place at the pentane sidechain. 
However, maintaining some potency could be attributed to side chain docking with the protein 
hydrophobic binding pocket. The modest antimalarial activity of benzoate ester 3.11 (IC50 = 0.48 
µM (D-6) and 0.38 µM (W-2)) could be due to the π–π stacking with amino acids within the 
receptor. In addition, oxidative metabolism could take place at the 4 position of the benzene ring. 
Of the ester derivatives, 4-fluoro ester 3.12, was the most active (IC50 = 0.24 µM (D-6) and 0.29 
µM (W-2)). This could be attributed to fluorine being as an isostere of hydrogen, that F-for-H 
exchange revealed increase the overall lipophilicity of the molecule. In addition, fluorine can act 
as a hydrogen-bond acceptor that can form a hydrogen bond with surrounding amino acids 
within the binding pocket. Fluorine blocks the metabolic process due to the powerful electron 
withdrawing properties of F and the strength of the C-F bond which, at about 108 kcal/mol, 
makes C-F bond chemically inert under most biological conditions.  
The moderate antimalarial activity of the p-methoxy ester 3.13 (IC50 = 0.33 µM (D-6) and 
0.48 µM (W-2)) could be due to the electron donating property of the methoxy group that 
decreases the tendency of ester hydrolysis, in addition to its capability to act as a proton acceptor 
within the protein binding pocket. In case of the cinnamate ester 3.14 (IC50 = 0.38 µM (D-6) and 
0.43 µM (W-2)), being a moderate activity could be attributed to the presence of atoms that are 
able to interact with the π system. The OCO-CH2=CH2 favorably adopts a coplanar arrangement 
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with the phenyl ring which allows of interaction between the lone pair on oxygen and the π-
system of the aromatic ring or the π-system of the olefin and the phenyl ring. This could give 
more stability to the ester and therefore increase resistance to hydrolysis. The lower antimalarial 
activity of 3.15 (IC50 = 0.41 µM (D-6) and 0.34 µM (W-2)) in comparison with a chloro 
substituent can be effective in inhibiting metabolic oxidation thereby increases its duration of 
action.  
Associated with those analogues, having electron-withdrawing groups is likely associated 
with their increased susceptibility to hydrolysis. In case of 3.25a the electron withdrawing 
properties of the CF3 moiety with the presence of the methoxy and phenyl ring could fit in a 
lipophilic pocket with in the protein. The electron withdrawing properties of F could render the 
ester hydrolysis of the whole compound and in result increased the activity of the 4-
fluorobenzoate in comparison with the other esters.  
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CHAPTER V 
EXPERIMENTAL APPROACH  
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5.1.GENERAL EXPERIMENTAL APPROACH 
Optical rotations were recorder using Rudolph Research Analytical Autopol V 
Polarimeter. Melting points were measured on an OptiMelt
®
 V.1061 (Stanford Research 
systems) instrument and were uncorrected. 
1
H and 
13
C NMe spectra were obtained on Bruker 
NMR spectrometers model DRX 600, DRX 500 and DRX 400 NMR spectrometers with 
standard pulse sequences, operating at 600, 500 and 400 MHz in 
1
H and 150, 125 and 100 MHz 
in 
13
C, respectively. The chemical shifts values were reported in parts per millon units (ppm) 
from trimethylsilane (TMS) using known solvent CDCl3, C6D6 chemical shifts. Coupling 
constants were recorder in Hertz (Hz), standard pulses were used for COSY, HSQC, HMBC, 
NOESY and DEPT experiments. Infrared (IR) spectra were recorded on a PerkinElmer Spectrum 
100FT-IR Spectrometer. High resolution mass spectra (HRMS) were measured with Waters 
Micromass Q-TOF micro mass spectrometer using electrospray ionization (ESI) source in 
negative or positive mode. Analytical HPLC was performed on an automated Waters Alliance 
system equipped with an Xterra® C18 column (3.9 X 100 mm) with a flow rate of 1 mL/min. and 
photodiode array detector (PDA). Flash chromatography was performed using silica gel 
(Whatman 60Å, 230-400 mesh). Analytical thin layer chromatography (TLC) was performed on 
EMD Chemical INC 25 TLC aluminum sheets, silica gel 60 F254 or GP Analtech TLC plates. All 
reaction solvents were purchased as HPLC grade and, where appropriate, distilled from CaH2 and 
then stored over 3 or 4 Å molecular sieves. Most commercial reagents were used without further 
purification unless otherwise noted in the procedure. All reagents and dry solvents were 
purchased from Sigma-Aldrich, Fluka, or Thermo Fisher Scientific. All round bottom flasks 
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were dried properly in a vacuum oven prior to reactions. Solvents and reagents transfers were 
accomplished via dried syringes or cannulas. All reactions were performed under argon 
atmosphere, unless otherwise specified. 
X-Ray crystallographic data for (3-methyloctahydro-1h-3,9a-epidioxybenzo[c]oxepin-5-ol) 
(3.7).  
C11H18O4, molecular weight = 214.25, clear colorless prism (0.38 x 0.30 x 0.16 mm), 
orthorhombic, space group P212121, a = 5.7823 (5) Å, b = 7.6135 (10) Å, c = 23.795(3) Å, v = 
1047.5 Å
3 
and z = 4 Å. dcalcd  = 1.359 mg m
-3
, 4872 independent reflections measured out to θmax 
= 36.6° with a Nonius KappaCCD diffractometer using Mo Kα radiation (λ = 0.71073 Å) with a 
graphite monochromator in the incident beam. The data were collected at room temperature by 
using the Ѡ scan technique. To correct for the crystal decomposition, the intensities were 
normalized with correction factors derived from the standards.  Multi-scan absorption correction 
was applied using Denzo and  Scalepack [145]. The structure was solved by direct methods as 
implemented by the SHELXTL97 system of programs. Full-matrix least-squares refinement was 
performed on 141 parameters using the 4872 reflections. The C-H distances were fixed at 0.82 Å 
and placed in idealized positions.  
Ethyl 2-(2-methyl-1,3-dioxolan-2-yl) acetate (3.1). 
A solution of ethyl acetoacetate (150.0 g, 1.15 mol), ethylene glycol (214 g, 3.44 mol), 
and p-TsOH•H2O (9.70g, 51 mmol) in a 1100 mL of benzene was refluxed for 5 h with 
continuous azeotropic H2O separation (Dean-Stark trap). The mixture was then cooled to 
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ambient temperature, concentrated to 500 mL in vacuo then washed sequentially with sat. aq. 
NaHCO3 (2 x 100 mL) and brine (100 mL), filtered over anhydrous Na2SO4  in vacuo. The crude 
was distilled under vacuum (20-25mbar) at temperature 109-110°C to afford 3.1 (167.3 g, 83%) 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3):  = 4.09 (q, J = 7.1 Hz, 2H), 3.91 (s, 4H), 2.59 
(s, 2H), 1.43 (s, 3H), 1.20 (t, J = 7.1 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3):  = 169.3, 
107.5, 64.7, 60.4, 44.1, 24.4, 14.1 ppm. IR (neat): 2984, 2890, 1732, 1447,1369, 1318, 
1240,1183, 1096, 1040, 949 cm
-1
 ESI-HRMS calcd. for C8H15O4 ([M + H]
+
) 175.0900, found 
175.0973. 
2-(2-Methyl-1,3-dioxolan-2-yl)acetaldehyde (3.2).  
To a 1000 mL 2-necked round-bottomed flask equipped with argon line and septa was 
added dry DCM (250 mL) and the ester 3.1 (55.09 g, 0.32 mol). The mixture was vigorously 
stirred at ‒78 °C for 15 min, whereupon DIBAL-H (57.92.18 g, 0.41 mol, 1.0 M solution in 
toluene) was added dropwise via cannula and the reaction mixture was then stirred at ‒78 °C for 
5 h. The reaction was checked by TLC for completion, and then quenched with MeOH (40 mL). 
The mixture was allowed to warm to ambient temperature stirred for 40 min. A saturated 
aqueous solution of Rochelle salt (200 mL) was added and the reaction mixture was stirred 
overnight.  The aqueous layer was separated and extracted with DCM (3 x 120 mL). The 
combined organic layers were washed with brine (2 x150 mL) and dried over anhydrous MgSO4 
and then the crude product was filtered through a pad of silica gel atop a pad of celite and the 
clear solution was concentrated by rotary evaporation. The crude product was distilled under 
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vacuum (41mbar) at 98-100°C to afford 3.2 (31.6 g, 76%) as a pale yellow oil; 
1
H NMR (400 
MHz, CDCl3):  = 9.73 (t, J = 2.9 Hz, 1H), 3.99 (m, 4H), 2.70 (d, J = 2.9 Hz, 2H), 1.41 (s, 3H) 
ppm; 
13
C NMR (100 M Hz, CDCl3):  = 200.2, 107.6, 64.8, 52.2, 24.9 ppm. IR (neat): 2986, 
2889, 1721, 1380, 1293, 1148, 1115, 1050, 948, 863 cm
‒1
. ESI-HRMS calcd. for C6H16NaO3 ([M 
+ Na]
+
) 153.0528, found 153.1689. 
2-(1-Hydroxy-2-(2-methyl-1,3-dioxolan-2-yl)ethyl)cyclohexan-1-one (3.3).  
To a 300 mL round-bottomed flask equipped with argon line and septum was added n-
BuLi (3.63 g, 56 mmol, 2.5 M solution in hexanes) to a -78⁰ C solution of i-pr2NH (5.73 g, 56 
mmol) in dry THF (150 mL) which was warmed to 0 °C and stirred for 30 min. The bath 
temperature was lowered to ‒78 °C and a solution of cyclohexanone (5.05 g, 51 mmol) in dry 
THF (40 mL) was added dropwise via cannula. The mixture was stirred at ‒78 °C for 2 h at 
which time the aldehyde 3.2 (6.71 g, 51 mmol) was added via syringe and the mixture stirred for 
1 h at ‒78 °C. The reaction was quenched with a glacial acetic acid (6.19 g, 103 mmol) and the 
bath was allowed to warm to ambient temperature naturally and the reaction mixture was stirred 
overnight. Saturated aqueous NH4Cl (100 mL) was added, followed by Et2O (120 mL). Phases 
were separated and the aqueous layer back-extracted with Et2O (3 x 100 mL). The combined 
organic layers were washed with water and brine (2 x100 mL) and dried over anhydrous Na2SO4. 
After filtration, the solvent was removed by rotary evaporation. The reaction product was then 
chromatographed over silica gel with 30% EtOAc /hexane to afford 3.3 as a colorless oil (7.8 g, 
66%). 
1
H NMR (400 MHz, CDCl3):  = 4.17 (m, 1H), 3.97 (br s, 4H), 3.54 (d, J = 2.8 Hz, 1H), 
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2.49 (dt, J = 11.3, 5.4 Hz, 1H), 2.41-2.25 (m, 2H), 2.13 (m, 1H), 2.03 (m, 1H), 1.86 (m, 2H), 
1.81-1.62 (m, 3H), 1.51 (m, 1H), 1.39 (s, 3H) ppm; 
13
C NMR (100 MHz, CDCl3):  = 213.1, 
110.2, 67.5, 64.6, 64.2, 55.7, 42.5, 41.9, 29.3, 27.7, 24.6, 24.0 ppm. IR (neat): 3519, 2935, 2867, 
1702, 1449, 1405, 1378, 1313, 1250, 1201, 1128, 1111, 1050, 948, 835, 818 cm
‒1
. ESI-HRMS 
calcd. for C12H20NaO4 ([M + Na]
+
) 251.1259, found 251.1264. 
2-(1-((Tert-butyldimethylsilyl)oxy)-2-(2-methyl-1,3-dioxolan-2-yl)ethyl)cyclohexan-1-one 
(3.4).  
To a 100 mL round-bottomed flask equipped with argon line and septum, a solution of 
alcohol 3.2 (2.6 g, 11.3 mmol) in dry DMF (30 mL) was added and stirred at  0 °C for 5 min. 
Then 2,6-Lutidine (5.9 g, 55 mmol) was added via syringe and the reaction mixture was stirred 
for 20 min. TBSCl (2.51 g, 16.7 mmol) was added to the above reaction mixture followed by 22 
mol % of DMAP and stirred at 0 °C for 3 h and then for 12 h at ambient temperature. Saturated 
aqueous NH4Cl (20 mL) was added followed by Et2O (80 mL). Phases were separated and the 
aqueous layer back-extracted with Et2O (3 x 50 mL). The combined organic layers were washed 
with water (100 mL) and brine (2 x100 mL) and dried over anhydrous Na2SO4. Solvent was 
removed by rotary evaporation. The crude product was purified by silica gel flash 
chromatography (30% EtOAc/hexane) to give 3.4 as a colorless oil (2.82, 72%). 
1
H NMR (400 
MHz, CDCl3):  = 4.37 (dt, J = 3.2, 7.2 Hz, 1H), 4.02-3.87 (m, 4H), 2.46 (m, 1H), 2.33 (m, 1H), 
2.25-2.15 (m, 2H), 2.01-1.84 (m, 3H), 1.70-1.52 (m, 4H), 1.41 (s, 3H), 0.88 (s, 9H), 0.07 (d, J = 
17.0 Hz, 6H) ppm; 13C NMR (100 MHz, CDCl3):  = 211.3, 109.3, 67.6, 64.3, 64.0, 56.7, 42.3, 
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41.8, 26.9, 26.8, 25.9, 24.8, 24.7, 18.0, ̶ 4.5 ppm. IR (neat): 2931, 2856, 1708, 1472, 1378, 1251, 
1165, 1113, 1046, 1030, 923, 830, 773 cm‒1. ESI-HRMS calcd. for C18H34NaO4Si ([M + 
Na]+) 365.2124, found 365.2111. 
Tert-butyldimethyl(2-(2-methyl-1,3-dioxolan-2-yl)-1-(1-oxaspiro[2.5]octan-4-
yl)ethoxy)silane (3.5). 
To a 100 mL round-bottomed flask equipped with argon line and septum, a suspension of 
NaH (0.83 g, 34 mmol, in 60% (w/w) mineral oil) in dry DMSO (30 mL) was added and stirred 
at ambient temperature for 5 h, then the mixture was added via cannula to a suspension of Me3SI 
(2.40 g, 11 mmol) in dry DMSO (15 mL) and dry THF (15 mL) stirred at 0 °C. The mixture was 
stirred at 0 °C for 40 min. A solution of ketone 3.4 (2.02 g, 5.9 mmol) in dry THF (12 mL) was 
added to the above mixture and stirred for 20 min at 0 °C. The mixture was then allowed to 
warm to ambient temperature and stirred for 15 h before being partitioned between Et2O (100 
mL) and brine (60 mL). Phases were separated and the aqueous layer back-extracted with Et2O 
(3 x 50 mL). The combined organic layers were washed with water (100 mL) and brine (100 mL) 
and dried over anhydrous Na2SO4. Solvent was removed by rotary evaporation. The crude 
product was purified by silica gel flash chromatography (30% EtOAc/hexane) to afford epoxide 
3.5 as a light yellow oil (1.14 g, 54 %).
1
H NMR (400 MHz, CDCl3):  = 3.91 (s br, 4H), 3.03 (d, 
J = 4.3 Hz, 1H), 2.41 (d, J = 4.3 Hz, 1H), 2.06 (d, J = 14.6 Hz, 1H), 1.94 (m, 1H), 1.92-1.80 (m, 
2H), 1.79-1.60 (m, 2H), 1.54-1.38 (m, 2H), 1.34 (s, 3H), 1.30-1.17 (m, 4H), 0.89 (s, 9H), 0.08 (s, 
6H) ppm; 
13
C NMR (100 MHz, CDCl3):  = 109.8, 68.6, 64.2, 64.0, 61.0, 50.4, 45.5, 41.5, 36.2, 
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25.9, 25.7, 24.8, 24.3, 23.6, 18.1, ‒3.9, ‒4.3 ppm. IR (neat): 2930, 2856, 1472, 1375, 1252, 1170, 
1100, 1037, 944, 771 cm
 ̶ 1
. ESI-HRMS calcd. for C19H36NaO4Si ([M + Na]
+
) 379.2281, found 
379.2276. 
(2-(1-((tert-butyldimethylsilyl)oxy)-2-(2-methyl-1,3-dioxolan-2-yl)ethyl)-1 
hydroperoxycyclohexyl)methanol (3.6).  
To a 100 mL round-bottomed flask equipped with argon line and septum, a solution of 
epoxide 3.5 (1.80 g, 5.1 mmol) in ethereal H2O2 (Et2O washed with NaCl – saturated H2O2, 50 
mL) was added and stirred at ambient temperature for 5 min before the catalyst (Na2MoO4·2H2O 
and glycine, 0.21 g, 0.5 mmol) was added. The mixture was stirred at the same temperature for 
24 h. water (60 mL) was added to the reaction mixture and then extracted EtOAc (3 x 80 mL). 
The combined organic layers were washed with water and brine (100 mL) and dried over 
anhydrous Na2SO4. Solvent was removed by rotary evaporation to afford hydroperoxide 3.6 as a 
light yellow oil (1.20 g, 61%). 
3-methyloctahydro-1h-3,9a-epidioxybenzo[c]oxepin-5-ol, rac-3.7. 
To a 150 mL round-bottomed flask were added 3.6 (1.15 g, 2.9 mmol), DCM (80 mL) 
and p-TsOH•H2O (0.28 g, 1.47 mmol). The mixture was stirred at ambient temperature for 24 h. 
Saturated aqueous NaHCO3 (100 mL) was added, then the reaction mixture was extracted with 
Et2O (3 x 125 mL). The combined organic layers were washed with water (100 mL) and brine 
(100 mL) and dried over anhydrous Na2SO4. Solvent was removed by rotary evaporation and the 
crude product was chromatographed on silica gel (20% EtOAc/hexane) to afford the rac-3.7 as a 
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crystalline solid (0.20 g, 32%). Mp: 109-111 °C. 1H NMR (400 MHz, C6D6):  = 4.02 (d, J = 
11.3 Hz, 1H, CH2a-10), 3.86 (d, J = 11.3 Hz, 1H, CH2b-10), 3.75 (m, 1H, CH-5), 3.64 (d, J = 
11.9 Hz, 1H, OH), 2.70 (dd, J = 3.2, 15.0 Hz, 1H, CH2a-4), 2.35 (dd, J = 3.1, 15.0 Hz, 1H, CH2b-
4), 1.75 (m, 1H, CH2a-7), 1.67-1.62 (m, 3H, CH-5a, CH2b-7, CH2a-9), 1.52 (d br, J = 12.8 Hz, 
1H, CH2a-6), 1.32 (m, 1H, CH2a-8), 1.31 (s, 3H, CH3-12), 1.21 (td, J = 4.5, 13.7 Hz, 1H, CH2b-9), 
0.98 (m, 1H, CH2b-6), 0.81 (tt, J = 3.6, 13.4 Hz, 1H, CH2a-8) ppm; 
13
C NMR (100 MHz, C6D6):  
= 105.1 (C-3), 82.8 (C-9a), 68.3 (C-5), 63.5 (C-10), 51.9 (C-5a), 44.9 (C-4), 35.2 (C-9), 27.1 (C-
7), 26.2 (C-12), 25.5 (C-6), 23.6 (C-8) ppm. IR (neat): 3413, 2928, 2856, 1463, 1361, 1252, 
1069, 1006, 938, 850, 771 cm
 ̶ 1
. ESI-HRMS calcd. for C11H18NaO4 ([M + Na]
+
) 237.1103, found 
237.0937; C11H19O4 ([M + H]
+
) 215.1283, found 215.1059. 
3-Methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl pentanoate (3.10).  
To a 10 mL round-bottom flask equipped with argon line and septum were added a 
solution of rac-3.7 (16 mg, 0.075 mmol) in dry DCM (2mL), valeric acid (0.09 mmol, 9.83 µL), 
EDC (0.09 mmol, 17.17 mg) and DMAP (1.82 mg, 0.015 mmol) and stirred at ambient 
temperature for 4 days. Additional amount of valeric acid (9.83 µL), EDC (8 mg) and DMAP (4 
mg) were added and stirred for 24 h. Reaction mixture allowed to stir at 40 °C for 1 h. Then the 
mixture was filtered, and the filtrate was collected and diluted by DCM (15 mL). Subsequently, 
the filtrate was washed by 0.1 N HCl (10 mL), saturated aqueous NaHCO3 (10 mL) and brine 10 
(mL), dried over anhydrous Na2SO4, concentrated by rotary evaporation and the crude product 
was chromatographed on silica gel (20 % EtOAc/hexane) to afford 3.10 (2.5 mg 11%). 
1
H NMR 
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(400 MHz, CDCl3): δ = 5.26 (s br, CH-5), 4.24 (d, J = 10.4 Hz, 1H, CH2a-10), 4.05 (dd, J = 0.9, 
10.4 Hz, 1H, CH2b-10), 2.70 (dd, J = 3.2, 15.8Hz, 1H, CH2a-4), 2.38-2.30 (m, 3H,  CH2-2´, CH2b-
4), 2.06 (m, 1H, CH-5a), 1.87 (d br, J = 12.5 Hz, 1H, CH2a-9), 1.78-1.60 (m, 5H, CH2a-6, CH2a-
7, CH2a-8, CH2-3´), 1.49 (m, 1H, CH2b-6), 1.30-1.20 (m, 6H, CH2b-9, CH3-12, CH2b-7, CH2b-8, 
CH2-4´), 0.93 (m, 3H, CH3-5´) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 173.6 (C-1´), 103.0 (C-
3), 82.5 (C-9a), 69.4 (C-5), 63.4 (C-10), 49.9 (C-5a), 43.1 (C-4), 35.8 (C-9), 34.5 (C-2´), 27.1 
(C-7), 26.2 (C-3´), 26.1 (C-12), 25.3 (C-6), 23.6 (C-8), 22.3 (C-4´), 13.7 (C-5´) ppm. ESI-HRMS 
calcd. for C16H26CsO5 ([M + Cs]
+
) 431.0835, found 431.0945. 
 3-Methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl benzoate (3.11).  
To a 5 mL round-bottom flask equipped with argon line and septum were added rac-3.7  
(20 mg, 0.093 mmol), CH3CN (1 mL), DMAP (45 mg, 0.37 mmol) and TMEDA (56 µL, 0.37 
mmol). The mixture was stirred at 0 °C for 10 min. Then benzoyl chloride (43 µL, 0.73 mmol) 
was added and the reaction mixture stirred at same temperature for 1 h. The mixture was allowed 
to stir at ambient temperature for 24 h. Water (2 mL) was added to the stirred mixture, which 
was extracted with EtOAc (15 mL). The organic phase was washed with brine (10 mL), dried 
over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude product was purified 
by flash chromatography over silica gel (30% EtOAc/hexane) to give 3.11 as a white solid (22 
mg, 74%). Mp: 100-102 °C. 
1
H NMR (400 MHz, CDCl3):  = 8.07 (d br, J = 7.4 Hz, 2H, CH-2´ 
and CH-6´), 7.57 (t br, 7.8 Hz, 1H, C-4´), 7.46 (t, J = 7.8 Hz, 2H, CH-3´ and CH-5´), 5.55 (ddd, 
J = 3.1, 6.4, 6.3 Hz, C-5), 4.37(d, J = 10.9 Hz, 1H, CH2a-10), 4.14 (dd, J = 1.7, 10.8 Hz, 1H, 
CH2b-10), 2.81 (dd, J = 3.5, 15.8Hz, 1H, CH2a-4), 2.45 (dd, J = 2.9, 15.8 Hz, 1H, CH2b-4), 2.15 
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(m, 1H, CH-5a), 1.91 (d br, J = 12.2 Hz, 1H, CH2a-9), 1.78-1.66 (m, 3H, CH2a-6, CH2a-7, CH2a-
8), 1.52 (td, J = 3.4, 12.9 Hz, 1H, CH2b-6), 1.37 (m, 1H, CH2b-9), 1.35 (s, 3H, CH3-12), 1.21 (m, 
2H, CH2b-7, CH2b-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 166.2 (C=O), 132.9 (C-4´), 130.6 
(C-1´), 129.7 (C-2´ and C-6´), 128.5 (C-3´ and C-5´), 103.2 (C-3), 82.6 (C-9a), 70.0 (C-5), 63.6 
(C-10), 50.3 (C-5a), 43.3 (C-4), 35.8 (C-9), 26.4 (C-6), 26.1 (C-12), 25.2 (C-7), 23.6 (C-8) ppm. 
IR (neat): 2934, 2864, 1710, 1601, 1449, 1374, 1314, 1274, 1220, 1205, 1183, 1160, 1136, 1111, 
1070, 1055, 1024, 966, 91, 887, 838, 821, 783 cm
‒1
. ESI-HRMS calcd. for C18H22CsO5 ([M + 
Cs]
+
) 451.0522 found 451.0526.  
3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl 4-fluorobenzoate (3.12).  
To a 15 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(20 mg, 0.093 mmol), CH3CN (5 mL), DMAP (45 mg, 0.37 mmol) and TMEDA (56 µL, 0.37 
mmol). The mixture was stirred at 0 °C for 10 min. Then, 4-fluorobenzoyl chloride (44 µL, 0.73 
mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture was 
allowed to stir at ambient temperature for 48 h. Water (5 mL) was added to the stirred mixture, 
which was extracted with EtOAc (20 mL). The organic phase was washed with brine (20 mL), 
dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography over silica gel (20% EtOAc/hexane) to give 3.12 as a light 
yellow solid (22 mg, 70%). Mp: 88-90 °C
 1
H NMR (400 MHz, CDCl3):  = 8.10 (m, 2H, CH-2´ 
and CH-6´), 7.13 (t br, J = 8.6 Hz, 2H, CH-3´ and CH-5´), 5.55 (m, C-5), 4.36(d, J = 11.0 Hz, 
1H, CH2a-10), 4.15 (dd, J = 1.8, 11.0 Hz, 1H, CH2b-10), 2.82 (dd, J = 3.6, 15.8 Hz, 1H, CH2a-4), 
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2.44 (dd, J = 2.9, 15.8 Hz, 1H, CH2b-4), 2.14 (m, 1H, CH-5a), 1.91 (d br, J = 13.1 Hz, 1H, CH2a-
9), 1.79-1.69 (m, 3H, CH2a-6, CH2a-7, CH2a-8), 1.46 (m, 1H, CH2b-6), 1.38 (m, 1H, CH2b-9), 1.36 
(s, 3H, CH3-12), 1.20 (m, 2H, CH2b-7, CH2b-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 165.8 
(C-4´; JFC = 252.4 Hz), 165.2 (C=O), 132.2 (C-2´ and C-6´; JFC = 9.2 Hz), 126.9 (C-1´; JFC = 2.8 
Hz), 115.5 (C-3´ and C-5´; JFC = 21.8Hz), 103.2 (C-3), 82.6 (C-9a), 70.2 (C-5), 63.6 (C-10), 50.3 
(C-5a), 43.3 (C-4), 35.8 (C-9), 26.4 (C-6), 26.1 (C-12), 25.3 (C-7), 23.6 (C-8) ppm. IR (neat): 
2931, 2862, 1704, 1603, 1507, 1453, 1410, 1374, 1279, 1223, 1151, 1110, 1016, 962, 856, 801, 
767 cm
‒1
. ESI-HRMS calcd. for C18H21FNaO5 ([M + Na]
+
) 359.1271, found 359.2250. 
3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl 4-methoxybenzoate (3.13).  
To a 15 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(20 mg, 0.093 mmol), CH3CN (5 mL), DMAP (45 mg, 0.37 mmol) and TMEDA (56 µL, 0.37 
mmol). The mixture was stirred at 0 °C for 10 min. Then, 4-methoxybenzoyl chloride (50 µL, 
0.37 mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture 
was allowed to stir at ambient temperature for 72 h. Water (5 mL) was added to the stirred 
mixture, which was extracted with EtOAc (20 mL). The organic phase was washed with brine 
(20 mL), dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography over silica gel (20% EtOAc/hexane) to give 3.13 
as a white solid (22 mg, 68%). Mp: 155-157 °C. 
1
H NMR (400 MHz, CDCl3):  = 8.04 (d br, J = 
8.8 Hz, 2H, CH-2´ and CH-6´), 6.94 (d br, J = 8.8 Hz, 2H, CH-3´ and CH-5´), 5.53 (ddd, J = 3.2, 
6.4, 6.4 Hz, C-5), 4.37 (d, J = 10.9 Hz, 1H, CH2a-10), 4.14 (dd, J = 1.8, 10.9 Hz, 1H, CH2b-10), 
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3.87(s, 3H, OCH3), 2.82 (dd, J = 3.6, 15.8Hz, 1H, CH2a-4), 2.43 (dd, J = 2.8, 15.8 Hz, 1H, CH2b-
4), 2.13 (m, 1H, CH-5a), 1.90 (dd br, J = 1.9, 11.8 Hz, 1H, CH2a-9), 1.77-1.69 (m, 3H, CH2a-6, 
CH2a-7, CH2a-8), 1.49 (ddd, J = 3.5, 12.8, 16.4 Hz, 1H, CH2b-6), 1.36 (m, 1H, CH2b-9), 1.35 (s, 
3H, CH3-12), 1.21 (m, 2H, CH2b-7, CH2b-8). ppm; 
13
C NMR (100 MHz, CDCl3):  = 165.9 
(C=O), 163.4 (C-4´), 131.7 (C-2´ and C-6´), 123.0 (C-1´), 113.7 (C-3´ and C-5´), 103.2 (C-3), 
82.6 (C-9a), 69.6 (C-5), 63.6 (C-10), 50.3 (C-5a), 43.4 (C-4), 35.9 (C-9), 26.4 (C-6), 26.1 (C-12), 
25.3 (C-7), 23.6 (C-8) ppm. IR (neat): 2923, 2859, 1710, 1604, 1578, 1512, 1451, 1350, 1248, 
1276, 1160, 1117, 1101, 1045, 1018, 967, 853, 820, 771 cm
‒1
. ESI-HRMS calcd. for 
C19H24NaO6 ([M + Na]
+
) 371.1471, found 371.1747; C19H24CsO6 ([M + Cs]
+
) 481.0627 found 
481.0659.  
3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl cinnamate (3.14).  
To a 15 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(50 mg, 0.23 mmol), CH3CN (7 mL), DMAP (114 mg, 0.93 mmol) and TMEDA (139 µL, 0.93 
mmol). The mixture was stirred at 0 °C for 10 min. Then, cinnamoyl chloride (155 mg, 0.93 
mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture was 
allowed to stir at ambient temperature for 72 h. Water (10 mL) was added to the stirred mixture, 
which was extracted with EtOAc (20 mL). The organic phase was washed with brine (20 mL), 
dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography over silica gel (20% EtOAc/hexane) to give 3.14 as yellow oil 
which solidified upon storage in the refrigerator (29 mg, 36%). 
1
H NMR (400 MHz, CDCl3):  = 
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7.71 (d, J = 16.0 Hz, 1H, CH-3´), 7.55 (s br, 2H, CH-2´´ and CH-6´´), 7.40 (s br, 3H, CH-3´´, 
CH-5´´, CH-4´´), 6.49 (d, J = 16.0 Hz, 1H, CH-2´), 5.45 (m, 1H, C-5), 4.32 (d, J = 10.8 Hz, 1H, 
CH2a-10), 4.11 (d, J = 10.8 Hz, 1H, CH2b-10), 2.78 (dd, J = 3.7, 15.9 Hz, 1H, CH2a-4), 2.43 (dd, 
J = 2.8, 15.9 Hz, 1H, CH2b-4), 2.10 (m, 1H, CH-5a), 1.90 (d br, J = 14.0 Hz, 1H, CH2a-9), 1.74-
1.65 (m, 3H, CH2a-6, CH2a-7, CH2a-8), 1.54 (m, 1H, CH2b-6), 1.47 (m, 1H, CH2b-9), 1.36 (s, 3H, 
CH3-12), 1.22 (m, 2H, CH2b-7, CH2b-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 166.8 (C=O), 
144.9 (C-3´), 134.4 (C-1´´), 130.3 (C-4´´), 128.8 (C-3´´ and C-5´´), 128.1 (C-2´´ and C-6´´), 
118.5 (C-2´),  103.1 (C-3), 82.6 (C-9a), 69.6 (C-5), 63.6 (C-10), 50.1 (C-5a), 43.3 (C-4), 35.8 (C-
9), 26.3 (C-6), 26.1 (C-12), 25.3 (C-7), 23.6 (C-8) ppm. IR (neat): 2931, 2863, 1702, 1636, 1449, 
1374,1310, 1275, 1202, 1180, 1156, 1130, 1072, 1054, 1024, 979,965, 916, 887, 836, 820, 767, 
711 cm
‒1
. ESI-HRMS calcd. for C20H24CsO5 ([M + Cs]
+
) 477.0678, found 477.0681.  
3-Methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl 4-chlorobenzoate (3.15).  
To a 15 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(30 mg, 0.14 mmol), CH3CN (5 mL), DMAP (68 mg, 0.56 mmol) and TMEDA (83 µL, 0.56 
mmol). The mixture was stirred at 0 °C for 10 min. Then, 4-chlorobenzoyl chloride (72 µL, 0.56 
mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture was 
allowed to stir at ambient temperature for 24 h. Water (5 mL) was added to the stirred mixture, 
which was extracted with EtOAc (20 mL). The organic phase was washed with brine (20 mL), 
dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude product was 
purified by flash chromatography over silica gel (20% EtOAc/hexane) to give 3.15 as white solid 
(24 mg, 49%). Mp: 110-112 °C. 
1
H NMR (400 MHz, CDCl3):  = 8.02 (d br, J = 8.6 Hz, 2H, 
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CH-2´ and CH-6´), 7.44 (d, J = 8.6 Hz, 2H, CH-3´ and CH-5´), 5.55 (ddd, J = 2.4, 6.0, 6.1 Hz, 
C-5), 4.35(d, J = 11.0 Hz, 1H, CH2a-10), 4.15 (dd, J = 1.8, 10.9 Hz, 1H, CH2b-10), 2.83 (dd, J = 
3.5, 15.8 Hz, 1H, CH2a-4), 2.45 (dd, J = 2.8, 15.8 Hz, 1H, CH2b-4), 2.16 (m, 1H, CH-5a), 1.92 
(dd br, J = 1.0, 13.1 Hz, 1H, CH2a-9), 1.78-1.65 (m, 3H, CH2a-6, CH2a-7, CH2a-8), 1.46 (ddd, J = 
3.6, 13.2, 16.4 Hz, 1H, CH2b-6), 1.37 (m, 1H, CH2b-9), 1.36 (s, 3H, CH3-12), 1.22 (m, 2H, CH2b-
7, CH2b-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 165.3 (C=O), 139.4 (C-4´), 131.1 (C-2´ and 
C-6´), 129.0 (C-1´), 128.8 (C-3´ and C-5´), 103.2 (C-3), 82.6 (C-9a), 70.4 (C-5), 63.6 (C-10), 
50.2 (C-5a), 43.3 (C-4), 35.8 (C-9), 26.4 (C-6), 26.1 (C-12), 25.3 (C-7), 23.6 (C-8) ppm. IR 
(neat): 2929, 2860, 1701, 1591, 1487, 1450, 1400, 1368, 1271, 1222, 1161, 1136, 1111, 1088, 
1014, 965, 854, 819, 750 cm
‒1
. ESI-HRMS calcd. for  C18H21ClCsO5 ([M + Cs]
+
) 485.0132, 
found 485.0169  .  
7a-(acetoxymethyl)octahydrobenzofuran-3-yl 4-fluorobenzoate (3.18).  
To a 15 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(60 mg, 0.28 mmol), CH3CN (7 mL), DMAP (137 mg, 1.12 mmol) and TMEDA (0.17 mL, 1.12 
mmol). The mixture was stirred at 0 °C for 10 min. Then, 4-fluorobenzoyl chloride (0.26 mL, 
2.24 mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture 
was allowed to stir at ambient temperature for 4 days. Water (10 mL) was added to the stirred 
mixture, which was extracted with EtOAc (20 mL). The organic phase was washed with brine 
(20 mL), dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography over silica gel (15% EtOAc/hexane) to give 3.18 
as white solid (28 mg, 29%). M.p. 91-93 °C. 
1
H NMR (400 MHz, CDCl3):  = 8.05 (dd, 2H, J = 
128
  
5.5, 8.7 Hz, CH-2´ and CH-6´), 7.14 (t br, J = 8.6 Hz, 2H, CH-3´ and CH-5´), 5.58 (td, 1H, J = 
1.7, 5.8 Hz, CH-3), 4.60 (d, J = 12.5 Hz, 1H, CH2a-8), 4.41 (dd, J = 6.0, 11.4 Hz, 1H, CH2a-2), 
4.32 (d, J = 12.5 Hz, 1H, CH2b-8), 3.99 (dd, J = 1.7, 11.4 Hz, 1H, CH2b-2), 2.36 (dd, J = 3.6, 12.2 
Hz, 1H, CH2a-7), 2.12 (s, 3H, CH3-11), 1.96-1.76 (m, 4H, CH2a-6, CH2a-5, CH2a-4, CH-3a), 1.53-
1.24 (m, 4H, CH2b-7, CH2b-5, CH2b-6, CH2b-4) ppm; 
13
C NMR (100 MHz, CDCl3):  = 171.3 (C-
10), 165.9 (C-4´; JFC = 253.1 Hz), 165.0 (C-13), 132.1 (C-2´ and C-6´; JFC = 9.4 Hz), 125.9 (C-
1´; JFC = 2.9 Hz), 115.7 (C-3´ and C-5´; JFC = 21.9Hz), 82.1 (C-7a), 75.1 (C-2), 72.6 (C-3), 60.8 
(C-8), 52.0 (C-3a), 33.3 (C-7), 25.5 (C-5), 22.4 (C-6), 22.2 (C-4), 21.0 (C-11) ppm. IR (neat): 
2945, 2874, 1720, 1604, 1506, 1458, 1412, 1392, 1368, 1333, 1307, 1273, 1241, 1229, 1156, 
1113, 1094, 1032, 1005, 967, 918, 873, 851, 803, 765 cm
‒1
. ESI-HRMS calcd. for 
C18H21FNaO5 ([M + Na]
+
) 359.1271, found 359.1235; C18H22FO5 ([M + H]
+
) 337.1451, found 
337.1451. 
3-methylhexahydro-1H-3,9a-epidioxybenzo[c]oxepin-5(5aH)-one (3.20).  
To a 25 mL round-bottom flask equipped with argon line and septum were added PCC 
(80 mg, 0.37 mmol) and Dry DCM (10 mL). The mixture was stirred at ambient temperature for 
5 min before a solution of rac-3.7 (53 mg, 0.25 mmol) in dry DCM (5 mL) was added via 
cannula to the above mixture and stirred at the same temperature for 48 h. The mixture was 
diluted with Et2O (10 mL) and concentrated by rotary evaporation. Crude material was purified 
by flash chromatography over silica gel (20% EtOAc/hexane) to give 3.20 as yellow oil which 
solidified upon storage in the refrigerator (29 mg, 55%). 
1
H NMR (400 MHz, CDCl3): δ = 4.14 
(d, J = 11.4 Hz, 1H, CH2a-10), 4.11 (d, J = 11.4 Hz, 1H, CH2b-10), 3.56 (d, J = 15.6 Hz, 1H, 
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CH2a-4), 2.93 (d, J = 15.6 Hz, 1H, CH2b-4), 2.36 (m, CH-5a), 2.32 (m, 1H, CH2a-6), 1.92-1.87 (d 
br, J = 14.1 Hz, 1H, CH2a-9), 1.80-1.70 (m, 2H, CH2a-7, CH2a-8), 1.44 (ddd, J = 4.4, 13.5, 18.0 
Hz, 1H, CH2b-9), 1.37 (s, 3H, CH3-12), 1.30-1.12 (m, 3H, CH2b-6, CH2b-7, CH2b-8), ppm; 
13
C 
NMR (100 MHz, CDCl3): δ = 204.9 (C-5), 103.0 (C-3), 83.4 (C-9a), 63.6 (C-10), 57.6 (C-5a), 
54.9 (C-4), 34.3 (C-9), 25.4 (C-12), 25.0 (C-6), 24.6 (C-7), 23.4 (C-8) ppm. IR (neat): 2935, 
2865, 1715, 1450, 1409, 1376, 1335, 1320, 1268, 1247, 1213, 1190, 1167, 1118, 1097, 1055, 
909, 881, 863, 827, 778 cm
‒1
. ESI-HRMS calcd. for C11H17O4 ([M + H]
+
) 213.1127, found 
213.1140.  
3-Methyl-5-methyleneoctahydro-1H-3,9a-epidioxybenzo[c]oxepine (3.21).  
To a 25 mL round-bottom flask equipped with argon line and septum containing 
Ph3PCH3Br (0.8 g, 2.24 mmol) was added KHMDS (4.5 mL, 2.2 mmol, 0.5 M solution in 
toluene). A solution of ketone 3.22 (50 mg, 0.24 mmol) in anhydrous THF (4 mL) was added 
dropwise to the above mixture via cannula at 0 °C, and the whole mixture was stirred for 1 h. 
Then the mixture was allowed to stir at ambient temperature for 12 h. The reaction mixture was 
then poured into saturated aqueous NH4Cl (10 mL) and the mixture was extracted with Et2O (2 x 
20 mL). The organic layers were separated, filtered over anhydrous Na2SO4 and concentrated by 
rotary evaporation. The crude product was purified by silica gel flash chromatography (50% 
Et2O/hexane) to afford the exomethylene 3.21 as a viscous, yellow oil (12 mg, 24%). 
1
H NMR 
(400 MHz, CDCl3):   = 5.13 (s, CH2a-13), 4.93 (s, CH2b-13), 3.55 (m, CH-5a), 3.41 (m, CH2-
10), 2.78 (d, J = 17.0 Hz, 1H, CH2a-4), 2.63 (d, J = 17.0 Hz, 1H, CH2b-4), 2.32 (m, 1H, CH2a-9), 
1.95 (m, 1H, CH2a-6), 1.62-1.40 (m, 3H, CH2b-7, CH2a-9, CH2a-6), 1.35-1.20 (m, 4H, CH2a-8 
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CH2b-9, CH2b-6, CH2a-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 150.7 (C-5), 105.9 (C-13), 
103.5 (C-3), 85.9 (C-9a), 71.9 (C-10), 66.1 (C-5a), 41.9 (C-4), 29.7 (C-9), 27.9 (C-7), 23.7 (C-
12), 21.2 (C-6), 20.8 (C-8) ppm;. IR (CHCl3): 2923, 2853, 1458, 1388, 1203, 1166, 1028, 966, 
890, 859, 805, 760 cm
‒1
. ESI-HRMS calcd. for C12H17O3 ([M - H]
-
) 209.11, found 209.11.  
3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl2-(((1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl)oxy)acetate (3.24).  
To a 50 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(100 mg, 0.46 mmol), CH3CN (20 mL), DMAP (171 mg, 1.40 mmol) and TMEDA (0.21 mL, 
1.40 mmol). The mixture was stirred at 0 °C for 10 min. Then, (−)-menthoxyacetyl chloride 
(0.31 mL, 1.40 mmol) was added and the reaction mixture stirred at same temperature for 1 h. 
The mixture was allowed to stir at ambient temperature for 48 h. Additional amount of (−)-
menthoxyacetyl chloride (0.20 mL) was added and mixture stirred for 24 h. After 72 h, DMAP 
(171 mg) and TMEDA (0.21 mL) were added and the reaction mixture allowed to stir at ambient 
temperature for 24 h. Water (15 mL) was added to the stirred mixture, which was extracted with 
EtOAc (2 x 20 mL). The organic phases were washed with brine (30 mL), dried over anhydrous 
Na2SO4, and concentrated by rotary evaporation. The crude product was purified by flash 
chromatography over silica gel (20% EtOAc/hexane) to give diastereomers 3.24 as white solid 
(77 mg, 40%). M.p.156-158 °C. 
1
H NMR (500 MHz, CDCl3):   = 5.32 (m, 1H, CH-5), 4.22 
(d, J = 10.9 Hz, 1H, CH2a-10), 4.18/4.17 (d, J = 16.1 Hz, 1H, CH2a-2′), 4.10/4.07 (d, J = 16.1 Hz, 
1H, CH2b-2′), 4.04 (dd, J = 2.1, 10.9 Hz, 1H, CH2b-10), 3.17 (dt, J = 4.5, 10.5 Hz, 1H, CH-1′′), 
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2.74 (dt, J = 3.5, 15.9 Hz, 1H, CH2a-4), 2.40 (ddd, J = 2.5, 5.5, 15.9 Hz, 1H, CH2b-4), 2.32 (m, 
1H, CH-5′′), 2.04-2.09 (m, 2H, CH-5a, CH2a-6), 1.75-1.60 (m, 6H), 1.47-1.43 (m, 1H), 1.35/1.34 
(s, 3H, CH3-12), 1.26-1.18 (m, 3H), 1.06-1.9 (m, 1H), 0.92 (t, J =  6.6 Hz, 6H, CH3-8, CH3-9), 
0.81 (d, J = 6.6 Hz, 3H, CH3-10) ppm; 
13
C NMR (125 MHz, CDCl3):   = 170.7/170.6 (C-1′), 
102.9 (C-3), 82.8 (C-9a), 80.4 (C-1′′), 70.1/70.0 (C-5),66.1/66.0 (C-2′), 63.4 (C-10), 50.0/49.9 
(C-5a), 48.0 (C-5′′), 43.1/43.0 (C-4), 40.07/40.01 (C-6′′), 35.7 (C-9), 34.3 (C-3′′), 31.5 (C-2′′), 
26.17/26.18 (C-7), 26.1 (C-12), 25.5 (C-6), 25.0 (C-5′′), 25.28 (C-4′′), 23.5/23.3 (C-8), 22.3 (C-
7′′), 20.1 (C-8′′ and C-9′′), 16.2 (C-10′′) ppm. IR (neat): 2926, 2868, 1750, 1454, 1377, 1196, 
1161, 1110, 1051, 963, 950, 915, 887, 834, 822, 788 cm
‒1
. ESI-HRMS calcd. for C46H76CsO12 
([2M + Cs]
+
) 953,4391 found 953.4387. 
(3R,5R,5aR,9aS)-3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-yl(R)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoate  (25a) and (3S, 5S, 5aS, 9aR)-3-methyloctahydro-
1H-3,9a-epidioxybenzo[c]oxepin-5-yl(R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate 
(3.25b).  
To a 50 mL round-bottom flask equipped with argon line and septum were added rac-3.7 
(195 mg, 0.91 mmol), CH3CN (25 mL), DMAP (334 mg, 2.73 mmol) and TMEDA (0.41 mL, 
2.73 mmol). The mixture was stirred at 0 °C for 10 min. Then, (R)-(−)-MTPA-Cl (0.34 mL, 1.82 
mmol) was added and the reaction mixture stirred at same temperature for 1 h. The mixture was 
allowed to stir at ambient temperature for 72 h. Water (20 mL) was added to the stirred mixture, 
which was extracted with EtOAc (2 x 25 mL). The organic phases were washed with brine (30 
mL), dried over anhydrous Na2SO4, and concentrated by rotary evaporation. The crude product 
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was purified by flash chromatography over silica gel (15% EtOAc/hexane) to give two 
diasteromers. The higher Rf material 3.25b (76 mg, 19%) was viscus oil. 
1
H NMR (600 MHz, 
CDCl3):  = 7.71 (m, 2H, CH-2´´ and CH-6´´), 7.42 (m, 3H, CH-3´´, CH-5´´, CH-4´´), 5.40 (dt, J 
= 3.3, 9.6 Hz, 1H, C-5), 4.19 (d, J = 11.0 Hz, 1H, CH2a-10), 4.05 (dd, J = 1.7, 11.1 Hz, 1H, 
CH2b-10), 3.65 (s, 3H, OCH3), 2.79 (dd, J = 3.0, 16.2 Hz, 1H, CH2a-4), 2.50 (dd, J = 2.8, 16.2 
Hz, 1H, CH2b-4), 2.10 (m, 1H, CH-5a), 1.88 (d br, J = 11.5 Hz, 1H, CH2a-9), 1.69-1.63 (m, 2H, 
CH2a-7, CH2a-8), 1.54 (m, 1H, CH2a-6), 1.34 (s, 3H, CH3-12), 1.32 (m, 1H, CH2b-9),1.19-1.12 
(m, 3H, CH2b-6, CH2b-7, CH2b-8) ppm; 
13
C NMR (150 MHz, CDCl3):  = 166.1 (C-1´), 132.2 
(C-1´´), 129.5 (C-4´´), 128.3 (C-3´´ and C-5´´), 127.2 (C-2´´ and C-6´´), 125.5 (C-3´; J CF = 238 
Hz), 102.6 (C-3), 83.8 (C-2´), 82.5 (C-9a), 73.2 (C-5), 63.4 (C-10), 55.6 (OCH3), 50.2 (C-5a), 
42.7 (C-4), 35.7 (C-9), 26.0 (C-6), 26.0 (C-12), 25.4 (C-7), 23.5 (C-8) ppm. ESI-HRMS calcd. 
for C21H25CsF3O5 ([M + Cs]
+
) 563.0658, found 563.0663.  
The lower Rf material 3.25a (82 mg, 22%) was viscus oil. 
1
H NMR (400 MHz, CDCl3):  
= 7.56 (m, 2H, CH-2´´ and CH-6´´), 7.43 (m, 3H, CH-3´´, CH-5´´, CH-4´´), 5.40 (dt, J = 3.1, 9.4 
Hz, 1H, C-5), 4.06 (d, J = 11.0 Hz, 1H, CH2a-10), 3.97 (dd, J = 1.7, 11.0 Hz, 1H, CH2b-10), 3.50 
(s, 3H, OCH3), 2.76 (dd, J = 3.5, 16.1 Hz, 1H, CH2a-4), 2.45 (dd, J = 2.8, 16.1 Hz, 1H, CH2b-4), 
2.08 (m, 1H, CH-5a), 1.84 (d br, J = 13.6 Hz, 1H, CH2a-9), 1.68-1.56 (m, 3H, CH2a-6, CH2a-7, 
CH2a-8), 1.35-1.26 (m, 2H, CH2b-6, CH2b-9), 1.24 (s, 3H, CH3-12), 1.19-1.10 (m, 2H, CH2b-7, 
CH2b-8) ppm; 
13
C NMR (100 MHz, CDCl3):  = 166.4 (C-1´), 131.7 (C-1´´), 129.6 (C-4´´), 
128.4 (C-3´´ and C-5´´), 127.8 (C-2´´ and C-6´´), 127.5 (C-3´; J CF = 228 Hz), 102.6 (C-3), 84.7 
(C-2´), 82.5 (C-9a), 73.2 (C-5), 63.4 (C-10), 55.1 (OCH3), 50.2 (C-5a), 42.7 (C-4), 35.7 (C-9), 
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26.0 (C-6), 26.0 (C-12), 25.4 (C-7), 23.5 (C-8) ppm. IR (neat): 2940, 2852, 1746, 1460, 1376, 
1271, 1161, 1127, 1023, 837, 718 cm
‒1
. ESI-HRMS calcd. for C21H25CsF3O5 ([M + Cs]
+
) 
563.0658, found 563.0691.  
(3R,5R,5aR,9aS)-3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-ol (3.7a).  
To a 25 mL round-bottom flask containing 3.25a (20 mg, 0.05 mmol), a warm solution of 
1N NaOH in MeOH (10 ml) was added. The mixture was allowed to stir at ambient temperature 
for 36 h. the mixture was then neutralized with few drops of dilute HCI. After removal of the 
MeOH by rotary evaporation, the residue was dissolved in CHCI3 (10 mL), and washed with 
H2O (10 ml). The aqueous layer was extracted with CHCI3 (2 x 10 mL). The combined organic 
layers were filtered over anhydrous Na2SO4 and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography over silica gel (20% EtOAc/hexane) to afford 3.7a 
as a crystalline solid (2.6 mg, 27%). Mp: 108-110 °C. 1H NMR (400 MHz, CDCl3):    = 4.19 
(d, J = 11.3 Hz, 1H, CH2a-10), 4.11 (dd, J = 1.4, 11.3 Hz, 1H, CH2b-10), 3.84 (m, 1H, CH-5), 
3.64 (d, J = 11.7 Hz, 1H, OH), 2.74 (dd, J = 3.3, 15.2 Hz, 1H, CH2a-4), 2.44 (dd, J = 3.1, 15.2 
Hz, 1H, CH2b-4), 1.90-1.58 (m, 6H, CH2a-7, CH2b-8, CH-5a, CH2b-7, CH2a-9, CH2a-6), 1.40 (s, 
3H, CH3-12), 1.33-1.20 (m, 3H, CH2a-8, CH2b-9, CH2b-6) ppm; 
13
C NMR (100 MHz, 
CDCl3):    = 105.2 (C-3), 83.8 (C-9a), 68.6 (C-5), 63.6 (C-10), 51.7 (C-5a), 44.8 (C-4), 35.1 (C-
9), 27.0 (C-7), 26.3 (C-12), 25.4 (C-6), 23.8 (C-8) ppm;. [α]D 
20
 = ‒100.5° (c = 0.016, CHCl3). IR 
(neat): 3426, 2928, 2856, 1462, 1449, 1376, 1361, 1252, 1161, 1048, 1030, 830, 771 cm
‒1
. ESI-
MS calcd. for C11H17O4  ([M - H]
-
) 213.1127,  found 213.0793.  
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(3S,5S,5aS,9aR)-3-methyloctahydro-1H-3,9a-epidioxybenzo[c]oxepin-5-ol (3.7b).  
To a 25 mL round-bottom flask containing 3.25b (24 mg, 0.06 mmol), a warm solution of 
1N NaOH in MeOH (10 ml) was added. The mixture was allowed to stir at ambient temperature 
for 36 h. the mixture was then neutralized with few drops of dilute HCI. After removal of the 
MeOH by rotary evaporation, the residue was dissolved in CHCI3 (10 mL), and washed with 
H2O (10 ml). The aqueous layer was extracted with CHCI3 (2 x 10 mL). The combined organic 
layers were filtered over anhydrous Na2SO4 and concentrated by rotary evaporation. The crude 
product was purified by flash chromatography over silica gel (20% EtOAc/hexane) to afford 
3.7b as a crystalline solid (2.9 mg, 24%). Mp: 107-109 °C. 1H NMR (400 MHz, CDCl3):  = 
4.19 (d, J = 11.3 Hz, 1H, CH2a-10), 4.11 (dd, J = 1.4, 11.3 Hz, 1H, CH2b-10), 3.84 (m, 1H, CH-
5), 3.64 (d, J = 11.7 Hz, 1H, OH), 2.74 (dd, J = 3.3, 15.2 Hz, 1H, CH2a-4), 2.44 (dd, J = 3.1, 15.2 
Hz, 1H, CH2b-4), 1.90-1.58 (m, 6H, CH2a-7, CH2b-8, CH-5a, CH2b-7, CH2a-9, CH2a-6), 1.40 (s, 
3H, CH3-12), 1.33-1.20 (m, 3H, CH2a-8, CH2b-9, CH2b-6) ppm; 
13
C NMR (100 MHz, 
CDCl3):  = 105.2 (C-3), 83.8 (C-9a), 68.6 (C-5), 63.6 (C-10), 51.7 (C-5a), 44.8 (C-4), 35.1 (C-
9), 27.0 (C-7), 26.3 (C-12), 25.4 (C-6), 23.8 (C-8) ppm ;. [α]D 
20
 = +100.5° (c = 0.020, CHCl3). 
IR (neat): 3417, 2931, 2862, 1449, 1387, 1357, 1240, 1221, 1160, 1111, 1092, 1030, 984, 903, 
882, 853, 832, 816 cm
‒1
.ESI-MS calcd. for C11H17O4  ([M - H]
-
) 213.1127,  found 213.0741. 
Rearrangement of racemic mixture (3.7) with FeBr2: Synthesis of ((3S,3aR,7aS)-3-
hydroxyhexahydrobenzofuran-7a(2H)-yl)methyl acetate (3.28).  
To a 5 mL round-bottom flask were added rac-3.7 (19 mg, 0.089 mmol), THF (1.2 mL), 
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and FeBr2 (0.038 g, 0.177 mmol). The mixture was stirred at ambient temperature under argon 
atmosphere for 2 h and then directly chromatographed over silica gel (60% EtOAc/hexane). The 
product 3.28 was isolated in 47% yield (9 mg). M.p.123-125°C. 
1
H NMR (600 MHz, 
CDCl3):   = 4.62 (dd, J = 1.5, 12.3 Hz, 1H, CH2a-8), 4.42 (td, J = 1.5, 5.5 Hz, 1H, CH-3), 4.26 
(d, J = 12.3 Hz, 1H, CH2b-8), 4.23 (dd, J = 5.2, 10.5 Hz, 1H, CH2a-2), 3.85 (dd, J = 1.6, 10.5 Hz, 
1H, CH2b-2), 2.30 (dt, J = 3.3 6.7 Hz, 1H, CH2a-7), 2.11 (s, 3H, CH3-11), 1.91 (m, 1H, CH2a-5), 
1.83 (m, 1H, CH2a-4), 1.76  (m, 1H, CH2a-6), 1.54 (m, 1H, CH-3a), 1.46 (m, 1H, CH2b-4), 1.35-
1.26 (m, 3H, CH2b-7, CH2b-5, CH2b-6,) ppm; 
13
C NMR (150 MHz, CDCl3):   = 171.8 (C-10), 
81.8 (C-7a), 75.2 (C-2), 72.2 (C-3), 61.8 (C-8), 53.4 (C-3a), 33.6 (C-7), 25.6 (C-5), 22.6 (C-6), 
21.7 (C-4), 21.0 (C-11) ppm;. IR (neat): 3394, 2944, 2881, 1740, 1481, 1451, 1387, 1368, 1353, 
1311, 1242, 1205, 1148, 1124, 1081, 1036, 1018, 1008, 1018, 973, 926, 870, 845, 755 cm
‒1
. ESI-
HRMS calcd. for C11H18NaO4 ([M + Na]
+
) 237.1103, found 237.1145. 
Rearrangement of ketone (3.20) with FeBr2: Synthesis of ((1S)-2-acetyl-1-
hydroxycyclohexyl)methyl acetate (3.35).  
To a 5 mL round-bottom flask were added 3.20 (20 mg, 0.09 mmol), THF (1.2 mL), and 
FeBr2 (0.041 g, 0.177 mmol). The mixture was stirred at ambient temperature under argon 
atmosphere for 2 h and then directly chromatographed over silica gel (60% EtOAc/hexane). The 
product 3.35 was isolated in 50% yield (10 mg). 
1
H NMR (400 MHz, CDCl3):   = 4.24 (d, J = 
12.0 Hz, 1H, CH2a-7), 4.18, (d, J = 12.0 Hz, 1H, CH2b-7), 2.68 (dd, J= 4.4, 9.8 Hz, 1H, CH-2), 
2.23 (s, 3H, CH3-12), 2.08 (s, 3H, CH3-10), 2.01-1.92 (m, 2H, CH2a-6, CH2a-3), 1.68-1.59 (m, 
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3H, CH2b-6, CH2a-4, CH2a-5), 1.43-1.34 (m, 3H, CH2b-3, CH2b-4, CH2b-5) ppm; 
13
C NMR (100 
MHz, CDCl3):   = 211.6 (C-11), 171.8 (C-9), 72.8 (C-1), 67.3 (C-7), 56.4 (C-2), 34.5 (C-6), 
30.9 (C-12), 25.2 (C-3), 23.8 (C-4), 22.1 (C-5), 20.8 (C-10) ppm. IR (neat): 3452, 2924, 2854, 
1740, 1705, 1366, 1259, 1236, 1186, 1090, 1014, 924, 800, 737 cm
‒1
;. ESI-HRMS calcd. for 
C11H18NaO4 ([M + Na]
+
) 237.1103, found 237.1132. 
5.2.BIOASSAY FOR ANTIMALARIAL ACTIVITY  
Synthesized compounds were tested in vitro against two P. falciparum malaria parasite 
clones, designated as Indochina (W-2) and Sierra Leone (D-6). The W-2 clone is chloroquine 
resistant whereas the D-6 clone is chloroquine-sensitive strain. This assay was performed at the 
NCNPR, University of Mississippi using the parasite lactate dehydrogenase (pLDH) assay 
developed by Makler et al., [146, 147]. This assay is based on the ability of pLDH enzyme of P. 
falciparum to reduce 3-acetylpyridine-adenine dinucleotide (APAD) to APADH. This reaction is 
achieved at a slow rate by human red blood cells LDH. The formation of APADH was monitored 
colorimetrically by the addition of nitroblue tetrazolium (NBT) which was reduced to form a 
blue formazan product. The antimalarial agents chloroquine and artemisinin were used as control 
drugs, while DMSO was used as a solvent control. In addition, the selectivity index of the 
antimalarial activity of the tested compounds was determined based on their in vitro cytotoxicity 
to mammalian cells.  
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 5.2.1. REAGENTS AND MATERIALS  
The two P. falciparum clones,W-2 and D-6 were obtained from Walter Reed Army 
Institute. Human blood and human serum were obtained from Interstate Blood Bank. Roswell 
Park Memorial Institute medium (RPMI 1640 medium), acetic acid and 96- well microplate were 
purchased from Thermo Fisher Scientific. APAD, NBT, PES, artemisinin, chloroquine, DMSO, 
amikacin, doxorubicin, Phosphate-buffered saline (PBS) and neutral red were purchased from 
Sigma-Aldrich. Vero cells (African green monkey kidney fibro-blast) purchased from American 
Type Culture Collection (ATCC).  
 5.2.2. IN VITRO ANTIMALARIAL ASSAY  
A suspension of red blood cells infected with W-2 or D-6 strain of P. falciparum that 
contains 2% parasitemia and 2% hematocrite in RPMI 1640 medium supplemented with 10% 
human serum and 60 µg/mL amikacin was dispensed into the wells of a 96- well flat-bottomed 
microtiter plate containing 10 µL of serially diluted test samples. The plates were incubated at 37 
ºC  in an environment of 90% N2, 5% O2, and 5% CO2 for 72 h. Next, 100 µl aliquots of the 
Malstat reagent was added to each well of a new 96-well microtiter plate. The cultures were 
resuspended from the assay plate by mixing each well up and down several times. A 20 µl from 
each well of the resuspended culture was removed and added to the plate containing the Malstat 
reagent and the plate was incubated at r.t., for 30 min. Further, to each well, 20 µl of a NBT/PES 
(1:1) solution (2 mg/ml and 0.1 mg/ml, respectively) was added. Plate was incubated in the dark 
for 1 h. The reaction was terminated by the addition of a 100 µl of a 5% acetic acid solution. The 
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plate was then read at 650 nm. Artemisinin and chloroquine were included in each assay as 
antimalarial drug controls. The IC50 values were computed from the dose response curves using 
XLfit 4.2.  
 5.2.3. IN VITRO CYTOTOXICITY ASSAY  
The assay was performed in 96-well tissue culture-treated plates as described earlier. 
Vero cells were seeded to the wells of 96-well plate at a density of 25,000 cells/well and 
incubated for 24 h. tested compounds at different concentrations were added and plates were 
again incubated for 48 h. The number of viable cells was determined by Neutral Red assay[148]. 
IC50 values were obtained from dose response curves. Doxorubicin was used as a positive control 
for cytotoxicity.  
a. Neutral Red assay 
Briefly, after incubating with the tested compounds, the cells were washed with PBS and 
incubated for 90 min with the medium containing Neutral Red (166 μg/mL). The cells were 
washed to eliminate extracellular dye. A solution of acidified isopropanol (0.33% HCl) was then 
added to lyse the cells. As a result, the absorbed dye was released from the viable cells. The 
absorbance was read at 540 nm. IC50 (the concentration of the test compounds that caused a 
growth inhibition of 50% after 48 h of exposure of the cells) was calculated from the dose curves 
created by plotting percent growth vs. the test concentration on a logarithmic scale using 
Microsoft Excel. All assays were performed in triplicate. 
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CHAPTER VI 
 CONCLUSIONS AND FUTURE PLANS 
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The goals of this dissertation were to: 1) synthesize 6-desmethyl-5-hydroxy-D-seco-
artemisinin, rac-3.7, following an apparently straightforward Chinese publication (Wu et al.), as 
a starting material and study the structure by single crystal X-ray diffractometry: 2) study SAR 
about the 5-position of the artemisinin-like template 3.7; 3) examine the effect of specific 
changes of the oxidation state of C-5 (sp
2
 3.20 and 3.21 vs sp
3
 3.7-3.15) on in vitro biological 
activity; 4) investigate Fe(II) promoted peroxide rearrangement (O1/O2-C3/C4) chemistry of C-5 
sp
2
 vs sp
3
 derivatives 3.7, 3.20, and 3.21 in an attempt to correlate C-4 radical stability with 
biological activity; 5) utilize the 5-hydroxy group of rac-3.7 to prepare and separate 
diastereomeric Mosher esters 3.25a and 3.25b and following saponification, isolate the 
artemisinin-superimposable (-)-3.7a and the reported (+)-3.7b (reported by Wu et al.), and 
compare in vitro biological activities of the enantiomeric pair 3.7a vs 3.7b as well as the 
racemate rac-3.7. Some debate exists in the literature regarding chirality and the issue of its 
effect on biological activity [76]. Our results conclusively demonstrate that chirality is a 
prerequisite for biological activity of artemisinin-like peroxides. 
Goal 1: The reported synthesis of rac-3.7 was far more difficult than reported by Wu, et 
al. Yields in general were inflated and numerous pitfalls in the chemistry were left out of the 
experimental procedures. Strangely, Wu chose to focus a chiral synthesis of 3.7 on the incorrect 
enantiomer of 3.7, that is 3.7b. No mention was made of this fact in the publication, although 
somehow Wu did manage to draw his chiral compound correctly. How he managed to draw the 
correct enantiomer 3.7b is a mystery.  His chiral synthesis involved an L-proline promoted Aldol 
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condensation with cyclohexanone; why he did not elect to prepare the correct enantiomer using 
D-proline is a mystery. Our explanation is that he reports high yields in this Aldol reaction, yet 
we were never able to obtain better than 10% yield with a two-week reaction time. Heating or 
other measures were ineffective in improving the yield and slow reaction time. Thus, the effort 
of repeating the entire process with D-proline was too great.  
Several of the compounds were surprisingly volatile towards conventional solvent 
removal, leading to a number of setbacks. The epoxide 3.5 and targets 3.7 were volatile under 
high vacuum. Unpredictable instability led to variable low yields in the epoxide opening reaction 
to give the highly unstable hydroperoxide 3.6. The confluence of unstable intermediates and 
volatile products led to low yields which, when compounded, led to very low overall yields. This 
was completely contrary to our reason for picking 3.7 which were its reported ease of synthesis 
and good yields. While no punitive measures exist to detract scientists from exaggerating their 
results, the time wasted making starting material for this project suggests that there should be 
some penalty for scientific dishonesty.  
Goal 2: The alcohol 3.7 was found to be highly unreactive. From the crystal structure of 
3.7, a tight hydrogen bond was observed between the alcohol and the adjacent ring ether oxygen. 
MM2 force field calculations showed a high relative E for the intramolecular bonded conformer 
of 3.7 (Erel = -2.75 Kcal/M for the IMHB conformer) with a measured bond length of 2 Å. These 
data explained the poor reactivity of 3.7 as only simple esters could be formed from unreactive 
alcohol 3.7. Other derivatives such as carbonates or carbamates, on attempted reaction with 
chloroformates or isocyanates, could not be formed. The more sterically exposed 5-alcohol 
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could not be formed by Mitsunobu reaction as the intermediate could not be formed for inversion 
from  to . Reduction of ketone 3.20 would just give back 3.7. 
The 8 synthesized esters, namely, racemic 3.10-3.15, diastereomers 3.24, 3.25a and 
3.25b, were prepared and tested in vitro against the P. falciparum parasite clones D-6 and W-2. 
For example, in the W2 clone, IC50 values ranging from 0.24 µM to 5.0 µM demonstrated a 
broad range of moderate activity. The n-pentanoate (0.55 µM) was comparable to the benzoate 
(0.48 µM), but within the benzoates, the p-fluoro- improved activity to 0.24 µM which was 
presumably a result of an in vitro metabolic effect. 
Goal 3: Oxidation of the alcohol 3.7 was difficult, but the ketone 3.20 could be formed 
and gave the most active compound, which even as a racemate had an IC50 value of 0.15 µM (D-
6) and 0.11 (W-2). Fe(II) promoted rearrangement of the ketone should afford a enol radical, 
more stable than the -hydroxy radical formed from 3.7. Formation of the exomethylene 
derivative 3.21 by Wittig reaction gave low yields but the product was submitted for bioassay 
and was about ten times less active than the ketone. Odd slow reactivity of 3.21 towards Fe(II) in 
vitro may be consistent with its low bioactivity. This result needs to be repeated before 
conclusions are reached. 
Goal 4: The Fe(II)- promoted biomimetic rearrangement of active analogs rac-3.7 and 
3.20 produces 3.28 and 3.35 respectively which were devoid of antimalarial activity. Formation 
of the product 3.28 is an indication of the low antimalarial activity of racemic 3.7 (IC50 = 8.01 
µM (D-6) and 8.30 µM (W-2)) probably due to instability of primary C4 radical 3.27 and 
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therefore, has less chance to alkylate plasmodial protein. However, formation of product 3.35 is 
associated with high antimalarial activity of the precursor 3.20 (IC50 = 0.15 nM (D-6) and 0.11 
µM (W-2)) perhaps due to a generation of a more stable primary C4 radical 3.29 and then this 
stable radical intermediate has a better chance to alkylate malarial protein. The exomethylene 
3.21 (IC50 = 1.64 (D-6) and 1.67 µM (W-2)) was 10 and 16 times less potent than 3.20 in (D-6) 
and (W-2) respectively, although it contains exomethylene group which hypothetically should 
have a stronger stabilizing effect on the generated C4 radical than the enol radical from the 
carbonyl in 3.20. This result is however preliminary and leads to speculation. For some reason, 
attempted Fe(II) reaction with exomethylene 3.21 was sluggish leading to a myriad of products. 
There is clearly an unexpected effect operative with the exomethylene peroxide that will require 
repetition of the experiment; perhaps with all three representative member (3.7, 3.20, 3.21) 
reacted on the same day under the same conditions. 
Goal 5: Approximately half of the antimalarial activity of rac-3.7, 8.01µM (D-6) and 
8.30 µM (W-2), was related to enantiopure (‒) 3.7a (IC50 = 5.86 µM (D-6) and 4.13 µM (W-2)), 
whereas the enantiopure (+) 3.7b was inactive. 
Future Goals: The most active analogs could be sent for in vivo antimalarial activity. 
Also, a diverse library of derivatives at C5 position (e.g. any chemistry that will work) can be 
synthesized and tested for in vitro antimalarial activity. The active analogs can be submitted for 
in vivo testing. The radical chemistry of the alcohol, ketone and exomethylene needs to be 
repeated under identical conditions.  
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Use of the ketone as a tether to derivatize the C4 position is highly important in regards 
to the molecular mechanism of action. Elimination of the C4 alcohol to form a C4-5 unsaturation 
would be most interesting.  Essentially, any chemistry that could be conducted to derivatize C4/5 
would lead to useful analogs for testing. 
The last comment is direct oxidation of artemisinin itself, an inexpensive starting material 
that has been shown to undergo catalytic oxidation at C-5. These results were reported recently 
and it was not reasonable to redo the entire project.  
The goal of derivatizing C4/C5 (and even C3) in order to study influencing the ensuing 
radical remains laudable from the perspective of drug design in infectious diseases and cancer. 
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HPLC analysis data for the tested compounds 
The purities of the tested compounds were determined using HPLC analysis with two different 
methods as given in the following table. 
 Method A Method B 
Equipment  Automated Waters Alliance system with a photodiode array (PDA) detector 
(210-400 nM), analysis was performed using Empower® software. 
Column LUNA® C18 column (4.60 x 250 mm i.d., 5µm) 
System 
Conditions 
 CH3OH/H2O: 75/25, flow rate: 
1ml/min, ambient temperature  
CH3CN/H2O: 75/25, flow rate: 
1ml/min, ambient temperature 
Compound Retention Time Purity % Retention Time Purity % 
rac-3.7 5.66 99.60 4.90 97.25 
3.11 8.50 98.87 5.13 98.79 
3.12 17.99 98.07 9.62 98.90 
3.13 18.94 99.17 8.50 97.34 
3.14 4.76 99.09 5.67 97.64 
3.15 27.06 95.63 13.22 96.57 
3.18 11.26 98.75 6.58 95.31 
3.20 2.71 99.21 2.57 98.95 
3.21 3.83 100 5.52 98.25 
3.24 3.14 93.67 - - 
3.25a 2.71 95.94 2.56 97.60 
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